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SUMMARY 
Phenylketonuria (PKU) is an autosomal recessive inborn error of metabolism (IEM) 
caused by mutations in the phenylalanine hydroxylase (PAH) gene. The molecular 
mechanism underlying deficiency of the PAH protein is, in most of the cases, loss of 
function due to protein misfolding. PAH mutations induce disturbed oligomerisation, 
decreased stability and accelerated degradation of hepatic PAH, a key enzyme in 
phenylalanine metabolism. Since the development of a phenylalanine-restricted diet in 
the 1950ies, PKU is a prototype for treatable inherited diseases. About 60 years later, the 
natural PAH cofactor tetrahydrobiopterin (BH4) was shown to act as a pharmacological 
chaperone stabilising the misfolded PAH protein. In consequence, BH4 (KUVAN
®) was 
introduced to the pharmaceutical market as an alternative treatment for BH4-responsive 
PAH deficiency. Therefore, PKU is also regarded as a prototype for a pharmacologically 
treatable protein misfolding disease. 
Despite the progress in PKU therapy, knowledge on the molecular basis of PKU and the 
BH4 mode of action was still incomplete. Biochemical and biophysical characterisation of 
purified variant PAH proteins, which were derived from patient’s mutations, aimed at a 
better understanding of the molecular mechanisms of PAH loss of function. We showed 
that local side-chain replacements induce global conformational changes with negative 
impact on molecular motions that are essential for physiological enzyme function. The 
development of a continuous real-time fluorescence-based assay of PAH activity allowed 
for robust analysis of steady state kinetics and allosteric behaviour of recombinantly 
expressed PAH proteins. We identified positive cooperativity of the PAH enzyme towards 
BH4, where cooperativity does not rely on the presence of phenylalanine but is 
determined by activating conformational rearrangements. In vivo investigations on the 
mode-of-action of BH4 revealed differences in pharmacodynamics but not in 
pharmacokinetics between different strains of PAH-deficient mice (wild-type, Pahenu1/1 
and Pahenu1/2). These observations pointed to a significant impact of the genotype on 
responsiveness to BH4.  
The available database information on PAH function associated with PAH mutations was 
based on non-standardised enzyme activity assays performed in different cellular 
systems and under different conditions usually focusing on single PAH mutations. These 
inconsistent data on PAH enzyme activity hindered robust prediction of the patient’s 
phenotype. Furthermore, assays on single PAH mutations do not reflect the high allelic 
and phenotypic heterogeneity of PKU with 89 % of patients being compound 
heterozygotes. In addition, the knowledge on enzyme function and regulation in the 
therapeutic and pathologic metabolic context was still scarce. In order to get more 
insight into the interplay of the PAH genotype, the phenylalanine concentration and BH4 
treatment, we performed functional analyses of both, single, purified PAH variants as 
well as PAH full genotypes in the physiological, pathological and therapeutic context. 
The analysis of PAH activity as a function of phenylalanine and BH4 concentrations 
enabled determination of the optimal working ranges of the enzyme and visualisation of 
differences in the regulation of PAH activity by BH4 and phenylalanine depending on the 
underlying genotype. Moreover, these PAH activity landscapes allowed for setting rules 
for dietary regimens and pharmacological treatment based on the genotype of the 
patient.  
Taken together, precise knowledge on the mechanism of the misfolding-induced loss of 
function in PAH deficiency enabled a better understanding of the molecular mode of 
action of pharmacological rescue of enzyme function by BH4. We implemented the 
combination of genotype-specific functional analyses together with biochemical, clinical 
and therapeutic data of individual patients as a powerful tool for phenotype prediction 
and paved the way for personalised medicine strategies in phenylketonuria. 
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1. INTRODUCTION 
1.1. Phenylketonuria (PKU)  
Phenylketonuria (PKU, OMIM 261600), an inborn error of phenylalanine metabolism, is 
a complex trait inherited in an autosomal recessive manner. The disorder is associated 
with a primary deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH, 
phenylalanine 4-monooxygenase, EC 1.14.16.1) due to mutations in the PAH gene 
(GenBank: AF404777) (Scriver, 2007; Williams et al., 2008; Blau et al., 2010c; Mitchell et 
al., 2011). The impaired catabolic disposal of phenylalanine caused by a complete or 
near-complete loss of PAH function results in an accumulation of toxic levels of the 
amino acid phenylalanine in body fluids and, as a consequence, leads to irreversible, 
profound mental disability (Mitchell et al., 2011). A large number of PAH mutations (663 
[public total] from www.hgmd.org) in combination with a high degree of compound 
heterozygosity (89 % of all PKU patients) (Zurflüh et al., 2008) and a wide variability in 
distribution of common mutations between ethnic groups and geographical areas make 
phenylketonuria a genetic disorder with marked allelic and phenotypic heterogeneity. In 
addition, the genotype-phenotype correlation is weak. These specific features of PKU 
challenge the therapy of affected individuals and emphasise the necessity for 
implementation of individualised treatment options. 
Epidemiology  
Phenylketonuria is the most prevalent disorder of amino acid metabolism, its occurrence 
varies widely around the world. In the USA, the PKU prevalence is estimated as 1:15 000 
live births while in Latin America it is lower and ranges from 1:25 000 to 1:50 000 (Blau 
et al., 2010c; Blau, 2013). In Asia, the prevalence is heterogeneous (1:15 000 – 1:100 500 
in China; lower than 1:200 000 in Thailand; 1:70 000 in Japan) (Williams et al., 2008; 
Blau et al., 2010c). The overall incidence of PKU in Caucasians is estimated as 1:10 000 
live births. However, this number again varies among different European populations. A 
high number of incidents in Europe is usually linked to a high degree of consanguinity 
(e.g. Turkey, 1:2 600 - 1:4 000) whereas in other European countries the PKU 
occurrence is lower (e.g. Germany 1:8 000; Finland 1:100 000 – 1:200 000) (Blau et al., 
2010c; Mitchell et al., 2011). An especially high prevalence of mild clinical phenotypes 
has been reported for the Spanish population (Blau et al., 2010c). Africa is known to 
have a low rate of PKU incidents (Blau et al., 2010c). 
Clinical presentation  
Untreated PKU results in a severe cognitive phenotype with irreversible mental 
disability. The clinical picture comprises a ‘musty odor’ to the baby’s sweat and urine 
due to the accumulation of phenylacetate in the body, high levels of phenylalanine in 
blood and body fluids (HPA), growth failure, severe mental retardation, seizures, 
microcephaly, EEG abnormalities, ataxia, demyelination, eczema, and albinism (fair skin, 
fair hair, blue eyes) (Williams et al., 2008; Blau et al., 2010c; Feillet et al., 2010; 
Somaraju and Merrin, 2010; van Spronsen, 2010; Mitchell et al., 2011; Blau et al., 2014). 
The progressive developmental delay may be accompanied by behavioural problems 
including self-harm, aggression, impulsiveness and psychosis (Blau et al., 2014). Autism 
and attention deficit hyperactivity (ADHD) are frequent (Blau et al., 2010c; Feillet et al., 
2010). Due to the introduction of newborn screening programs, nowadays, symptomatic 
PKU is rarely observed in developing countries (Mitchell et al., 2011). However, even in 
treated PKU adults, reduced emotional wellbeing, depression, social isolation and low 
self-esteem have been reported (Blau et al., 2010c). 
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PKU pathogenesis 
Although PAH mutations disrupt phenylalanine homeostasis in the liver, the clinical 
effect is almost completely restricted to the brain (Williams et al., 2008; Blau et al., 
2014). However, the aetiology of cognitive problems and anomalies in brain 
development still remain unclear. Yet, some mechanisms explaining the pathological 
changes have been proposed. First, increased concentrations of phenylalanine in blood 
have a competitive inhibitory effect on the transport of other amino acids (e.g. large 
neutral amino acids, LNAA) through the blood-brain barrier. This leads to disturbed 
synthesis of intracerebral proteins and alter myelin metabolism (Williams et al., 2008; 
van Spronsen et al., 2009; Anderson and Leuzzi, 2010; Blau et al., 2014). In addition, 
reduced levels of other crucial amino acids such as tyrosine, tryptophan and methionine 
severely impair the correct synthesis of neurotransmitters (dopamine, noradrenalin, 
serotonin) resulting in behavioural problems and motor deficits (Muntau et al., 2000; 
Feillet et al., 2010). Moreover, high levels of phenylalanine in brain are believed to affect 
the activity of key enzymes such as pyruvate kinase, tyrosine hydroxylase, tryptophan 
hydroxylase and HMG-CoA reductase (van Spronsen et al., 2009; Blau et al., 2014). 
Diagnostics and differential diagnosis 
Due to the severity of untreated PKU, infants benefit from presymptomatic screening and 
early treatment that prevents neurological damage. In developed countries PKU is 
identified soon after birth by national neonatal screening programs. Blood samples 
(dried blood spots) are usually collected between the age of 1 and 7 days of life and the 
concentration of blood phenylalanine is measured using tandem mass spectrometry. 
Hyperphenylalaninemia (HPA, >120 µmol phenylalanine/l) accompanied by normal or 
reduced tyrosine concentrations (Phe/Tyr ratio >2) and normal concentrations of the 
remaining amino acids point to impairment of PAH function (Blau et al., 2010c; Blau et 
al., 2011). However, once HPA has been identified in the initial screen, additional testing 
must be performed in order to establish the definite basis of HPA. In 2-3 % of all cases 
elevated blood phenylalanine concentrations do not result from primary PAH deficiency 
but are caused by defects in genes involved in BH4 metabolism that cause secondary 
PAH deficiency (BH4-deficient HPA, OMIM 264070) (Blau et al., 2010c; Blau et al., 2011; 
Mitchell et al., 2011). These are ruled out by analysis of pterins in the urine and 
determination of dihydropteridine reductase activity (DHPR) in erythrocytes. In the case 
of pathological results neurotransmitter metabolite concentrations in cerebrospinal fluid 
have to be assessed to specifically dissect the defect in biopterin metabolism (Mitchell et 
al., 2011; Blau et al., 2011). In addition, it has to be taken into consideration that 
elevated blood phenylalanine levels in the newborn may be also caused by liver 
dysfunction or other inborn errors of metabolism involving the liver such as 
galactosemia (OMIM 230400). The precise identification of the underlying genetic cause 
of HPA is of utmost relevance since the treatment of the affected individuals strongly 
differs depending on the genetic background. In the case of confirmed HPA due to PAH 
deficiency, molecular genetic analysis of the PAH gene can be performed but it is not a 
prerequisite for the implementation of a low-phenylalanine diet (Blau et al., 2010c; Blau 
et al., 2011; Blau et al., 2014). PKU patients need regular monitoring as their therapy 
needs modification according to age and metabolic requirements.  
 Historical background and scientific breakthroughs in PKU 1.1.1
Phenylketonuria is the prototype of an inborn error of amino acid metabolism where 
metabolic abnormalities were shown to have severe neurological effects and that 
exemplified how treatment can dramatically affect the clinical manifestation of a genetic 
disease (Williams et al., 2008; Blau et al., 2010c). In addition, the history of PKU is an 
excellent example of how continuous efforts towards a deeper and broader 
understanding of the underlying molecular mechanisms may improve treatment and 
outcome for patients (Blau et al., 2014). The milestones and breakthroughs in the history 
of phenylketonuria are as follows: 
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 1934 - first description of PKU by the Norwegian physician Absjørn Følling. 
Følling examined two mentally retarded children and performed a detailed 
chemical analysis of their urine samples including organic extraction and 
purification of chemical compounds (Blau et al., 2014). He linked the presence of 
one of the substances in the urine (phenylpyruvic acid) to the intellectual 
impairment of his patients and proposed the name ‘imbecillitas phenylpyruvica’ 
to describe the relation between the observed phenotype and excreted substance 
(Christ, 2003). 
 1935 - 1937 - Lionel Penrose introduced the name ‘phenylketonuria’ (Penrose, 
1935; Penrose and Quastel, 1937). 
 1953 - George Jervis identified the inability to convert phenylalanine to tyrosine 
as a cause of phenylketonuria. This led to the recognition of PKU as a disorder 
with underlying enzyme deficiency (Jervis, 1953). 
 1953 - Horst Bickel developed the first phenylalanine-free protein substitute and 
introduced the low phenylalanine diet as a treatment option to ameliorate HPA in 
PKU patients and to potentially prevent mental retardation in the affected 
individuals (Bickel et al., 1953). Since then, the phenylalanine-restricted diet 
became a standard treatment with greatest benefits if introduced in the newborn 
period. 
 1957 – Willard Centerwall developed the so-called ‘diaper test’ as a first 
screening method for PKU where the addition of ferric chloride to the wet diaper 
of PKU babies made the urine turn green. However, the test could only be 
performed at 5-6 weeks of age allowing enough time for phenylpyruvic acid to 
build up. This was too late to prevent the irreversible damage in the first 6 weeks 
of life (Centerwall, 1957; Centerwall et al., 1960). 
 1958 – 1963 - Robert Guthrie developed a simple and inexpensive screening test 
using dried blood spots on filter cards. This allowed for early diagnosis, treatment 
and prevention of neurological damage in PKU (Guthrie and Susi, 1963). 
 1957 – Seymour Kaufman discovered the PAH enzyme (Kaufman, 1957). 
 1958 - 1963 – Seymour Kaufman discovered the PAH natural cofactor 
tetrahydrobiopterin (BH4) (Kaufman, 1958; Kaufman, 1963). 
 1982 – Savio Woo cloned the human phenylalanine hydroxylase gene (PAH, 
GenBank cDNA sequence U49897.1) (Woo et al., 1983). 
 1988 - 1993 – introduction of PKU mouse models (Bode et al., 1988; McDonald et 
al., 1990; Shedlovsky et al., 1993; McDonald, 1994). 
 1996 – Ray Stevens determined the first composite three-dimensional (3D) 
structure of the PAH enzyme (Erlandsen et al., 1997b; Erlandsen et al., 1997a). 
 1990s – Charles Scriver and colleagues founded the first online database 
gathering information on PAH gene, mutations, polymorphisms, genotypes and 
published in vitro studies on the PAH protein (www.pahdb.mcgill.ca) (Hoang et 
al., 1996). 
 1999 – Kure observed that pharmacological doses of BH4 reduced blood 
phenylalanine concentrations in 4 patients with PAH deficiency (Kure et al., 
1999).  
 2002 – Muntau showed in a clinical study that BH4 reduces blood phenylalanine 
concentrations, rescues in vivo PAH enzyme activity and increases dietary 
phenylalanine tolerance in the majority of PAH-deficient patients with residual 
enzyme activity. Therefore, pharmacological treatment with BH4 was proposed as 
an alternative to the phenylalanine-restricted diet. A new PKU phenotype 
emerged: BH4-responsive PAH deficiency (Muntau et al., 2002). 
 2005 – Phase I clinical studies (PKU-005) on sapropterin dihydrochloride tablets 
(the synthetic form of BH4) were initiated in accordance with the ICH E6 
guideline on Good Clinical Practice (EMA. CHMP Assessment Report for Kuvan, 
2008). 
 2007 – 2008 – KUVAN® (active substance: sapropterin dihydrochloride, 6R-BH4 
stereoisomer) was approved by the FDA and the EMA as an orphan drug to treat 
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patients with BH4-responsive PAH deficiency (Levy et al., 2007; Feillet et al., 
2008; Lee et al., 2008; Trefz et al., 2009a). 
 Classification 1.1.2
A classification of the severity of the disease is needed for predicting the putative course 
of the disease and to assist the patient with optimal treatment options. Establishing a 
reliable clinical and biochemical classification is easier in diseases where biological 
markers are known. However, in many cases, classification procedures may be associate 
with pitfalls and have to be carried out due diligence, especially when a biomarker is 
associated with different diseases and/or phenotypes. 
PKU classification 
In PKU, blood phenylalanine concentrations in untreated individuals serve as biological 
marker and therefore PKU classification was, for a long time, mainly based on the 
degree of blood phenylalanine elevation. Although accepted worldwide, this 
classification is not fully accurate. This is due to the fact that phenylalanine 
concentrations are usually measured in newborns (samples are collected between first 
and seventh day of life) at the time when phenylalanine concentrations may not yet have 
reached highest values. Additional factors that may affect phenylalanine read-outs are 
neonatal catabolism, the diet received at the time of blood sampling and the time when 
the newborn was delivered since preterm babies do not have fully developed metabolic 
pathways (Blau, 2006; Blau et al., 2011; Blau et al., 2014). Therefore, to improve PKU 
classification of biochemical severity, daily phenylalanine tolerance has been established 
as an additional, stable parameter (Blau et al., 2011). It describes the daily dietary 
phenylalanine intake, which is tolerated by the organism without leading to increased 
blood phenylalanine levels. It is of particular importance to determine the phenylalanine 
tolerance under well-standardised conditions using very precise dietary protocols (Blau 
et al., 2011). PKU classification based on the two parameters, pretreatment blood 
phenylalanine concentration and dietary phenylalanine tolerance, is summarised in 
Table 1. 
 
Table 1. Classification of the primary hyperphenylalaninemias. 
 Blood phenylalanine values before treatment Dietary phenylalanine tolerance 
Classical PKU/Type I > 20 mg/dl (> 1200 µmol/l) < 20 mg/kg/day 
Mild PKU/Type II > 10 mg/dl (> 600 µmol/l) 20-50 mg/kg/day 
Persistent HPA/Type III < 10 mg/dl (< 600 µmol/l) > 50 mg/kg/day 
Atypical PKU 2.5 - 20 mg/dl 
(150 - 1200 µmol/l) 
variable 
Healthy individual 50-120 µmol/l not restricted 
The table was adapted from Muntau et al., 2000; Blau et al., 2010c; Blau et al., 2011; Mitchell et al., 2011 
 
An additional parameter, which proved to be clinically useful for discrimination between 
the mild and severe forms of PKU is the phenylalanine to tyrosine (Phe/Tyr) ratio 
(Eastman et al., 2000; Zytkovicz et al., 2001; Ceglarek et al., 2002; Blau, 2006; Contreras 
et al., 2015). It was shown that this parameter may improve the specificity and the 
positive predictive value for the diagnosis of severe PKU and reduce the number of false 
positives (Chace et al., 1998; Ceglarek et al., 2002). Due to that fact the Phe/Tyr ratio was 
successfully introduced by the New England Newborn Screening Program (Zytkovicz et 
al., 2001) where patients presenting the mean value of the Phe/Tyr ratio of ≥ 5 
accompanied by mean phenylalanine levels of 477 µmol/l or greater were considered as 
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severe classical PKU whereas patients with mean values of Phe/Tyr ratio of ≥ 1.5 and 
mean phenylalanine values of 215 µmol/l were classified as having mild forms of PKU. 
Although the clinical relevance of the Phe/Tyr ratio as a routine biomarker still needs 
further evaluation (Singh et al., 2014), recent recommendations for diagnostic testing 
propose quantification and evaluation of phenylalanine level, Phe/Tyr ratio and the 
complete amino acid profile (Vockley et al., 2014). 
All in all, there is a constant need to improve the current classification in order to better 
capture intricacies of the PKU trait. In particular, classification of PKU on the basis of 
blood phenylalanine levels does not account for the phenotype of BH4-responsive PAH 
deficiency. 
PKU phenotypes 
PAH-deficient phenotypes vary from a mild form with a slight increase in blood 
phenylalanine levels to a classic phenotype with pronounced HPA.  
Classical PKU is the most severe form of PAH deficiency associated with highly elevated 
blood phenylalanine concentrations (>1200 µmol/l), very low daily tolerance of the 
dietary phenylalanine intake (< 250 mg) and markedly reduced activity of the PAH 
enzyme. Patients presenting with classical PKU require strict dietary management in 
order to keep their plasma phenylalanine concentrations at a safe level. Within this 
group, if untreated, individuals develop profound and irreversible intellectual disability 
(Mitchell et al., 2011).  
Patients classified as mild PKU show blood phenylalanine levels between 600 and 1200 
µmol/l and a higher daily phenylalanine tolerance (250 - 400 mg per day). Most of them 
are functional hemizygotes with one severe and one mild mutation. In mild PKU, a 
phenylalanine-restricted diet is needed to keep phenylalanine values in the physiological 
range.  
The group of patients with persistent HPA with blood phenylalanine concentrations 
below 600 µmol/l under normal diet is often considered not to be in need of special 
dietary regimens. However, this is a matter of debate between experts and it is important 
to note that the untreated females with persistent HPA can experience maternal 
phenylketonuria with severe embryofetopathy (Mitchell et al., 2011). 
BH4-responsive PAH deficiency emerged as a new phenotype in PKU. An initial study 
on 4 Japanese patients with PAH deficiency (Kure et al., 1999) reported that the 
administration of 5-10 mg/kg body weight of BH4 in the course of a BH4 loading test 
reduced plasma phenylalanine concentrations. This phenomenon was later confirmed by 
different metabolic centres (Lindner et al., 2001; Spaapen et al., 2001; Steinfeld et al., 
2002), a retrospective study on BH4 loading tests (Bernegger and Blau, 2002) and a 
clinical study involving a large cohort of PKU patients (Muntau et al., 2002) and it was 
recognised that pharmacological doses of BH4 can significantly reduce or normalise 
blood phenylalanine levels in PAH-deficient patients. BH4 responsiveness is ascertained 
with BH4 loading tests (see chapter 1.4.2) and a widely accepted cut-off allowing for 
classification of the patient as BH4-responsive is described as at least 30 % reduction in 
blood phenylalanine concentration after administration of BH4 (Muntau et al., 2002). The 
response to pharmacological treatment depends on the blood phenylalanine level and 
the frequency of BH4 responsiveness is highest in mild HPA and mild PKU where 
patients present some residual PAH enzyme function (Bernegger and Blau, 2002; 
Muntau et al., 2002; Spaapen and Rubio-Gozalbo, 2003; Fiege and Blau, 2007; 
Dobrowolski et al., 2011). Although a number of PAH mutations have been identified to 
be frequently associated with response to BH4 treatment (Blau and Erlandsen, 2004; 
Zurflüh et al., 2008; Dobrowolski et al., 2011), PAH genotyping is still not sufficient to 
reliably predict responsiveness as other modifying factors, e.g. interallelic 
complementation may modulate the response (Dipple and McCabe, 2000; Spaapen and 
Rubio-Gozalbo, 2003; Leandro et al., 2006; Trefz et al., 2009b). Taken together, the 
discovery of BH4-responsive individuals among PKU patients led to a new treatment 
option that became accessible after approval of the BH4 compound. Nevertheless, it has 
to be kept in mind that depending on the genetic background of the analysed population 
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only a subset of about 10 % to 62 % of all patients (Bernegger and Blau, 2002; Muntau 
et al., 2002; Lindner et al., 2003; Desviat et al., 2004; Matalon et al., 2005; Mitchell et al., 
2005; Zurflüh et al., 2006; Zurflüh et al., 2008; Dobrowolski et al., 2009; Karacić  et al., 
2009; Muntau and Gersting, 2010; Bélanger-Quintana et al., 2011; Keil et al., 2013) 
benefit from the new drug and that patients with severe clinical phenotypes are in 
general not BH4-responsive. From a clinical point of view, the clear identification and 
selection of BH4-responsive patients is still challenging mainly due to a weak genotype-
phenotype correlation. Appropriate testing comprises newborn screening and PAH 
genotyping, short-term BH4 loading tests and long-term BH4 treatment tests (Blau et al., 
2009; Blau et al., 2010c) (see chapter 1.4.2). 
 
Atypical PKU describes a rare situation (2-3 % of all HPA incidents) where elevated 
levels of blood phenylalanine are due to BH4 deficiency. Defects in BH4 metabolism 
(synthesis and recycling) show more severe progression than PAH deficiency. Moreover, 
treatment is substantially different. BH4-deficient patients do not respond to low 
phenylalanine diet alone. Instead, only early supplementation with precursors of 
dopamine, serotonin and BH4 is effective (Blau et al., 2010c; Blau et al., 2011; Opladen et 
al., 2012). This underscores how important it is to always consider the differential 
diagnosis once HPA is confirmed. 
 Treatment options 1.1.3
The primary goal of PKU treatment is to achieve the best-possible neurocognitive and 
psychosocial development of the infant. To this end, the treatment should be introduced 
soon after birth and, if possible, continued throughout life according to international 
guidelines (Vockley et al., 2014). The treatment aims to maintain blood phenylalanine 
concentrations within the recommended range of 120 to 360 µmol/l, although those 
values vary between clinics and countries and are also dependent on the age of the 
patient (Blau, 2010a; Mitchell et al., 2011; Blau et al., 2014; Longo et al., 2014; Vockley 
et al., 2014;). 
Low-phenylalanine diet  
Dietary restriction of phenylalanine was introduced in 1953 by Horst Bickel (Bickel et al., 
1953) and since then it has been a mainstay in PKU treatment. The diet is introduced 
immediately after PAH deficiency has been confirmed and is sufficient to protect the 
developing nervous system from toxic effects of HPA allowing for a near-normal 
cognitive development of the infant. The diet is designed in such a way that it allows to 
lower blood phenylalanine concentrations but at the same time provides sufficient 
amounts of tyrosine and nutrients required for normal growth and development of the 
patient (Somaraju and Merrin, 2010). All high protein food such as meat, fish, eggs, 
standard bread and most cheese as well as children’s favourites such as chocolate and 
wine gums have to be excluded from the diet. Some low-protein fruit and vegetables are 
allowed in restricted amounts. Since this regime would not provide sufficient protein 
amount for normal growth, supplements of phenylalanine-free amino acids have to be 
taken on a daily basis (Williams et al., 2008; Blau et al., 2010c; van Spronsen, 2010). The 
diet has to be tailored to each individual taking into consideration the daily 
phenylalanine tolerance, age, growth and activity. Marked fluctuations in phenylalanine 
levels should be avoided and therefore the diet has to be accompanied by regular and 
frequent measurements of phenylalanine values. In general, phenylalanine 
concentrations of 40 – 360 µmol/l are regarded as safe (Blau et al., 2010c; Mitchell et al., 
2011).   
Nowadays, experts recommend a life-long low phenylalanine diet (Phenylketonuria, 
1993; National Institutes of Health Consensus Development, 2001; Williams et al., 2008; 
Mitchell et al., 2011; Vockley et al., 2014). However, strict dietary management is 
particularly important in early life since a significant inverse correlation between 
phenylalanine values and IQ has been reported in children up to 12 years where each 
   INTRODUCTION 
 7 
100 µmol/l increase in mean blood phenylalanine concentration was predicted to result 
in 1.3 - 3.1 point reduction in IQ (Waisbren et al., 2007; Feillet et al., 2010; Mitchell et 
al., 2011). On the other hand, late diagnosed young children showed marked and rapid 
benefit from dietary treatment although most of them retain a clearly observed degree of 
intellectual disability and almost all display significant learning problems (Blau et al., 
2014). In adulthood some relaxation of the diet is possible, however, there is no 
consensus to which extent the diet can be omitted and therefore adult patients require 
an individual management (Feillet et al., 2010). Adherence to the phenylalanine-
restricted diet is especially important for women who plan a pregnancy since high 
phenylalanine levels are teratogenic and are often associated with an increased risk for a 
miscarriage (Williams et al., 2008; Mitchell et al., 2011; Waisbren et al., 2015). In 
addition, maternal phenylalanine concentrations around 900 µmol/l lead to mental 
disability, microcephaly and congenital heart disease in the offspring and values of 
around 360 µmol/l may still result in reduced cognitive ability and facial dysmorphisms 
(Blau et al., 2010c). Thus, a strict dietary treatment has to be introduced before 
conception and continued during the pregnancy. Moreover, during pregnancy PAH-
deficient women should undergo continuous nutritional guidance in order to ensure an 
adequate energy intake and normal weight gain and at the same time maintain low 
plasma phenylalanine concentrations. 
Although PKU patients clearly benefit from dietary treatment, the long-term adherence 
to the diet is poor since, at first sight easy to handle, the dietary regime is burdensome 
and associated with social repercussions. During infancy the adherence to the diet is in 
general good, mostly due to parents control. However, as children get older and are not 
allowed to choose their food randomly as their peers normally would, adherence to the 
diet deteriorates. In addition, the difficulties linked to the dietary regime, the unpleasant 
taste of amino-acids supplements, psychosocial and emotional factors, and lack of 
reimbursement for low-protein special foods result in a poor compliance (Blau et al., 
2009; Blau et al., 2010c; Blau, 2013). In consequence, by late adolescence and 
adulthood, at least 75 % of PKU patients do not adhere to the dietary treatment (Koch et 
al., 2002; Walter et al., 2002; Somaraju and Merrin, 2010; Mitchell et al., 2011). The 
discontinuation of dietary management in adolescence is not life-threatening. However, 
it leads to subtle but measurable deficits in neuropsychological functioning during adult 
life including reduced attention span, slow motor reaction time, slow information-
processing abilities, increased muscle tone, low bone mineral content (Mitchell et al., 
2011). 
BH4 treatment 
For a detailed description of BH4 treatment refer to chapter 1.4.2. 
 
Apart from diet and BH4 treatment, there are other alternative forms of therapy, which 
are under investigation and/or in clinical trials. These include transplantation of isolated 
liver cells, orthotopic liver transplantation, enzyme replacement therapy, the use of 
glycomacropeptides or large neutral amino acids (LNAA) supplementation. 
Enzyme replacement therapy  
The main goal of PAH enzyme replacement therapy is to efficiently deliver the whole 
functional enzyme into the organism. Since the purification of recombinantly expressed 
human PAH in a large scale is difficult due to its instability, complex activity and BH4 
requirement, there was a need for an alternative. PAL (phenylalanine ammonia lyase; EC 
4.3.1.5) is a non-mammalian enzyme that converts phenylalanine to two non-toxic 
metabolites: ammonia and trans-cinnamic acid and it does not require a cofactor for its 
full function (Mitchell et al., 2011; Bélanger-Quintana et al., 2011). The original PAL 
gene from Anabaena varabilis was genetically modified, recombinantly expressed in E. 
coli and subsequently modified with polyethylene glycol (PEG) to reduce immunogeneity 
(Gamez et al., 2007; Sarkissian et al., 2008). This procedure resulted in the so-called 
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rAvPAL-PEG. Preclinical studies have shown promising results using PAL in the PKU 
mouse model (Sarkissian et al., 2008; Sarkissian et al., 2011) with decreasing blood 
phenylalanine levels followed by alleviation of the PKU phenotype. An additional 
improvement came with the development of the oral form of PEGylated PAL (Kang et al., 
2010). Recently, first-in-human trials were performed on a group of 25 adult classical 
PKU patients in order to investigate the safety, tolerability and efficacy of a single-dose 
rAvPAL-PEG (Longo et al., 2014; van Spronsen and Derks, 2014). The drug was shown to 
be overall well tolerable and significantly reduced phenylalanine blood concentrations at 
a dose of 0.1 mg/kg body weight. Only minor adverse effects were reported such as 
injection-site bruising, rash, pain, swelling or muscle spasms. However, still additional 
studies are needed to in-depth analyse the observed immunological response and the 
appearance of anti-PEG antibodies as this might be the limiting factor for the 
implementation of repeated administrations of the rAvPAL-PEG. 
Gene therapy approaches  
Gene therapy for PKU has been so far studied only in orthologous mouse models. The 
trials using an adeno-associated virus vector directed to the liver led to a correction of 
hyperphenylalaninemia without side effects for up to one year (Oh et al., 2004; Ding et 
al., 2006; Harding et al., 2006). In addition, the study of Rebuffat et al., 2010 has shown 
that intramuscular injection of PAH gene vectors in Pah-deficient mice resulted in 
restoration of hepatic PAH activity. However, in order to introduce this treatment into 
clinical routine, there is still a need to optimise gene delivery and safety of the gene 
therapy (Brunetti-Pierri, 2008; Suda et al., 2009). Recently, the transplantation of liver 
cells with fully active PAH enzyme emerged as a potential alternative approach (Blau et 
al., 2010c). 
Large neutral aminoacids (LNAA) 
Phenylalanine is known to compete with LNAA for transport across the blood-brain 
barrier. The supplementation with LNAA showed to reduce phenylalanine uptake into 
the brain despite consistently high blood phenylalanine levels (Pietz et al., 1999; Moats 
et al., 2003). On the other hand, since a similar transporter for LNAA exists in the 
intestine, the supplementation with a special mixture of amino acids and LNAA was 
shown to decrease blood phenylalanine concentrations by 39 % and had a beneficial 
effect on executive function (Matalon et al., 2006; Matalon et al., 2007). Therefore, in 
future, this treatment option may be used to help to protect brain from toxic effects of 
phenylalanine, improve the concentration level in nonadherent adults and potentially 
allow for diet relaxation. 
1.2. Human phenylalanine hydroxylase (PAH)  
Phenylalanine hydroxylase is a cytosolic enzyme mainly expressed in the liver (0.1 -0.3 
% of total liver protein) (Blau, 2006). Lower but still significant amounts of the PAH 
enzyme are expressed in human kidneys and, to a much lower extent, in the pancreas. 
Expression of the enzyme in the human brain was postulated but has still not been 
proven (Blau, 2006; Donlon et al., 2008).  
PAH belongs to the family of biopterin-dependent aromatic amino acid hydroxylases 
including tryptophan hydroxylase (TPH; EC 1.14.16.4) and tyrosine hydroxylase (TH; EC 
1.14.16.2). The aromatic amino acid hydroxylases show a high degree of sequence 
similarity (approximately 65 % sequence identity and 80 % sequence homology of the 
catalytic domains) and are structurally and functionally related enzymes. PAH, TPH and 
TH catalyse rate-limiting steps in neurotransmitter synthesis pathways and depend on a 
non-heme iron atom and the cofactor, BH4 (Flatmark and Stevens, 1999). 
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1.2.1 The PAH gene  
The human phenylalanine hydroxylase locus (PAH; GeneBank accession number 
AF404777 and cDNA Reference Sequence No. U49897.1) maps to chromosome 12 (band 
region 12q23.21) (Lidsky et al., 1985). The PAH gene consists of 13 exons (that 
constitute less than 3 % of the genomic PAH sequence) and 12 introns (Woo et al., 
1983). The shortest exon is 57 bp long (exon 9), while exon 13 is the longest one and 
spans over 892 bp. The shortest and the longest introns comprise 556 bp (intron 10) and 
17 874 bp (intron 2), respectively. The genomic PAH sequence is rich in GC regions 
(40.7 %) and this content is slightly above the mean value for human genes (37 – 38 %) 
(Donlon et al., 2008). 
To date, a total of 663 mutations have been identified in the PAH gene 
(www.hgmd.cf.ac.uk: data taken from public total, accession date 3rd April 2015) and 
this number is still increasing. The vast majority of these mutations are missense 
(approximately 62 %) followed by splice variants (14 %), small deletions (11 %), and 
nonsense mutations (5 %). Small insertions, small indels, gross deletions, gross 
insertions/duplications and complex rearrangements together account for about 8 % of 
all PAH mutations (combined data from www.pahdb.mcgill.ca and www.hgmd.cf.ac.uk 
and Blau et al., 2014). PAH mutations are spread throughout the whole gene sequence, 
however, the highest frequency of mutations was found in exon 7 (Bjørgo et al., 1998) as 
well as in exons 6 and 11 (Blau et al., 2014). Most of the mutations map to the catalytic 
domain (61.2 %), followed by the regulatory (16.8 %) and oligomerisation (5.2 %) 
domains (Blau et al., 2014). 
Interestingly, although hundreds of mutations have been reported and the occurrence of 
the mutations depends on the ethnic background of a certain population, only few alleles 
are relatively common and account for the majority of disease-causing PAH mutations 
while the rest of the mutations is rare (Donlon et al., 2008). Previously, 29 mutations 
have been identified as being frequent in the European population (Zschocke, 2003).  
1.2.2 The PAH protein structure 
The mammalian PAH monomer consists of 452 amino acids, shows a molecular weight 
of 52 kDa and structurally consists of three domains (Figure 1).  
 
 
Figure 1. Cartoon-view of the crystal structure of a PAH monomer. The N-terminal domain is marked in 
dark blue, the catalytic domain is shown in dark green while the C-terminal domain is shown in magenta.  
 
The N-terminal regulatory domain (residues 1-142) includes a short intrinsic 
autoregulatory sequence (IARS, residues 1 – 33, Kobe et al., 1999) as well as a 
phosphorylation site at Ser16 (Pey et al., 2004b; Flydal and Martinez, 2013). The IARS 
extends across the active site of the catalytic domain (Kobe et al., 1999) thus restricting 
the access of the substrate and the cofactor to the active site (Flydal and Martinez, 2013). 
In addition, the 1,2-dihydroxypropyl side chain of the BH4 molecule interacts with the 
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backbone of Ser23 of the IARS domain. This interaction is crucial for inducing the 
conformational changes associated with the inhibitory regulatory effect of the BH4 
cofactor (Teigen and Martinez, 2003). The flexible regulatory domain is also important 
for other regulatory properties of the PAH enzyme such as the activation by the substrate 
phenylalanine. Yet, it is still not clear whether this domain possesses an allosteric 
binding site for phenylalanine (Fitzpatrick, 2012; Flydal and Martinez, 2013). 
Interestingly, the low sequence homology in this protein region among aromatic amino 
acids hydroxylases may explain differences in the regulatory properties between 
phenylalanine, tryptophan, and tyrosine hydroxylases (Blau, 2006; Fitzpatrick, 1999).  
 
The catalytic domain (residues 143-410) comprises the active site with binding sites for 
phenylalanine, BH4 and the ferrous iron atom (Erlandsen et al., 1998).  
 
The C-terminal oligomerisation domain (residues 411-452) comprises a dimerisation 
motif (411-424) and a tetramerisation motif (428-452), which is a 40 Å long helix 
responsible for assembling the PAH tetramer via hydrophobic coiled-coil interactions of 
four monomers (Flydal and Martinez, 2013). Therefore, the tetramerisation region is 
considered to be important for transferring the cooperative conformational changes from 
one dimer to the other (Fusetti et al., 1998).  
 
At physiological conditions, the PAH enzyme exists in a pH-dependent and substrate-
dependent equilibrium of homotetramers and homodimers (Martinez et al., 1995; 
Gjetting et al., 2001b; Gjetting et al., 2001a; Erlandsen et al., 2003) with the tetramer 
being a fully active, functional unit. The PAH tetramer is constructed as a ‘dimer of 
dimers’ where dimers are assembled asymmetrically through C-terminal tetramerisation 
motifs (Figure 2).  
 
Figure 2. The 3D structure of the human PAH tetramer. Four PAH monomers are assembled 
asymmetrically through the C-terminal coiled-coil motifs. The 3D model was created using unpublished data 
obtained from crystallisation of the full-length human PAH by our research group in collaboration with 
Professor Patrick Cramer. 
 
To date, only composite models of tetrameric PAH are available. These are created using 
truncated structures of human and rat PAH apoenzyme as well as the structures obtained 
after crystallisation of the enzyme with inhibitors or substrate analogues (Erlandsen et 
al., 1998; Erlandsen et al., 2000; Andersen et al., 2001; Andersen et al., 2002; Andersen 
et al., 2003). In cooperation with the laboratory of Professor Patrick Cramer at the Gene 
Centre in Munich we recently solved the crystal structure of full-length human 
phenylalanine hydroxylase with a resolution of 4.6 Å. The analysis of this structure 
revealed new insights into behaviour and function of the enzyme. We observed a 
pronounced asymmetry between two dimer interfaces and a different orientation of the 
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tetramerisation motifs than previously reported. This structure also allowed for 
identifying the functional network of PAH mutations involved in BH4 responsiveness 
(unpublished data and personal communication S.W. Gersting). 
1.2.3 PAH function and catalytic activity (phenylalanine hydroxylating system) 
Phenylalanine hydroxylase catalyses the rate-limiting step in the catabolic pathway of 
the essential amino acid phenylalanine. Under physiological conditions almost 75 % of 
the dietary intake of phenylalanine is catabolised and hydroxylated to tyrosine (Scriver 
and Waters, 1999; Underhaug et al., 2012; Flydal and Martinez, 2013), whereas the 
remaining portion is used in anabolic processes of protein production. 
The hydroxylation reaction requires, besides the PAH enzyme, two additional substrates, 
dioxygen (O2) and the enzyme’s natural cofactor, BH4 ((6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin) as a physiological electron donor (Haavik et al., 1986; Kappock and 
Caradonna, 1996; Flatmark and Stevens, 1999; Fitzpatrick, 2012). During the reaction, a 
hydroxyl group is added to the phenyl group of phenylalanine forming tyrosine and at 
the same time BH4 is oxidised to dihydrobiopterin (BH2). In the next step, BH2 is 
regenerated to BH4 by dihydropteridin reductase (DHPR), whereas the product of the 
reaction, tyrosine, is used in the synthesis of neurotransmitters, melanin and thyroid 
hormones (Figure 3). 
The enzymatic activity of human PAH is tightly regulated in order to maintain the 
homeostasis between the degradation of excess phenylalanine and the preservation of a 
certain phenylalanine and tyrosine pool critical for anabolic processes (Flydal and 
Martinez, 2013; Pey, 2013). The specific regulation of mammalian PAH function is 
mediated by three main factors: concentrations of the phenylalanine substrate and the 
cofactor tetrahydrobiopterin and by phosphorylation at residue Ser16 (Fitzpatrick, 2012; 
Flydal and Martinez, 2013). The pronounced flexibility of the PAH quaternary structure 
through which the regulatory properties are exerted is an essential basis for PAH 
regulation (Flydal and Martinez, 2013). 
                            
 
Figure 3. Overview on the reaction catalysed by PAH. The reaction requires dioxygen and BH4 as electron 
donors. During the reaction, BH4 is oxidised to BH2, which is then regenerated to BH4. The product of the 
reaction, tyrosine, is a precursor of neurotransmitters (dopamine, adrenaline, noradrenaline) and hormones 
(triiodothyronine and thyroxine) as well as pigments (melanin).  
 
The substrate phenylalanine acts as a positive allosteric effector inducing in a positive 
cooperative manner the catalytically active form of PAH and increasing the specific 
activity of the enzyme by several fold (Martinez et al., 1995; Fitzpatrick, 2012). Both 
activation and cooperativity are related to gross conformational changes occurring in the 
PAH protein upon substrate binding (Kleppe et al., 1999; Fitzpatrick, 2012; unpublished 
data). These include the displacement of the autoregulatory sequence and a series of 
conformational changes leading to propagation of the activating process throughout the 
PAH tetramer (Thórólfsson et al., 2003). The current model explaining this allosteric 
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regulation via the substrate describes the transition of the PAH protein from a low active, 
tense conformation (t-state) to a more active and high-affinity relaxed form (r-state). This 
hypothesis is supported by experimental evidence obtained using dynamic light 
scattering and tryptophan scans (Thórólfsson et al., 2003; Kemsley et al., 2003; Stokka et 
al., 2004; Fitzpatrick, 2012; Flydal and Martinez, 2013). 
The cofactor BH4 acts as a negative effector that inhibits PAH function leading to a 
formation of an inactive dead-end PAH-BH4 complex and stabilisation of the t-state 
(Phillips et al., 1983; Kaufman, 1993; Thöny et al., 2000; Gersting et al., 2010a; 
Underhaug et al., 2012; Flydal and Martinez, 2013). The inhibitory regulatory effect of 
the BH4 cofactor is exerted by the interaction of the 1,2-dihydroxypropyl side-chain of 
the BH4 molecule with residue Ser23 in the IARS sequence of the N-terminal domain 
(Teigen and Martinez, 2003). This interaction triggers a series of changes in the 
hydrogen bonding network between residue Ser23, Glu21 and residue Tyr377 and, in 
consequence, leads to rearrangement of the N-terminal domain and the closure of the 
active site. The formation of a PAH-BH4 complex results in concordant decreased 
concentrations of both free BH4 and free PAH enzyme because concentrations of BH4 
and PAH subunits in the liver (8-9 µM) are approximately equimolar. In this case, 
phenylalanine simultaneously controls the availability of BH4 and the amount of active 
PAH by regulating the activation of PAH (Mitnaul and Shiman, 1995; Thöny et al., 2000). 
Accordingly, there are two significant pools of BH4 found in hepatocytes: metabolically 
active, free BH4 and the inactive form of the cofactor bound to the enzyme (Mitnaul and 
Shiman, 1995).  
The posttranslational PAH phosphorylation at Ser16 is mediated by cAMP and a 
Ca2+/calmodulin dependent protein kinase (Kaufman, 1993; Fitzpatrick, 2012) and it 
results in an increase of both, PAH activity and the apparent affinity for the substrate 
(Døskeland et al., 1996; Miranda et al., 2002). The phosphorylation rate was shown in 
vitro to be increased in the presence of the substrate and decreased in the presence of 
BH4 (Kaufman, 1993; Døskeland et al., 1996). Similarly to phenylalanine, 
phosphorylation leads to a rearrangement and reorientation of the regulatory domain 
opening the active site (Fitzpatrick, 2012). 
Taken together, all regulatory mechanisms of PAH activity are mediated by small 
molecule binding or phosphorylation and structurally exerted by a number of 
conformational changes within the protein subunits and subsequently in the PAH 
homotetramer. 
1.3. Mechanisms of loss of function in PAH deficiency  
PAH deficiency is due to mutations in the human PAH gene and, as described in chapter 
1.2.1, more than 663 variants have been reported so far (www.hgmd.cf.ac.uk: data taken 
from public total, accession date 3rd April 2015). Modification of the variant PAH protein 
function strongly depends on the nature of the DNA alteration. In the last years, 
missense mutation-induced protein misfolding was identified as one of the main 
molecular mechanisms causing loss of function of the PAH enzyme (Waters et al., 1998a; 
Waters et al., 1998b; Waters et al., 1999; Waters et al., 2000; Gamez et al., 2000; Pey et 
al., 2003; Gersting et al., 2008).  
1.3.1 Effects of nonsense and splicing mutations in the PAH gene 
Nonsense and splicing mutations can lead to various alterations of the DNA primary 
sequence including the introduction of a premature STOP codon, frameshifts as well as 
insertions or deletions of one or multiple nucleotides. In most cases, this has devastating 
consequences for the coded product leading to the formation of a truncated or 
incomplete and therefore non-functional protein.  
In PKU, splice and nonsense variants, deletions, insertions and indels account for about 
40 % of all PAH mutations listed in databases (Blau et al., 2014). In most cases, 
homozygosity for one of these mutations leads to a near-complete loss of enzyme 
function. Consequently, carriers of these mutations in the homozygous state generally 
   INTRODUCTION 
 13 
suffer from a severe PKU phenotype and mostly do not respond to pharmacological 
treatment with the cofactor BH4.  
1.3.2 Effects of missense mutations in the PAH gene 
In general, missense mutations lead to single amino acid substitutions in the translated 
polypeptide chain and they can induce diverse pathogenic processes that can disturb the 
protein on many different levels.  
Effects of missense PAH mutations on PAH catalytic and regulatory properties  
In vitro analyses of several PAH missense mutations revealed that amino acid 
substitution may alter kinetic properties of the mutant enzyme. This may result in 
decreased values of the enzyme’s maximum activity (Vmax), decreased affinity for the 
substrate ([S]0.5) and/or decreased affinity for the cofactor ([C]0.5) (Blau, 2006). PAH 
missense mutations that influence kinetic and regulatory parameters of the PAH protein 
are located not only in the active site (Asp143, Glu280, Pro281, Gly247) but also in 
positions distant from it (Arg252, Ala259, Val388, Arg408) (Kobe et al., 1999; Erlandsen 
and Stevens, 1999; Gersting et al., 2008).  
One of the PAH mutation affecting PAH kinetic parameters, rigorously studied in several 
in vitro systems, was p.Asp143Gly (Knappskog et al., 1996a; Erlandsen and Stevens, 
1999). The residue Asp143 is located at the entrance to the active site and therefore may 
control the access of the substrate and cofactor to the active core. Indeed, studies 
confirmed p.Asp143Gly being a pure kinetic variant with relatively high enzyme activity 
but strongly reduced affinities for substrate phenylalanine and cofactor BH4. In addition, 
unaffected PAH oligomerisation was reported for this PAH variant.  
Another PAH mutant, which was reported as a kinetic variant is p.Val388Met (Leandro et 
al., 2000). Studies showed reduced catalytic activity when expressed in the eukaryotic 
system. Moreover, data on purified variant PAH pointed to a strongly decreased affinity 
of the enzyme to the cofactor and to a lower extent to substrate phenylalanine. However, 
for this variant also accelerated protein degradation pointing to alterations of protein 
folding was reported (Gamez et al., 2000).  
Further evaluation of PAH variants suggested that mutations can abolish or significantly 
reduce phenylalanine-binding (Gjetting et al., 2001b) to the putative substrate binding 
site in the N-terminal domain (Hufton et al., 1995; Kappock and Caradonna, 1996; Kobe 
et al., 1999). In addition, many structural hypothesis exist suggesting missense 
mutation-induced conformational changes of the structure of the active site and changes 
in the electrostatic potential of the active site. Furthermore, it is also proposed that some 
of the PAH mutations (Tyr337, Arg252) can affect the interaction between Ser23 and 
Asp27 in the IARS sequence thus having an impact on the regulatory properties of the 
enzyme (Erlandsen and Stevens, 1999). 
Effects of missense PAH mutations on folding, assembly and thermodynamic stability 
of the protein 
Despite having a direct influence on catalytic properties of the enzyme, missense 
mutations can also have a major impact on structure and conformation of the affected 
protein. In addition, they can disturb protein interaction with proteins of the protein 
homeostasis network and thus disturb the homeostasis boundaries of the affected 
protein (Wiseman et al., 2007; Powers et al., 2009; Pey, 2013). As a consequence, the 
availability of properly folded and functional protein is reduced. This condition is 
referred to as a protein misfolding disease with loss of function, also known as a 
conformational disease. This particular molecular phenotype is often observed in inborn 
errors of metabolism such as PAH deficiency (Bross et al., 1999; Muntau et al., 2014). 
Under physiological conditions, each protein has a certain set of values of energetic 
parameters that allow for its proper folding and full activity e.g. thermodynamic stability 
and folding/misfolding/unfolding rates (Balch et al., 2008; Pey, 2013). In addition, to 
achieve its native state, each protein also has to interact with the so-called cellular 
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protein homeostasis network, which includes all factors responsible for correct protein 
synthesis, folding, trafficking and degradation such as molecular chaperones, native 
states ligands, heat shock proteins as well as unfolded protein response or antioxidant 
response (Powers et al., 2009). The components of the protein homeostasis network as 
well as their concentrations may vary depending on the cell type and cell function 
(Powers et al., 2009). Nevertheless, all elements of the protein homeostasis network have 
to work in a very complex and well-orchestrated manner allowing for preservation of the 
efficient function of the protein even under unfavourable conditions such as 
environmental stress or genetic factors (Pey, 2013). The folding energetics, which a 
protein must possess in order to fulfil its biological function, in the context of a given 
homeostasis network capacity in a certain cell is described as protein homeostasis 
boundaries (Powers et al., 2009; Pey, 2013). In this view, stress factors such as missense 
mutations may challenge protein folding by changing protein energetics or they may 
affect protein-protein interactions necessary for maintaining proper function of the 
protein. As a result, the affected protein is pushed outside of its homeostasis boundaries. 
In consequence, this leads to global destabilisation of the protein, reduced 
thermodynamic stability of the functional native state, a decreased rate of correct 
folding, an increased propensity to unfold, impaired assembly and degradation (Waters, 
2001; Powers et al., 2009; Pey, 2013) (Figure 4).  
 
Figure 4. Graphic representation of the so-called ‘protein homeostasis boundary’. In their native state 
and under favourable environmental conditions proteins are described by their specific energetic parameters 
(folding rate, misfolding rate and thermodynamic stability). When challenged, proteins may fall outside their 
homeostasis boundary (represented as violet area). This can result in a disease phenotype of loss of function 
or aggregation (shown by red and black circles). Figure taken from Powers et al., 2009. 
 
In PAH deficiency, the molecular mechanism of loss of function due to protein 
misfolding was demonstrated to be associated with disturbed oligomerisation, decreased 
proteolytic and thermodynamic stability, increased susceptibility towards aggregation, 
accelerated degradation or reduced folding efficiency (Knappskog et al., 1996b; Eiken et 
al., 1996; Waters et al., 1999; Waters et al., 2000; Gamez et al., 2000; Waters, 2001; 
Gjetting et al., 2001a; Waters, 2003; Pey et al., 2003; Pey et al., 2007; Martinez et al., 
2008; Gersting et al., 2008; Muntau and Gersting, 2010; Cerreto et al., 2011; Gomes, 
2012; Pey, 2013; Muntau et al., 2014). Recently, more efforts have been made to further 
clarify the molecular basis of functional impairment in PAH deficiency. It was shown that 
PAH missense mutations affect enzyme allostery rather than enzyme activity (Gersting et 
al., 2008). This suggested altered protein conformation and impaired molecular motions 
needed for promoting regulatory processes such as activation and inhibition throughout 
the oligomeric PAH structure. However, all pathological processes induced by PAH 
mutations are likely to be mutually dependent and a combined action of all disturbances 
leads to loss of PAH enzyme function and alters the phenylalanine hydroxylation system 
(Waters et al., 2000; Gjetting et al., 2001a; Muntau and Gersting, 2010). 
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1.4. Tetrahydrobiopterin (BH4) 
Tetrahydrobiopterin (BH4, 6R-L-erythro-5,6,7,8-tetrahydrobiopterin) is an essential 
cofactor for various processes and enzymes (Thöny et al., 2000). In the late 1950ies BH4 
was recognised to be an essential cofactor for the phenylalanine hydroxylase enzyme 
(Kaufman, 1958; Kaufman, 1963). Subsequently, two other amino acids hydroxylases, 
tryptophan hydroxylase (TPH, EC 1.14.16.4) (Friedman et al., 1972) and tyrosine 
hydroxylase (TH, EC 1.14.16.2) (Nagatsu et al., 1964; Shiman et al., 1971; Blau, 2006) 
were shown to have a strong requirement for BH4 to exert their catalytic function. 
Furthermore, BH4 was found to be an important cofactor also for alkylglycerol 
monooxygenase (AGMO, EC 1.14.16.5) (Tietz et al., 1964) and all three isoforms of nitric 
oxide synthase (NOS, EC 1.14.13.39) (Kwon et al., 1989; Tayeh and Marletta, 1989; 
Mayer et al., 1991; Gorren and Mayer, 2002). Therefore, tetrahydrobiopterin has 
multiple roles in human biochemistry. On the one hand, BH4 is involved in the 
conversion of the amino acids phenylalanine, tyrosine and tryptophan to the various 
neurotransmitters dopamine, serotonin, melatonin, norepinephrine (noradrenaline) and 
epinephrine (adrenaline). On the other hand, since BH4 is involved in production of nitric 
oxide, it was suggested that the cofactor may play a role in cardiovascular diseases 
(Werner et al., 2011). Consistently, depletion of BH4 was shown to contribute to vascular 
pathophysiology, hypertension, cardiac hypertrophy and ischemia physiology (Moens 
and Kass, 2006; Moens and Kass, 2007; Werner et al., 2011). In addition, reduced 
concentrations of BH4 were reported in several neurological diseases including 
Alzheimer’s disease, Parkinson’s disease, autism and depression (Thöny et al., 2000; 
Foxton et al., 2007). Supplementation with exogenous BH4 turned out to improve 
endothelial function in smokers and in patients with hypercholesterolemia, coronary 
artery disease, and diabetics (Moens and Kass, 2006). Because of its pivotal role in the 
physiological processes described above, BH4 is an emerging therapeutic agent in the 
fields of inborn errors of metabolism and cardiovascular diseases.  
1.4.1 BH4 structure and synthesis 
BH4 is a heterocyclic compound composed of a pterin ring and a 1,2-dihydroxypropyl 
side chain (Figure 5). Tetrahydrobiopterin is very unstable and in aqueous solutions it 
undergoes auto-oxidation forming inactive 7,8-dihydrobiopterin (BH2) (Thöny et al., 
2000; Moens and Kass, 2006). 
 
Figure 5. Chemical structure of tetrahydrobiopterin. BH4 is composed of a pterin ring and a 1,2-
dihydroxypropyl side chain. 
In vivo, BH4 is synthesised either de novo or regenerated via the so-called salvage 
pathway (Blau, 2006; Werner et al., 2011). De novo BH4 biosynthesis (Figure 6) is 
carried out by three key enzymes: guanidine triphosphate cyclohydrolase (GTP 
cyclohydrolase I; GTPCH; EC 3.5.4.16), 6-pyruvoyl-tetrahydropterin synthase (PTPS, EC 
4.6.1.10) and sepiapterin reductase (SR, EC 1.1.1.153) (Thöny et al., 2000; Werner et al., 
2011). In the first step guanosine triphosphate (GTP) is converted to the unstable 
intermediate 7,8-dihydroneopterin triphosphate (H2NTP). This reaction is carried out by 
the rate-limiting GTPCH enzyme, which is strongly regulated at both the transcriptional 
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(cytokines, calcium, endotoxins) and post-translational level where BH4 itself serves as 
an inhibitor of GTPCH activity. Interestingly, phenylalanine displays a positive feedback 
on GTPCH function. Next, H2NTP is converted by PTPS to the second unstable 
intermediate 6-pyruvoyl-5,6,7,8-tetrahydrobiopterin (PTP) in a Mg2+ and Zn2+ dependent 
reaction. The final step is the NADPH-dependent reduction of PTP catalysed by the 
homodimeric enzyme sepiapterin reductase to the final product, BH4 (Thöny et al., 2000; 
Blau, 2006; Werner et al., 2011).  
 
 
Figure 6. Schematic representation of de novo BH4 biosynthesis and the salvage pathway. The de novo 
pathway is marked by the box and it comprises reactions catalysed by GTPCH (GTP cyclohydrolase I), PTPS 
(6-pyruvoyl-tetrahydropterin synthase), SR (sepiapterin reductase) and alternatively by CR (carbonyl 
reductase) and AR (aldose reductase). The conversion of PTP to BH4 occurs via two additional intermediates: 
1’-Oxo-PH4 (1’-oxo-tetrahydropterin) and 2’-Oxo-PH4 (2’-oxo- tetrahydropterin). The salvage pathway 
regenerates the oxidised form of BH4 (by-product of the phenylalanine hydroxylation reaction) in a chain of 
reactions catalysed by PCD (pterin-4a-carbinolamine dehydratase) and DHPR (dihydropteridine reductase) 
or DHFR (dihydrofolate reductase). Alternatively, BH4 is produced from sepiapterin using SR (sepiapterin 
reductase), and alternatively carbonyl reductase (CR). Adapted from Blau, 2006 and Werner et al., 2011 
 
The salvage pathway (Figure 6) regenerates BH4 from its oxidised forms (7,8-
dihydrobiopterin and sepiapterin) in two independent NADPH-dependent reactions 
catalysed mainly by sepiapterin reductase (SR), dihydrofolate reductase (DHFR, EC 
1.5.1.3) and dihydropteridine reductase (DHPR, EC 1.5.1.34). The alternative way of BH4 
regeneration is crucial in phenylalanine metabolism since it ensures a continuous supply 
of the cofactor and prevents accumulation of harmful intermediates produced after BH4 
oxidation. Although important, the reaction is not sufficient to fully compensate for the 
defects in tetrahydrobiopterin biosynthesis or recycling (Thöny et al., 2000; Moens and 
Kass, 2006). 
1.4.2 Pharmacological treatment of PAH-deficient patients with BH4 
The discovery of the phenotype of BH4-responsive PAH deficiency (see 1.1.2) prompted 
a clinical study in our laboratory. This work demonstrated that i) the majority of patients 
with mild PAH deficiency phenotypes respond to pharmacological treatment with BH4, ii) 
BH4 rescues in vivo phenylalanine oxidation and iii) increases dietary phenylalanine 
tolerance in these patients (Muntau et al., 2002). In consequence, a synthetic form of 
BH4 (a dihydrochloride salt formulation of the biologically active 6R-diastereoisomer of 
BH4; sapropterin dihydrochloride) was approved in the USA and Canada in 2007 (FDA) 
and in Europe in 2008 (EMA) as an orphan drug to treat BH4-responsive PAH deficiency 
(Levy et al., 2007; Feillet et al., 2008; Lee et al., 2008). The goal of this treatment 
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strategy is to enhance the activity of the variant PAH enzyme and thereby restore the 
phenylalanine metabolism, to decrease plasma phenylalanine concentrations, decrease 
phenylalanine accumulation and, in turn, increase daily phenylalanine intake (Blau, 
2010a; Muntau et al., 2014). BH4 treatment requires combined efforts and excellent 
teamwork of metabolic paediatricians, dietitians, biochmists as well as the parents of 
PKU children. In addition, many parameters show interindividual variability and thus 
have to be considered on a personalised basis. These concern the type of BH4-response 
such as the patient being a fast or a slow responder or the dosage needed as well as the 
desired target blood phenylalanine concentration. Therefore, the supplementation with 
BH4 has to be individually tailored and adjusted to the patient’s need. 
Genotyping 
The attitude towards PAH genotyping on a routine basis is different from country to 
country and even from centre to centre within one country. In Germany, about 50 % of 
all patients are genotyped immediately after newborn screening and subsequent 
confirmation of diagnosis (Blau et al., 2010c). Many mutations have been linked to BH4-
responsiveness because they occurred in homozygous or functional hemizygous 
patients, who were clearly shown to respond to the drug (Bernegger and Blau, 2002; 
Muntau et al., 2002; Blau and Erlandsen, 2004; Desviat et al., 2004; Zurflüh et al., 2008). 
However, it has to be taken into consideration that genotype-phenotype correlation in 
patients with PAH deficiency is not always reliable and a number of missense PAH 
mutations and resulting PAH genotypes are considered as inconsistently linked to 
clinical phenotypes (Kayaalp et al., 1997; Guldberg et al., 1998a; Scriver and Waters, 
1999; Muntau et al., 2002; Pey et al., 2003; Fiori et al., 2005; Leuzzi et al., 2006; Pey et 
al., 2007; Yildirim et al., 2007; Zurflüh et al., 2008; Santos et al., 2010; Sarkissian et al., 
2012b; Blau et al., 2014). The information on BH4 responsive and unresponsive PAH 
mutations and genotypes as well as patient’s data is available on BIOPKU and PAHdb 
databases (www.biopku.org; http://www.pahdb.mcgill.ca; Blau et al., 2014; Wettstein et 
al., 2015).  
Short-term BH4 loading tests 
After identification of the patient by newborn screening and confirmation of 
hyperphenylalaninemia by an independent laboratory method, a short-term BH4 loading 
test is usually performed. It assesses blood phenylalanine concentrations after a single 
dose of 20 mg/kg body weight BH4 over a period of 24 to 72 hours. Patients who respond 
to the drug with a decrease in phenylalanine concentrations of at least 30 % suffer from 
BH4-responsive PAH deficiency or one of the very rare forms of primary BH4 deficiency 
(Blau, 2010a; Blau et al., 2010c; Blau et al., 2011). The latter in general show a very 
rapid and pronounced decrease of phenylalanine concentrations and additionally show 
abnormal pterins in the urine. In the presence of PAH deficiency results can differ 
depending on the underlying genotype or the metabolic state at the time of testing 
(Staudigl et al., 2011; Elsas et al., 2011). False negative test results exclusively based on 
short-term BH4 loading tests may irretrievably exclude the patient from pharmacological 
treatment because obtained results will not be questioned by physicians dealing with the 
patient in future. This leads to the necessity to perform an additional long-term BH4 
treatment test in those patients with a genotype compatible with BH4-responsiveness 
and ambiguous or negative test results upon short-term tests. 
Long-term BH4 treatment test 
In Europe, KUVAN® is approved for patients older than 4 years (Blau, 2010a). It is thus 
at the discretion of the physician and of the patient’s parents, whether a long-term BH4 
treatment test will be performed already in the newborn period or later. Most clinical 
centres carry it out at the age of 4 years in order to conclusively answer the question 
whether the patient is eligible for a pharmacological treatment (Prof. Ania C. Muntau, 
personal communication). Different to the short-term loading test, the efficacy endpoint 
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of the long-term treatment test is not the blood phenylalanine concentration, but dietary 
phenylalanine tolerance (Leuders et al., 2014). During the treatment period, blood 
phenylalanine concentrations are kept constant at the therapeutic target level of 42 to 
240 µmol/l and the phenylalanine supply is stepwise raised. The increase is stopped, 
when blood phenylalanine concentrations are constantly at the upper limit of the target 
range. The individual benefit of the patient from the pharmacological treatment is 
defined as the difference between the tolerance without BH4 and the maximum 
phenylalanine tolerance under BH4 treatment. The treatment is only continued, when the 
increase in tolerance is considered clinically relevant at an individual basis.  
Long-term BH4 treatment 
Long-term BH4 treatment (KUVAN
®) is implemented in a patient that has undergone the 
diagnostic procedures described above and was considered to benefit either by 
optimised long-term blood phenylalanine concentrations, the predictor for 
neurocognitive outcome, or by significant increase in phenylalanine tolerance, or a 
combination of the two. The drug is available as soluble tablets containing 100 mg of the 
active ingredient, sapropterin dihydrochloride (EMA. Kuvan EU Summary of Product 
Characteristics, 2008; Blau, 2010a; Blau, 2013). In addition, the product contains 
mannitol, anhydrous calcium hydrogen phosphate, crospovidone type A, ascorbic acid, 
sodium stearyl fumarate, and riboflavin. From all additional components, ascorbic acid is 
of specific importance for the treatment since it protects BH4 from undue oxidation 
(EMA. Kuvan EU Summary of Product Characteristics, 2008; Blau, 2010a). The daily 
dosage has to be individually adjusted according to the patient’s residual PAH activity 
and dietary phenylalanine supply. In general, the treatment is started with 10 mg/kg 
body weight as single daily dose, this can be titrated to a maximum of 20 mg/kg body 
weight, if needed (EMA. Kuvan EU Summary of Product Characteristics, 2008). In 
practice, a single dose of the drug is sufficient to maintain stable blood phenylalanine 
concentrations over a 24 h period without substantial increase in phenylalanine 
concentration after food intake (personal communication A. Muntau). PKU patients who 
respond to BH4 treatment can be divided into two groups. The first group of patients can 
completely discontinue the low phenylalanine diet and be treated with sapropterin 
dihydrochloride only, whereas the second group needs a combination of sapropterin 
dihydrochloride supplementation together with a diet, which allows for a higher content 
in natural protein depending on the degree of response to BH4. Therefore, the 
supplementation with sapropterin dihydrochloride reduces nutritional deficiencies, 
significantly improves quality of life and, in turn, allows for better adherence to the 
treatment (EMA. Kuvan EU Summary of Product Characteristics, 2008; Blau, 2010a, Keil 
et al., 2013; Trefz et al., 2015).  
The most frequent adverse events reported during the phase III clinical studies 
conducted prior approval of sapropterin dihydrochloride were headache, vomiting, 
cough, rash, upper abdominal pain, diarrhoea, nausea, and rhinorrhoea (Blau, 2010a; 
Burton et al., 2011; Blau, 2013). In clinical routine, serious side effects are very rare and 
generally dose-dependent (Trefz et al., 2015).  
Post approval activities 
After KUVAN® was approved, a multinational drug registry study was designed to 
analyse and collect the information on long-term outcomes of PKU patients treated with 
sapropterin dihydrochloride (The Kuvan Adult Maternal and Pediatric European 
Registry; KAMPER) (Blau, 2010a; Trefz et al., 2015). The study was started in 2009 and 
is planned to be terminated in 2024 (15-years study). Data on BH4-responsive patients 
are collected in more than 100 centres in 11 European countries. The aim of the study is 
to assess the overall long-term safety of the treatment as well as to analyse the safety in 
specific groups of patients such as children below 4 years of age, pregnant women and 
elder patients (Blau, 2010a). 
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1.4.3 BH4 as a pharmacological chaperone 
Since the introduction of BH4 treatment for PAH-deficient patients many studies have 
been conducted in order to analyse and elucidate the BH4 mode of action. Although the 
mechanisms of responsiveness to BH4 are multifactorial (Erlandsen et al., 2004; Pey et 
al., 2004a; Okano et al., 2007; Gersting et al., 2008; Lagler et al., 2010; Staudigl et al., 
2011; Sarkissian et al., 2012a), it is commonly accepted that BH4 exerts its function as a 
pharmacological chaperone stabilising misfolded PAH variants (Erlandsen et al., 2004; 
Pey et al., 2004a; Perez et al., 2005; Aguado et al., 2006; Martinez et al., 2008; Gersting 
et al., 2010b; Muntau and Gersting, 2010; Sarkissian et al., 2012a; Underhaug et al., 
2012; Pey, 2013). 
Pharmacological chaperones 
The concept of a pharmacological chaperone was introduced at the end of the last 
century when it was shown that the imino sugar migalastat rescues the activity of α-
galactosidase A in Fabry disease (Fan et al., 1999). Since then only two compounds have 
been approved on the market as pharmacological chaperones: sapropterin 
dihydrochloride for PKU treatment (Burnett, 2007; Levy et al., 2007; Thompson, 2008) 
and tafamidis for the treatment of transthyretin-related hereditary amyloidosis (Bulawa 
et al., 2012). 
A pharmacological chaperone is a small molecule often resembling natural ligands of the 
target protein (e.g. protein cofactors, agonists, antagonists, competitive inhibitors) that 
binds specifically and reversibly to the misfolded target and rescues protein function by 
improving protein folding and by stabilising the protein structure (Leandro and Gomes, 
2008; Muntau and Gersting, 2010; Underhaug et al., 2012; Muntau et al., 2014). The 
correction of misfolding by pharmacological chaperones can be exerted in four ways: i) 
the altered protein can be thermodynamically stabilised ii) the folding rate can be 
increased by pharmacological chaperones that stabilises the folding transition states iii) 
the misfolding rate can be decreased by stabilisation of the native state of the protein 
and iv) the combination of all mechanisms. In consequence, the defective protein can 
regain optimal values for correct overall protein function and go back to its specific 
homeostasis boundries (Figure 7) (Powers et al., 2009). The stabilising process induced 
by a pharmacological chaperone is often achieved at the cost of a certain degree of 
inhibition of protein function (Fan, 2008; Muntau et al., 2014). Yet, this inhibition may be 
overruled by an increase of the amount of functional protein within the cell (Fan, 2008; 
Muntau and Gersting, 2010; Muntau et al., 2014). 
There are defined rules that a molecule has to fulfill in order to be regarded as an active 
pharmacological chaperone. First, the pharmacological chaperone has to bind reversibly 
to the target protein with high affinity thus ascertaining its usage at low dosages. 
Second, binding of the molecule has to induce conformational changes of the target 
protein structure. Third, inhibitory compounds are more likely to exert their chaperone 
role at higher efficacy than nonspecific stabilisers. In addition, the targeted variant 
protein has to show instability, however, must still posses some residual activity. Last but 
not least, the pharmacological chaperone is only effective when a small change in the 
target protein can make a big difference concerning the phenotypic outcome rescuing 
loss of function of the target protein (Underhaug et al., 2012; Muntau et al., 2014). 
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Figure 7. Effects of pharmacological chaperones on the misfolded protein. The affected protein (e.g. due 
to missense mutations) is pushed outside its homeostasis boundary (red circle). The pharmacological 
chaperone binds to the misfolded protein increasing thermal and conformational stability of the protein. As a 
result, the protein may be pushed back to the near-optimal setting rescuing the loss of function genotype. 
Taken from Powers et al., 2009. 
The pharmacological chaperone effect of BH4 
Experimental studies using purified PAH proteins revealed stabilisation of the misfolded 
protein by BH4 against denaturation and degradation (Doskeland and Flatmark, 1996; 
Erlandsen et al., 2004; Pey et al., 2004a; Perez et al., 2005; Aguado et al., 2006; Gersting 
et al., 2010b; Muntau and Gersting, 2010). In line with in vitro studies, pharmacological 
doses of the BH4 cofactor were shown to stabilise wild-type PAH levels in mouse livers 
(Thöny et al., 2004; Scavelli et al., 2005). Studies on the Pahenu1 mouse model for BH4-
responsive PAH deficiency demonstrated that the loss of function phenotype results from 
a loss of PAH that is a consequence of protein misfolding and aggregation followed by 
accelerated degradation (Gersting et al., 2010b). BH4 alleviates this pathophysiological 
triad by conformational stabilisation of the protein leading to an increase in the effective 
functional PAH concentration and to a correction of the loss of function phenotype. 
Moreover, data obtained in vitro and in vivo showed that BH4 works in a selective 
manner confined to the pathological metabolic state. Recent studies suggest that the 
observed rescue of PAH activity upon BH4 treatment requires a well balanced metabolic 
environment of the phenylalanine substrate and the BH4 cofactor (Gersting et al., 2010b; 
Muntau and Gersting, 2010; Staudigl et al., 2011; Sarkissian et al., 2012b; Pey, 2013; 
Muntau et al., 2014). Moreover, the underlying genotype (Staudigl et al., 2011) as well as 
ubiquitin-dependent degradation (Sarkissian et al., 2012a) of PAH variants also play an 
important role. 
 
The success of the use of the natural compound BH4 to correct the loss of function 
phenotype in PAH deficiency triggered studies to identify BH4 derivatives or new 
molecules that could efficiently stabilise the PAH enzyme but show more favourable 
pharmacokinetic and pharmacodynamic properties as well as improved synthesis, 
bioavailability and stability. To date, four compounds, 5-benzylhydantoin, 6-amino-5-
(benzylamino)-uracil, 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-1-
one and 5,6-dimethyl-3-(4-methyl-2-pyridinyl)-2-thioxo-2,3-dihydrothieno[2,3-
d]pyrimidin-4(1H)-one have been demonstrated to improve PAH stability, increase in 
vivo phenylalanine oxidation and reduce blood phenylalanine levels (Pey et al., 2008; 
Santos-Sierra et al., 2012). 
1.5. Genotype-phenotype correlation in phenylketonuria 
After many diseases have been identified as simple monogenic disorders with mendelian 
type of inheritance, systematic mutation analyses have been prompted in order to 
establish genotype-phenotype correlations and to provide reliable predictions of the 
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course of the disease and ease management decisions. However, most studies failed to 
establish robust genotype-phenotype correlations. This is due to the fact that phenotypic 
manifestation is often modified and influenced by many additional genetic, epistatic and 
environmental factors as well as differences in the homeostasis and metabolism of 
individual patients (Dipple and McCabe, 2000; Scriver, 2007; Elsas et al., 2011; Pey, 
2013).  
In PKU, as in many other monogenic diseases, the primary goal of genotyping followed 
by research on genotype-phenotype correlations was to determine whether genotype 
analysis could be sufficient to properly predict the severity and the course of the disease 
(Guldberg et al., 1998a). Many researchers additionally hoped that genotyping would 
allow for predicting the type and level of responsiveness to BH4 supplementation as this 
would allow for straightforward introduction of adequate treatment without performing 
additional clinical tests (Blau et al., 2011; Mitchell et al., 2011). Indeed, the first 
publications analysing these aspects were promising (Okano et al., 1991; Guldberg et al., 
1998a; Blau et al., 2011). However, more intricate in vitro studies (Staudigl et al., 2011) 
and studies on larger groups of PKU patients (Sarkissian et al., 2012b) demonstrated that 
the genotype in many cases does not reliably predict BH4 responsiveness. This is mainly 
due to the fact that PKU is a complex disease arising from the genotype (underlying 
mutations), the enzymatic phenotype (PAH enzyme activity), the metabolic phenotype 
(blood phenylalanine levels), the cognitive phenotype (IQ, mental retardation, impaired 
cognitive development) and the therapeutic phenotype (BH4 treatment). Furthermore, 
distinct modulators (discussed below and summarised in Table 2) may affect each of 
these levels and by this weaker genotype-phenotype correlation (Scriver and Waters, 
1999; Waters, 2001; Santos et al., 2010; Mitchell et al., 2011). 
The PAH genotype  
Phenylketonuria due to deficiency of PAH is characterised by high allelic heterogeneity 
with > 660 mutations (www.hgmd.cf.ac.uk) affecting the PAH gene. In addition, about 89 
% of PKU patients are compound heterozygous (Zurflüh et al., 2008). Especially these 
two genetic factors make the prediction of genotype-phenotype correlations in 
phenylketonuria extremely difficult (Guldberg et al., 1998b; Guldberg et al., 1998a; 
Waters et al., 1998b; Mirisola et al., 2001; Pey et al., 2003; Rivera et al., 2011). In 
addition, the possibility of having more than two mutations on the homologous alleles 
has also to be kept in mind. In line with this statement, the necessity to perform 
complete sequencing of the whole gene has to be taken into consideration as 
introduction of additional mutations can further add to alteration of the gene product 
(Scriver and Waters, 1999).  
Disconcordances at the level of the enzymatic phenotype 
The function of variant PAH enzymes can be modulated in various ways. As discussed in 
chapter 1.3.2 PAH mutations can have an unpredictable impact on the speed and 
effectiveness of protein translation, regulatory properties, kinetic parameters, capacity of 
protein folding, thermodynamic stability, protein conformation and the quaternary 
structure of the enzyme. All this may render the protein prone to aggregation and 
accelerated degradation and in turn may lead to a decreased abundance of the 
intracellular effective protein amount. On the other hand, inter-individual variability in 
the quality and quantity of proteolytic and folding systems as well as chaperone function 
may play an important role and further add to inconsistencies of genotype-phenotype 
correlations (Scriver and Waters, 1999; Waters, 2001; Mitchell et al., 2011). One of the 
modulators of protein function is interallelic complementation (IAC). IAC is a well-known 
phenomenon in human genetics contributing to genotype-phenotype correlation 
especially in compound heterozygosity. The theory of interallelic complementation 
originates from work of Brenner (Brenner, 1959) and Fincham (Fincham and 
Coddington, 1963; Fincham and Stadler, 1965) and refers to the specific protein-protein 
interactions occurring in multimeric proteins where the hybrid is assembled from 
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products of two mutated alleles. Complementation at the level of protein is usually 
considered in terms of enzyme activity. Mutant proteins in the homomultimeric state, 
which originates from protein subunits encoded by one mutant allele, show either 
decreased or abolished activity while those defects may be mutually corrected in 
heteromultimers, composed of subunits encoded by both mutant alleles as well as the 
wild-type allele, resulting in a partial restoration of protein function. The phenomenon 
was explained in 1960s by the ‘good corrects bad’ hypothesis, which implies 
stabilisation of a misfolded monomer in the presence of the unaltered wild-type 
monomer (Crick and Orgel, 1964). This theory was further expanded to allosteric 
enzymes, which are characterised by a very delicate balance between their active and 
inactive state. Accordingly, a mutation within such a protein, not necessarily directly 
associated with a ligand binding site, may result in trapping the enzyme in one state or 
another. In this case, disturbed balance may be either corrected or restored by another 
mutant. This is known as the ‘bad corrects bad’ hypothesis (Monod, 1965; Monod et al., 
1965; McGavin, 1968). A number of PAH compound heterozygous genotypes were 
analysed in a prokaryotic expression system showing negative IAC (Kaufman et al., 1975; 
Waters et al., 2001; Waters, 2001; Leandro et al., 2006; Leandro et al., 2011). Therefore, 
IAC may explain why compound heterozygous genotypes consisting of two mutations 
with similar severity may induce milder or more severe phenotypes than predicted by 
each of the mutations.  
 
Table 2. Factors affecting reliable prediction of genotype-phenotype correlations in phenylketonuria 
 Affected unit Modyfying factors 
Genotype (allelic interaction) PAH gene 
High allelic heterogeneity 
Compound heterozygosity 
Additional mutations in cis 
Phenotype   
PAH protein PAH polypeptide Translation, chaperones, proteases 
Enzymatic phenotype PAH tetramer Hydroxylation reaction 
Interallelic complementation 
Protein stability 
Tetramer assembly 
Synthesis and recycling of the 
cofactor 
Metabolic phenotype Phenylalanine homeostasis 
Phenylalanine intake 
Phenylalanine disposal 
Intestinal absorption 
 
Cognitive phenotype IQ and executive function 
Function of the blood-brain barrier 
Expression of certain transporters 
e.g. for LNAA 
Therapeutic phenotype Treatment 
Diet only, diet in combination with 
BH4 treatment, supplementation 
with BH4 only, no treatment 
Additional factors 
Calculation of in vitro PAH 
enzyme activity 
Estimation of BH4-responsiveness 
Different transfection methods and 
protocols for PAH activity assays 
Protocol differences for BH4 loading 
tests performed in clinical centres 
Table adapted and modified from Scriver and Waters, 1999.  
Disconcordances at the level of the metabolic phenotype 
Measures of the metabolic phenotype are blood phenylalanine values and dietary 
tolerance for the phenylalanine intake. Since this metabolic homeostasis is a complex 
process, inter-individual differences in the intestinal absorption, hepatic uptake and the 
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disposal of amino acid by hydroxylation, transamination and decarboxylation may in part 
account for discrepancies observed (Treacy et al., 1996; Scriver and Waters, 1999; Fiege 
et al., 2004). 
Disconcordances at the level of the cognitive phenotype 
Studies have shown that IQ scores in untreated patients or even in siblings carrying the 
same PAH genotype might show significant differences (Ramus et al., 1993; Scriver and 
Waters, 1999). Moreover, even when the metabolic phenotype in two individuals is 
similar, the cognitive phenotypes might be diverse (Moller et al., 1998; Weglage et al., 
1998). This discordance may be explained by differences in the function of the blood-
brain barrier (BBB) leading to two different kinetics of phenylalanine uptake through the 
BBB and this can subsequently modulate the phenylalanine content in brain (Moller et 
al., 1998; Scriver and Waters, 1999; Mitchell et al., 2011). 
Additional factors hampering reliable genotype-phenotype correlation in 
phenylketonuria 
Although PAH mutations can be classified based on the level of PAH function as severe 
(very low enzyme activity) or mild (substantial residual enzyme activity) different 
individuals, even siblings, may show great differences of the disease phenotype (Dipple 
and McCabe, 2000; Waters, 2001). Also in the case of homozygous or functional 
hemizygous PKU patients, where the prediction should be quite straightforward, 
discrepancies exist (Kayaalp et al., 1997; Guldberg et al., 1998a; Scriver and Waters, 
1999; Muntau et al., 2002; Fiori et al., 2005; Leuzzi et al., 2006; Yildirim et al., 2007; 
Zurflüh et al., 2008; Santos et al., 2010; Sarkissian et al., 2012b; Blau et al., 2014).  
This might be the result of the fact that all existing information on the effect of PAH 
mutations on PAH function was generated by in vitro studies performed using purified 
PAH protein or eukaryotically expressed PAH. There are no data available on in vivo 
variant PAH function since a liver biopsy is considered as an unjustified invasive 
intervention (Blau, 2006). Therefore, currently used data on enzyme activity and residual 
protein amount originates from PAH proteins expressed using different expression 
methods, vectors and expression systems (e.g. E.coli, COS-7, HEK293, TnT system). 
Moreover, methods for measurement of PAH activity may vary (e.g. incubation time and 
the cofactor used). All this may lead to overestimation of in vitro activities, variability in 
measured in vitro PAH activity even for single mutations as well as incorrect calculation 
of  “predicted residual activity” (PRA) for compound heterozygotes where PRA is 
expressed as the mean of monoallelic in vitro enzyme activities for two mutations 
constituting the PAH genotype.  
As to estimation of BH4-responsiveness, many efforts have been made to identify BH4-
responsive genotypes and mutations. Genotype analysis of a large group of PKU patients 
listed in BIOPKU database (Zurflüh et al., 2008) allowed for identification of the so-called 
most common responsive PAH mutations (p.Ala403Val, p.Arg261Gln, p.Tyr414Cys, 
p.Ala300Ser, p.Val245Ala, p.Leu48Ser, p.Glu390Gly and p.Arg241Cys) (Wettstein et al., 
2015). However, frequent inconsistencies as to BH4-responsiveness even in the patients 
with the same genotype were observed in the presence of p.Leu48Ser, p.Ile65Thr, 
p.Arg158Gln, p.Arg261Gln, p.Tyr414Cys, p.Glu390Gly, p.Val388Met (Kayaalp et al., 
1997; Muntau et al., 2002; Fiori et al., 2005; Leuzzi et al., 2006; Yildirim et al., 2007; 
Zurflüh et al., 2008; Santos et al., 2010; Sarkissian et al., 2012b; Blau et al., 2014). In 
addition, discrepancies in the PKU phenotype were reported even among individuals 
bearing two null mutations (p.[Arg252Trp];[Pro281Leu], p.[Arg261Stop];[Pro281Leu], 
p.[Gln355_Tyr356insGlyLeuGln];[Gln355_Tyr356insGlyLeuGln], 
p.[Arg408Trp];[Pro281Leu]) for which the expected classical PKU was not observed or 
BH4-responsiveness has been reported (Santos et al., 2010; Leuders et al., 2014). In the 
same study, the general hypothesis that the presence of the less severe allele determines 
the severity of the disease (Guldberg et al., 1998b; Guldberg et al., 1998a; Santos et al., 
2010) was not confirmed. These inconsistencies may result from molecular modifying 
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factors described above, however, weak genotype-phenotype correlation may also result 
from differences in BH4 loading test protocols (Fiege and Blau, 2007; Sarkissian et al., 
2012b). This includes the dosages of BH4 used, the initial phenylalanine values of the 
patients at the beginning of the test, dietary fluctuations during the loading tests and the 
duration of the test (Zurflüh et al., 2008; Sarkissian et al., 2012b; Leuders et al., 2014). 
Moreover, there are reports on patients showing BH4-responsiveness in a single loading 
test but when the patients were exposed to long-term treatment no response was 
observed (Zurflüh et al., 2008; Leuders et al., 2014). 
 
Taken together, further research is needed for in-depth analysis of variant PAH function 
as prerequisite for solid phenotype-genotype correlations in phenylketonuria. However, 
many in vivo factors modulate the behaviour of the endogenous PAH protein in a 
complex way (e.g. interallelic complementation, metabolic environment). Their careful 
consideration in experimental set-ups may foster a reliable transfer of results obtained 
by in vitro studies into the in vivo situation.  
 AIMS OF THIS WORK 
 25 
2. AIMS OF THIS WORK 
In the past 15 years, huge effort has been undertaken to elucidate the molecular 
mechanisms underlying phenylketonuria and successful pharmacological treatment of 
PAH deficiency by BH4. Missense mutations in the PAH gene were shown to induce 
protein misfolding with loss of function of variant PAH proteins. Conformational 
stabilisation of misfolded variant PAH was dissected as the mode-of-action of 
pharmacological doses of BH4. Despite this progress there was still a significant gap of 
knowledge regarding PAH function in vivo. In particular, our understanding of PAH 
function in relation to the patient’s metabolic state and BH4-therapy was incomplete.  
We addressed these questions in three scientific projects that comprise the cumulative 
part of this thesis. The first one focused on fine-mapping of BH4-dependent PAH enzyme 
kinetic parameters. Here, we aimed to develop a robust continuous assay for high-
throughput measurement of PAH activity and to improve our understanding of BH4 
binding-induced molecular motions driving PAH kinetics. Based on the novel assay, in 
the second project, we aimed to analyse the impact of varying substrate and cofactor 
concentrations on PAH function of recombinantly expressed and purified wild-type and 
variant PAH. In addition, we aimed to retrace experimental findings in vitro with patient 
data derived from oral BH4 loading tests. The third project aimed to establish a cell-
based assay of PAH function that reliably mimics the patient’s situation in vivo. This 
comprised mapping of the country-specific distribution of PAH genotypes in Europe and 
Middle East, genotype-specific PAH functional analyses, and investigations of PAH 
function in the pathological metabolic context additionally addressing the impact of 
pharmacological doses of BH4. 
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3. CUMULATIVE THESIS: Summary of Published Results 
3.1. PAPER 1: Activation of phenylalanine hydroxylase induces positive 
cooperativity toward the natural cofactor. 
Gersting SW, Staudigl M, Truger MS, Messing DD, Danecka MK, Sommerhoff CP, 
Kemter KF, Muntau AC. 
The Journal of Biological Chemistry, 2010; 285 (40): 30686-30697. 
 
The function of tetrameric PAH is tightly and complexly regulated by the substrate, L-
phenylalanine, the cofactor, BH4, as well as by phosphorylation. These regulatory 
mechanisms require the PAH enzyme to be highly flexible in order to transmit reversible 
conformational changes occurring upon binding of enzyme’s effectors throughout the 
protein. In addition, it has been previously shown that alterations in enzyme kinetic 
parameters of variant PAH reflect mutation-induced structural alterations. Thus, in-depth 
evaluation of kinetics and allostery of PAH protein appeared to be useful when assessing 
to which extent local single amino acid replacement lead to global conformational 
alterations compromising enzyme function. Yet, current standard PAH activity assays are 
laborious, time consuming and designed as end-point measurements. Therefore, we 
aimed to develop an automated continuous real-time assay of PAH activity for robust 
though comprehensive analyses of steady state enzyme kinetics. 
Application of the fluorescence-based multi-well assay revealed an initial high activity 
burst phase followed by a linear steady-state rate of the enzymatic reaction for activated 
(pre-incubated with L-phenylalanine) wild-type PAH enzyme. In contrast, the non-
activated PAH exhibited an initial lag-phase followed by a linear phase of product (L-Tyr) 
formation. Further analysis of L-phenylalanine dependent wild-type PAH kinetics showed 
the well-known allosteric behaviour for the activated PAH enzyme whereas binding of 
phenylalanine to the non-activated enzyme was found to be non-cooperative. These 
kinetic data were in line with the kinetic data obtained from discontinuous assays. 
Noteworthy, the analysis of BH4-dependent kinetics led to previously unknown findings. 
Although non-activated wild-type PAH followed a non-cooperative Michaelis-Menten 
kinetic model, the activated enzyme clearly showed a sigmoidal, allosteric behaviour. 
This provided evidence for BH4-dependent cooperativity with PAH activation as a 
prerequisite. To investigate whether the shift in enzyme kinetics from Michaelis-Menten 
to the Hill model is due to the presence of the L-phenylalanine substrate itself or it rather 
depends on conformational changes and rearrangements within the protein, three pre-
activated genetics PAH variants (human p.Arg68Ser, truncated human 103-427 PAH and 
murine p.Val106Ala) were analysed and their behaviour was compared to that of the 
wild-type PAH. Pre-incubation of the wild-type enzyme with phenylalanine led to a series 
of structural and functional changes as seen by a red-shifted and enhanced tryptophan 
emission, a right-shifted thermal denaturation profile, increased Vmax and the switch 
from non-cooperative to positive cooperative kinetics accounting for activation. Data on 
variant PAH provided evidence that BH4-dependent positive cooperativity of the 
activated enzyme does not rely on the presence of L-Phe but is determined by activating 
conformational rearrangements. 
Taken together, our new continuous multi-well PAH activity assay proved to be faster 
and more efficient but as precise and accurate in evaluating PAH kinetics and allostery 
as the standard methods. This technique revealed a previously unknown positive 
cooperativity of pre-activated PAH towards BH4 that relies on activating conformational 
rearrangements. Moreover, we showed that the presence of L-Phe affects the BH4-
dependent kinetic properties of PAH protein. These findings may thus have implications 
for an individualised therapy of patients with PAH deficiency. In addition, our data 
supported the notion that the patient’s metabolic state may have a greater impact on 
conformation and function of the PAH enzyme that it was previously appreciated.  
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3.2. PAPER 2: The interplay between genotype, metabolic state and cofactor 
treatment governs phenylalanine hydroxylase function and drug 
response. 
Staudigl M, Gersting, SW, Danecka MK, Messing DD, Woidy M, Pinkas D, Kemter KF, 
Blau N, Muntau AC.  
Human Molecular Genetics, 2011; 20 (13): 2628-2641. 
 
The discovery of a pharmacological treatment for phenylketonuria raised new questions 
about function and dysfunction of phenylalanine hydroxylase. In addition, in vitro data as 
well as observations made in daily clinical practice suggested that the influence of 
substrate and cofactor concentrations on PAH enzyme function and on the response to 
the pharmacological treatment with BH4 might be of even more functional and 
therapeutic relevance than previously estimated. Moreover, the information on the 
behaviour of the PAH enzyme in the pathological and therapeutic setting is still scarce.  
In order to investigate the interdependent effects of substrate and cofactor on PAH 
enzyme kinetics of different PAH variants we i) adapted our continuous real-time activity 
assay to cover an expanded range of phenylalanine and BH4 concentrations; ii) depicted 
obtained results as three-dimensional color-coded activity landscapes; iii) described the 
optimal working ranges for purified wild-type and variant PAH; iv) substantiated our 
findings in an eukaryotic expression system, and v) translated in vitro observations into 
the human situation by analysing literature data on the results of oral BH4 loading tests 
from PAH-deficient patients. 
The analysis of the wild-type PAH kinetics under physiological to supraphysiological 
concentrations of phenylalanine and BH4 allowed for depicting the optimal working 
range for the enzyme (252 – 2026 µM L-Phe; 44-306 µM BH4) as well as the peak activity 
(561 µM L-Phe; 125 µM BH4). The data provided evidence that phenylalanine 
concentrations for the optimal working range of the wild-type PAH enzyme were lower 
whereas BH4 concentrations were higher than previously assumed. Moreover, it was 
shown that with increasing phenylalanine concentrations more BH4 is needed to 
maintain the same level of PAH activity. In addition, a mutual interdependence of 
cofactor and substrate inhibition was found. Next, activity landscapes of eight purified 
PAH variants were performed and the results were compared with those obtained for the 
wild-type. The presence of PAH missense mutations led to various alterations with 
respect to the extension and position of optimal working ranges of activity landscapes. 
The observed differences in the patterns of activity landscapes included broadening or 
narrowing of the working optima, shifts of the peak activities towards higher or lower 
phenylalanine concentrations and/or towards cofactor concentrations. This 
comprehensive analysis of PAH activity landscapes revealed that differences in the 
regulation of PAH activity by BH4 and L-phenylalanine in vitro strongly depend on the 
analysed variant and therefore, in vivo, on the underlying genotype. In the next step, 
activity landscapes were in part reinvestigated in the eukaryotic system with stable 
expression of the wild-type and two PAH variants. The kinetic behaviours of all PAH 
proteins expressed in eukaryotic cells were in line with key findings of the activity 
landscapes obtained using purified PAH. The in vitro observations were transferred to 
the human situation by analysing literature data derived from BH4-loading tests 
performed in PAH-deficient patients. This allowed to further substantiate that enzyme 
function in the individual patient at a given time point is the resultant of the metabolic 
state and the dosage of cofactor treatment both in turn determined by the underlying 
PAH genotype. 
Taken together, our approach allowed for detailed visualisation and better understanding 
of conditions corresponding to those occurring in physiological and pathological 
situations in PKU patients and in the therapeutic context upon cofactor treatment. In 
addition, our findings may set the basis for a mutation-dependent individualised dietary 
treatment of PKU patients. Moreover, this work pinpoints the importance of genotyping 
PKU patients and underscores the need for more personalised testing procedures.
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3.3. PAPER 3: Mapping the functional landscape of frequent phenylalanine 
hydroxylase genotypes promotes personalised medicine in 
phenylketonuria. 
Danecka MK, Woidy M, Zschocke J, Feillet F, Muntau AC, Gersting, SW.  
Journal of Medical Genetics, 2015; 52 (3): 175-185.  
 
Phenylketonuria is characterised by pronounced allelic heterogeneity with a high 
number of PAH gene mutations, high incidence of compound heterozygosity and the 
variability in distribution of common mutations between ethnic groups and geographical 
regions. In addition, a continuum of residual in vivo PAH activity, depending on the 
underlying mutations, results in phenotypic heterogeneity where the clinical picture 
ranges from mild HPA to severe classical PKU. The discovery of a BH4-responsive 
phenotype further adds to the phenotypic variability of PAH deficiency. Many efforts 
have been undertaken to characterise PAH function and to establish robust genotype-
phenotype relationships. Yet, available data on residual PAH activity is restricted to 
single mutations that were expressed in different cellular systems and assayed by means 
of diverse enzyme assay protocols. Moreover, non-invasive functional assays, for 
example, in blood cells, are not feasible because metabolic PAH function is restricted to 
the liver and liver biopsies are considered as unjustified interventions. Thus, present in 
vitro data on PAH activity of single variant PAH proteins do not reliably reflect PAH 
function of majority of the PKU patients who show compound heterozygosity. Therefore 
a significant gap of knowledge concerns the enzymatic function of PAH reflecting full 
PAH genotypes. In addition, our previous work revealed that PAH activity also depends 
on the metabolic phenotype and a potential pharmacologic administration of BH4. 
Furthermore, although public databases (PAHdb, BIOPKU) provide general information 
on PAH mutations and associated phenotypes there is no database access on occurrence 
and frequency of full PKU genotypes.  
In order to provide genotype-specific data on PAH function and to develop a consistent 
model assessing PAH activity arising from two different alleles we i) mapped the most 
common PAH genotypes in Europe and Middle East; ii) determined PAH residual 
function of the 30 most frequent homozygous and compound heterozygous genotypes in 
a cell based model; iii) presented data as three-dimensional PAH activity landscapes and 
iv) assessed the PAH working optima of full PAH genotypes. 
First, a comprehensive literature search was performed in order to determine the 
frequency and region-specific distribution of PAH genotypes. Due to a shared ethnic 
background the research focused on Europe and the Middle East. Data from 20 countries 
spanning from Portugal to Iran were selected resulting in a study population of 3066 
PKU patients displaying 690 different genotypes based on 264 mutations. Overall, the 
type and frequency of single PAH mutations in our study population matched well with 
frequencies described in the databases. The two predominant PAH mutations were p. 
Gln355_Tyr356insGlyLeuGln and p.Arg408Trp and both showed a region-specific 
distribution. The majority of genotypes was compound heterozygous (91 %), which is in 
line with literature data. The 30 most frequent genotypes, which encode expressible PAH 
proteins from both alleles, covered 55 % of patients in our study population. 
Residual function of wild-type and the 30 most frequent PAH genotypes was assessed in 
COS-7 cells transiently expressing variant PAH encoded by both alleles of the respective 
PAH genotypes. PAH activity was determined at broad ranges of cofactor and substrate 
concentrations mimicking alteration in the metabolic state as well as a pharmacological 
treatment with BH4. The activity landscape of wild-type PAH showed peak enzyme 
activity at 431 µM L-phenylalanine and 130 µM BH4, which was in line with data 
previously obtained for purified PAH. At L-phenylalanine concentrations above the 
therapeutic threshold of 360 µM the enzyme showed a need for increased BH4 
concentrations to maintain the same level of activity. Residual PAH activity ranged from 
1.7 % up to 11 % for all full PAH genotypes. We classified PAH genotypes into three 
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groups depending on the residual activity: < 3.5 % (group 1), ≥ 3.5 % and < 5 % (group 
2) and ≥ 5 % (group 3). Next, we related residual activities with patterns of the activity 
landscapes and phenotypic data from PKU patients. Group 1 genotypes showed very low 
activity with no defined peak of enzyme activity. Clinical phenotypes retrieved from the 
BIOPKU database showed a consistent association with BH4 non-responsive classical 
PKU. In group 2, enzyme activities were still low, however, an area of peak activity 
mapping to the area of wild-type PAH was delimitable. This group was associated with 
phenotypic heterogeneity with both mild and classical PKU phenotypes and a significant 
share of patients responding to BH4. Genotypes from group 3 showed considerable 
residual activities with delimitable peak areas with two exceptions. However, the 
position and shape of areas of peak enzyme activity showed large variations within this 
group. Some genotypes induced a left shift of the peak activity, which mapped to 
significantly lower phenylalanine concentrations than observed for the wild-type. On the 
other hand, some genotypes induced a right-shift of peak enzyme activity towards higher 
phenylalanine concentrations. Interestingly, all but one of these genotypes contained the 
mutation p.Arg261Gln. A broadening of the optimal working range was observed for four 
genotypes and three out of four contained p.Arg261Gln. On the other hand, a narrow 
optimal working range was identified in eight genotypes with p.Leu48Ser and 
p.Arg408Trp being leading mutations in this group. Six genotypes were identified as 
being associated with a shift of peak activity towards higher BH4 concentrations. Most of 
these genotypes contained mutations associated with inconsistent genotype-phenotype 
correlations (p.Leu48Ser, p.Ile65Thr, p.Ala300Ser). Group 3 genotypes with a defined 
area of peak activity were predominantly associated with MHP or mild PKU and high 
response rates to BH4 cofactor treatment. Only five genotypes in this group showed 
unresponsiveness to BH4 treatment and predominance of classical PKU. Interestingly, 
three of these genotypes contained p. Gln355_Tyr356insGlyLeuGln and three genotypes 
were associated with peak activities at increased cofactor concentrations.  
The analysis of full PAH genotypes allowed for the recognition of four orienteering rules, 
which may set the basis for personalised medicine strategies: i) low residual activity is 
associated with mostly BH4 unresponsive classical PKU ii) a lack of a defined area of 
peak activity leads to a loss of response to BH4 iii) the occurrence of clinically 
inconsistent phenotypes with low rates of BH4 response may be linked to a need for 
higher BH4 dosages iv) high residual activity, a defined peak of activity and normal need 
for BH4 are associated with mostly responsive mild PKU or mild HPA. Additionally, the 
observed changes in patterns of the PAH activity landscapes allowed for identifying 
hypotheses concerning dietary treatment of PAH patients. Patients carrying genotypes 
that induced a right-shift in vitro may be associated with higher phenylalanine tolerance, 
hence, allowing for a less restrictive regime of the low-phenylalanine diet. On the other 
hand, carriers of genotypes with narrow working optima and/or shift of the activity 
landscapes towards lower substrate values in vitro, may need particularly strict dietary 
control. These concepts have to be confirmed by clinical studies that are currently 
planned. In addition, some genotypes induced an increased need for BH4. This may have 
implications on the pharmacological treatment of patients carrying these genotypes as 
well as on BH4 response tests. BH4 dosages used in standard tests may be insufficient to 
achieve an increase in enzyme activity and a decrease in phenylalanine concentrations. 
In conclusion, our work exemplifies how application of molecular genetics may translate 
into medical practice. It gives new significance to gene analysis of the PAH locus in 
clinical routine and shows the importance of considering functional analysis of full 
genotypes. The generation of activity landscapes in the metabolic and therapeutic space 
provided clinically relevant new insights into genotype-related impaired PAH function 
beyond the known link between residual activity and clinical phenotype. In the presence 
of specific genotypes we observed different patterns of activity landscape architecture 
and established orienteering rules for their interpretation. In addition, the work provides 
a web-based tool to assist clinicians in clinical care of PKU patients. Furthermore, we 
showed that analysis of genotype-related PAH activity landscapes together with available 
information on clinical phenotypes may significantly improve clinical management. 
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Therefore, in future this approach may set the basis for implementation of personalised 
medicine strategies concerning both, the dietary regimes and pharmacological treatment 
of PKU patients. 
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4. DISCUSSION AND OUTLOOK 
In 1999, the oral administration of BH4 was reported to decrease pathologic blood 
phenylalanine concentrations in a group of PAH-deficient PKU patients. Applicability of 
this observation to clinical practice was substantiated in a clinical trial study carried out 
in our centre as well as by numerous case reports and retrospective studies, where 
predominantly mild phenotypes of PAH deficiency responded to BH4 and treatment was 
associated with enhanced PAH enzyme function in vivo. Since then, the field of 
phenylketonuria research focused on the molecular mechanisms underlying BH4 
responsiveness as well as on the mode of action of the BH4 molecule. Many in vitro 
studies, including work performed in our laboratory, have shown that BH4 acts as a 
pharmacological chaperone stabilising the PAH protein and therefore correcting the loss 
of function phenotype. In 2007 and 2008, the synthetic form of BH4 (sapropterin 
dihydrochloride, KUVAN®) was approved by the FDA and the EMA, respectively, as an 
orphan drug to treat BH4-responsive PAH deficiency. This new treatment significantly 
improved the quality of life of PAH-deficient patients responding to BH4. In many cases, 
the pharmacological therapy allowed to relax or completely terminate the burdensome 
phenylalanine-restricted diet. Yet, there is still need for improvement in the 
pharmacological treatment of PKU patients. First, current therapeutic protocols are not 
personalised and not always maximum efficacy of the drug is achieved in the individual 
patient. Second, there is a demand to develop derivatives of the approved drug with 
better bioavailability, enhanced pharmacodynamics and improved pharmacokinetics. 
Third, there is a high need to identify novel compounds with pharmacological chaperone 
effect that would allow for an enlargement of the target group including PKU patients 
that are not yet amenable to pharmacological treatment.  
Among the challenges in the clinical management of PKU patients, the low reliability in 
prediction of the clinical course, even if genotyping is performed, as well as 
contradictory data on PAH function associated with single PAH mutations, which are 
derived from databases or case reports, may further complicate pharmacological 
treatment. These difficulties and pitfalls were, at least in part, due to high allelic 
heterogeneity and compound heterozygosity among PKU patients, inconsistent 
phenotypes, the lack of models to establish robust genotype-phenotype correlations and 
the absence of in vitro data on PAH activity of full PAH genotypes. Moreover, there was a 
significant gap of knowledge regarding PAH function in the metabolic context of the 
individual patient. Differences between medical centres regarding BH4 loading test 
protocols additionally added to misperceptions regarding BH4-responsive and non-
responsive PAH genotypes. As a consequence, these uncertainties resulted in persistent 
questioning of the necessity of genotyping of PAH-deficient patients and hindered the 
progress of the development of personalised treatment strategies in PKU. 
Therefore, we sought to generate data on PAH function associated with individual 
genotypes that reflect the situation in vivo. In particular, we aimed to further improve the 
understanding of the interplay between the phenylalanine substrate, the BH4 
cofactor/drug, the genotype underlying PAH deficiency and PAH enzyme function. We 
designed a three-step research project where we first developed a continuous 
fluorescence-based PAH activity assay, which allowed for measuring PAH kinetics in a 
robust and efficient way. Our assay was then applied to analyse PAH function of 
recombinantly expressed and purified wild-type and variant PAH proteins at a broad 
range of phenylalanine and BH4 concentrations. In the final step, we adapted and 
modified the PAH activity assay enabling the determination of PAH function of full PAH 
genotypes in a cell based model. This model allowed mimicking the pathological 
(phenylalanine) and therapeutic (BH4) states as observed in PKU patients.  
The application of the real-time PAH activity assay revealed a previously not described 
positive cooperativity of the PAH protein towards the cofactor BH4. In-depth 
spectroscopic analyses uncovered PAH activating conformational changes as a 
prerequisite for BH4-dependent positive cooperativity. In addition, we showed that the 
presence of phenylalanine affects the BH4-dependent kinetic properties of PAH. These 
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results supported the notion that a patient’s metabolic state may have a significant effect 
on the interplay of the BH4 drug and its target. In other words, the metabolic control of 
blood phenylalanine levels interferes with the effect of BH4 on conformation and function 
of the PAH enzyme. 
Next, high-throughput analyses assessed enzyme activity of recombinantly expressed 
PAH at a broad range of substrate and cofactor concentrations. This 96-well based 
method enabled the establishment of three dimensional PAH activity landscapes. Here, 
we determined the optimal working ranges for the wild-type and PAH variants. 
Furthermore, the landscapes revealed important differences in the regulation of PAH 
activity by BH4 and phenylalanine and helped to visualise the interdependence of 
substrate and cofactor concentrations on variant PAH enzyme activity. Interestingly, we 
showed that phenylalanine concentrations for optimal working range of PAH are lower 
whereas BH4 concentrations are higher than it was previously assumed. From the 
physiological point of view, maximum PAH activity at lower phenylalanine 
concentrations seem to be reasonable since liver phenylalanine concentrations are 
expected to reach levels up to 500 µM under physiological conditions rather than values 
of 1000 µM, which are used in standard PAH activity assays. A combination of data 
derived from PAH activity landscapes with data on BH4 loading tests performed in PAH-
deficient patients led to the conclusion that the outcome of a BH4 loading test may much 
more vary in function of individual test circumstances than previously assumed. In 
particular, the level of blood phenylalanine may have a significant effect on the test 
outcome. 
As a third step, we generated activity landscapes of full PAH genotypes, expressed in 
eukaryotic cells under conditions that mimic the patients’ metabolic or therapeutic 
states. The validity of this method may be substantiated by the fact that observations on 
homozygous genotypes were in line with our previous results on purified variant PAH 
proteins reflecting single mutations. Several patterns of changes in the architecture of 
PAH activity landscapes were observed. We combined data from our functional analyses 
with biochemical, clinical, and therapeutic data derived from PKU patients. This 
approach allowed for generating hypotheses on the mechanisms behind individual 
genotypes. In particular, these observations may be of practical relevance for the clinical 
management of patients and we established orienteering rules for the implementation of 
personalised medicine strategies in PAH deficient patients. As an example, a shift in 
maximum PAH activity towards higher BH4 concentrations observed for some genotypes 
may indicate a higher need for BH4 to achieve optimal enzymatic phenylalanine turnover 
in the patient. As a consequence, in order to avoid false negative results with respect to 
the drug response, which is defined as the maximum drop in blood phenylalanine levels, 
BH4 loading tests could be performed at higher doses of BH4 or at an increased duration 
time of the test. On the other hand, our data may indicate that genotypes associated with 
residual function of less than 3.5 % or associated with a complete loss of a delimitable 
area of peak activity are associated with non-responsiveness to BH4. In these cases, 
extended testing of patients that were non-responsive to BH4 using standard protocols 
could be avoided. The observation of a shift of peak activity towards higher 
phenylalanine concentrations may exemplify how the analysis of genotype-specific PAH 
activity landscapes could aid in the dietary management of PKU patients. Patients 
carrying genotypes associated with peak PAH activity at phenylalanine concentrations 
above the therapeutic target may exhibit suboptimal residual PAH activity in the target 
range. Given that an increase in blood phenylalanine would be associated with an 
increase in PAH function, shifting the therapeutic target towards higher phenylalanine 
values may be associated with a significant increase in phenylalanine tolerance. In 
addition, we categorised PAH genotypes with respect to the associated functional 
parameters derived from PAH activity landscapes. This allowed to establish genotype-
phenotype correlations with respect to the biochemical phenotype (blood phenylalanine) 
and the pharmacological phenotype (response to BH4-treatment). However, the 
establishment of a robust model that would allow for reliable predictions requires the 
analysis of a higher number of PAH activity landscapes, a project that is in progress in 
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our laboratory. In order to further increase the evidence of our in vitro data, patient 
studies may address efficiency of BH4 treatment as well as validity of BH4 loading tests 
under consideration of individual genotypes and of varying blood phenylalanine 
concentrations. Moreover, varying BH4 concentrations, the effect of BH4 in healthy 
individuals, the time to onset of action and the effect duration of the drug will be tested 
in more detail. 
In conclusion, our work pinpoints the significance of genotyping PKU patients in clinical 
routine and shows the importance of considering functional analysis of full PAH 
genotypes. In addition, our findings underscore the need for more personalised testing 
procedures addressing individual patient characteristics, the metabolic state and the 
dosage of the test compound in order to reliably identify BH4 responsive PAH-deficient 
patients. Furthermore, our study may set the basis for genotype-specific personalised 
PKU therapy with respect to both, pharmacological treatment with BH4 and 
phenylalanine restricted dietary regimens.  
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Cooperativity toward the Natural Cofactor*!S
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Protein misfolding with loss-of-function of the enzyme phe-
nylalanine hydroxylase (PAH) is themolecular basis of phenylk-
etonuria inmany individuals carryingmissensemutations in the
PAH gene. PAH is complexly regulatedby its substrate L-Phenylal-
anine and its natural cofactor 6R-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4). Sapropterin dihydrochloride, the synthetic
form of BH4, was recently approved as the first pharmacological
chaperone to correct the loss-of-function phenotype. However,
current knowledge about enzyme function and regulation in the
therapeutic setting is scarce. This illustrates the need for com-
prehensive analyses of steady state kinetics and allostery beyond
single residual enzyme activity determinations to retrace the
structural impact of missense mutations on the phenylalanine
hydroxylating system. Current standard PAH activity assays are
either indirect (NADH) or discontinuous due to substrate and
product separation before detection. We developed an auto-
mated fluorescence-based continuous real-time PAH activity
assay that proved to be faster and more efficient but as precise
and accurate as standardmethods.Wild-type PAHkinetic anal-
yses using the newassay revealed cooperativity of activatedPAH
toward BH4, a previously unknown finding. Analyses of struc-
turally preactivated variants substantiated BH4-dependent
cooperativity of the activated enzyme that does not rely on the
presence of L-Phenylalanine but is determined by activating
conformational rearrangements. These findings may have
implications for an individualized therapy, as they support the
hypothesis that the patient’s metabolic state has a more signifi-
cant effect on the interplay of the drug and the conformation
and function of the target protein than currently appreciated.
Phenylalanine hydroxylase (PAH4; EC 1.14.16.1) is a non-
heme iron monoxygenase that catalyzes the hydroxylation of
the substrate L-Phe to L-Tyr in the presence of its natural cofac-
tor 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and molec-
ular dioxygen. Mutations in the PAH gene can lead to protein
misfolding with loss of function and subsequently to phenylke-
tonuria ([MIM 261600]), the most common inborn error of
amino acidmetabolism in European-descended populations (1,
2). Pharmacological doses of BH4 can correct protein misfold-
ing in a significant number of patientswith PAHdeficiency, and
sapropterin dihydrochloride, the synthetic form of the natural
PAH cofactor, was recently approved as the first pharmacolog-
ical chaperone to treat phenylketonuria patients (3–5).
The enzyme is a homotetramer built as a dimer of dimers
with each subunit consisting of an N-terminal regulatory
domain (residues 1–142), a catalytic domain (residues 143–
410), and a C-terminal oligomerization domain (residues 411–
452). Elaborate functional and kinetic studies have revealed
complex enzyme regulation by its substrate and cofactor as well
as by phosphorylation (6–8). Binding of the substrate induces a
catalytically competent (activated) enzyme, whereas binding of
BH4 leads to formation of an inactive dead-end PAH-BH4 com-
plex (9–12). These regulatory mechanisms require reversible
conformational changes that are transmitted throughout the
enzyme upon binding of BH4 and L-Phe (13). Structural analy-
ses of BH4 binding revealed that the cofactor interacts with the
N-terminal autoregulatory sequence and the pterin binding
loop, leading to stabilizing hydrogen bonds and to formation of
a binary enzyme-BH4 complex (14). The largest conformational
changes were observed upon binding of L-Phe, where local
changes at the active site are propagated globally through
hinge-bending motions in the catalytic domain, also altering
the position and orientation of bound BH4 (13, 15) and of the
regulatory domain (16).
Analyses of the effects of missense mutations in the PAH
gene on PAH enzyme kinetic properties have shown that resid-
ual enzyme activity generally is high, yet allostery is often dis-
turbed (17–19), with reduced cooperativity for substrate bind-
ing, decreased substrate activation, or altered affinity to the
substrate and the cofactor. Thus, the evaluation of kinetics and
allostery can help to assess to which extent local single amino
acid replacements lead to global conformational alterations
compromising enzyme function. In this context, comprehen-
sive steady state kinetic analyses beyond single determination
of residual enzyme activity are needed to retrace the structural
impact of missense mutations on the phenylalanine hydroxy-
lating system.Yet, the current standard activity assays requiring
substrate and product separation before L-Tyr detection by
radioactivity or fluorescence signals (20–22) are laborious and
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time consuming. In addition, designed as end-point measure-
ments, these discontinuous assays assume a linear range of
activity for the time period chosen, although variations of tem-
perature and pH aswell as concentrations of enzyme, substrate,
and cofactor can dramatically change the linearity of a reaction
over the fixed time window (23). Therefore, we aimed to
develop an automated continuous real-time assay of PAHactiv-
ity. Our new fluorescence-based multi-well assay has given rise
to the possibility of evaluating PAH kinetics and allostery faster
and more efficiently but as precisely and accurately as the
standard methods. Surprisingly, by application of this tech-
nique, the data obtained for BH4-dependent PAH kinetics did
not fit to thewell acceptedmodel of a single hyperbolic function
(Michaelis-Menten kinetic model). Instead, a good fit was
found using a sigmoidal binding curve (Hill kinetic model).
Although positive cooperativity for the binding of L-Phe has
been extensively studied (24, 25), cooperativity toward BH4 has
not been described to date. However, cofactor-dependent
kinetic studies were routinely performed using the non-acti-
vated PAH enzyme (19, 26), whereas an L-Phe preincubated
(activated) enzyme was applied in our experiments.
Thus, we aimed to characterize BH4-dependent PAH kinet-
ics in more detail and to investigate whether activation of PAH
is a prerequisite for the positive cooperativity observed. Real-
time fluorescence kinetic analyses using L-Phe-activated and
non-activated PAH were performed. Furthermore, genetic
variants of PAH, which are structurally preactivated by single
amino acid replacements, were analyzed. To discriminate
between non-cooperative and cooperative enzyme kinetics, in-
depth model comparisons by nonlinear regression analysis
were conducted with fitting of the data to the Michaelis-Men-
ten or the Hill kinetic model.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant PAH Enzymes—
The cDNA of human phenylalanine hydroxylase (EST clone
obtained from Imagines, formerly RZPD,Germany) was cloned
into the pMAL-c2E and pMAL-c2X expression vectors (New
EnglandBiolabs) encoding anN-terminalmaltose-binding pro-
tein (MBP) tag and enterokinase or Factor Xa cleavage sites,
respectively. PAH mutants were constructed by site-directed
mutagenesis as described (17). Escherichia coli DH5! were
transformed with the expression vector for wild-type and
mutant MBP-PAH fusion proteins. Proteins were purified by
affinity chromatography (MBP Trap, GE Healthcare) followed
by size-exclusion chromatography using aHiLoad 26/60 Super-
dex 200 column (GE Healthcare) on an ÄKTAxpress system as
previously described (17). The isolated tetrameric fusion pro-
teins were collected, and protein concentrations were deter-
mined spectrophotometrically using "280 (1 mg/ml) ! 1.63. Tet-
rameric fusion protein was cleaved by factor Xa (10 units of
factor Xa:1mg of fusion protein) at 4 °C for 16 h and isolated by
size-exclusion chromatography using aHiLoad 16/60 Superdex
200 prep grade column (GE Healthcare). Protein concentra-
tions of the cleaved tetrameric PAH were determined spectro-
photometrically using "280 (1 mg/ml) ! 1.0.
Verifying Direct Fluorescence Detection of Enzymatic L-Tyr
Production—To verify the spectral separation needed for the
direct in-well fluorescence detection of enzymatic L-Tyr pro-
duction, L-Tyr (0–150 #M) (Sigma) in 17 mMNaHepes, pH 7.3,
was added to all wells of a 96-well plate (NUNCF96) containing
a reaction mixture with 1 mg/ml catalase (Sigma), 10 #M fer-
rous ammonium sulfate (Fe2") (Fluka), and L-Phe (0–1000#M)
(Sigma) yet lacking the apoenzyme andBH4. L-Tyr fluorescence
intensity was subsequentlymeasured using a fluorescence pho-
tometer (FLUOstar OPTIMA, BMG Labtech) at an excitation
wavelength of 274 nm and an emission wavelength of 304 nm.
Individual experiments were assayed as triplicates. All concen-
trations mentioned refer to a final volume of 204 #l.
Quantification of L-Tyr Production—For the quantification
of L-Tyr production, standards consisting of L-Tyr (0–463 #M)
and L-Phe (547 #M) in 17 mM NaHepes, pH 7.3, 1 mg/ml cata-
lase, and 10 #M ferrous ammonium sulfate were measured
before each experiment using the fluorescence photometer
(excitation 274 nm, emission 304 nm). Individual experiments
were assayed as triplicates before enzyme kinetic measure-
ments on each experimental day. All concentrationsmentioned
refer to a final volume of 204 #l.
Analysis of the Inner Filter Effect (IFE) of BH4—A 96-well
plate was prepared with L-Tyr (0–150 #M) in 17 mM NaHepes,
pH 7.3, and a standard reaction mixture containing the stan-
dard concentration of 1mM L-Phe in 17mMNaHepes, pH 7.3, 1
mg/ml catalase, 10 #M ferrous ammonium sulfate, and 15 mM
NaHepes, pH 7.0. Subsequent to injection of BH4 (0–125 #M)
(6R-L-erythro-5,6,7,8-tetrahydrobiopterin, Schircks Laborato-
ries) stabilized in 2 mM dithiothreitol (DTT) (Fluka), L-Tyr
fluorescence intensity was measured using the fluorescence
photometer (excitation 274 nm, emission 304 nm). The IFE of
BH4 was corrected by defining a correction factor for each BH4
concentration added to the reaction mixture: q ! f (at each
[BH4])/f (fluorophore alone), where f is the fluorescence inten-
sity, and q is the correction factor for the substrate concentra-
tion (27, 28). All measurements were assayed as triplicates
before enzyme kinetic measurements on each experimental
day. All concentrations mentioned refer to a final volume of
204 #l.
Time-dependent Enzyme Activity Measurement—For time-
dependent enzyme activity measurements, the assay was per-
formed with and without preincubation of the enzyme with 1
mML-Phe.A reaction buffer containing 1mg/ml catalase, 10#M
ferrous ammonium sulfate, and the tetrameric MBP-PAH
fusion protein (0.01 mg/ml) was prepared. After preincubation
with 1 mM L-Phe in 22.35 mM NaHepes, pH 7.3, for 5 min at
25 °C, the reaction was initiated by the addition of 75 #M BH4
stabilized in 2 mM DTT. For enzyme activity measurements
without L-Phe preincubation, the reaction was initiated by
simultaneous injection of 1 mM L-Phe and 75 #M BH4.
Time-dependent substrate production was assessed by
detection of the increase in L-Tyr fluorescence intensity at an
excitationwavelength of 274 nmand an emissionwavelength of
304 nm using a fluorescence spectrophotometer (Cary Eclipse,
Varian). All concentrations mentioned refer to the final con-
centration in a 204-#l reaction mixture.
PAH Cooperativity for BH4
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Multiwell Enzyme Activity Assay with and without L-Phe
Preactivation—For PAH activity measurement, L-Phe in 22.35
mM NaHepes, pH 7.3, was added to 12 wells of a 96-well plate
with varying L-Phe concentrations (0–1000 !M) or at a con-
stant L-Phe concentration (1 mM) using the injection system of
a fluorescence photometer. A reaction buffer containing 1
mg/ml catalase, 10 !M ferrous ammonium sulfate, and the tet-
rameric MBP-PAH fusion protein (0.01 mg/ml) was prepared
and injected in all 12 wells. After preincubationwith L-Phe for 5
min at 25 °C, the reaction was initiated by the addition of BH4
stabilized in DTT for a final concentration of 75 !M BH4 with
varying L-Phe concentrations (0–1000!M) or varying BH4 con-
centrations (0–125 !M) at 1 L-Phe concentration (1 mM) and 2
mM DTT.
For enzyme activitymeasurementswithout L-Phe preincuba-
tion, the reaction buffer was prepared and injected to 12 wells.
The reaction was initiated by simultaneous injection of varying
L-Phe concentrations (0–1000 !M) and 1 BH4 concentration
(75 !M) or 1 L-Phe concentration (1 mM) and varying BH4 con-
centrations (0–125 !M).
Steady state kinetics of PAH were determined at 25 °C and
a 60-s measurement time per well. Substrate production was
assessed by detection of the increase in L-Tyr fluorescence
intensity at an excitation wavelength of 274 nm and an emis-
sion wavelength of 304 nm using a fluorescence photometer
(FLUOstar OPTIMA, BMG Labtech) and assayed as dupli-
cates on 3 consecutive days. Fluorescence intensity signals
were corrected for the quenching effect of BH4. All concen-
trations mentioned refer to the final concentration in a
204 !l reaction mixture.
For all enzyme activitymeasurements, fluorescence intensity
was recorded and, after subtraction of the blank reaction, con-
verted to enzyme activity units (nmol Tyr/min ! mg protein)
using the standard curve obtained by L-Tyr concentration
measurements. Data were analyzed by nonlinear regression
analysis using the single hyperbolic model (Michaelis-Menten
kinetic model),
v "
Vmax"S#
Km # "S#
(Eq. 1)
where v is the observed rate of enzyme catalysis, Vmax is the
maximum rate of enzyme catalysis, [S] is the substrate concen-
tration, and Km is the substrate concentration at which Vmax/2
is reached and the sigmoidal kineticmodel (Hill kineticmodel),
v "
Vmax
!1 # "EC50"S# #h$
(Eq. 2)
where v is the observed rate of enzyme catalysis, Vmax is the
maximum rate of enzyme catalysis, [S] is the substrate concen-
tration, EC50 is the substrate concentration at which Vmax/2 is
reached, and h is the Hill coefficient (GraphPad Prism 4.0c).
Values are given as themean$ S.E. of three independent exper-
iments. The coefficient of variation was determined as the ratio
of the S.D. to the mean value. Comparison of model fitting was
performed using the F-test (GraphPad Prism QuickCal), resid-
uals of values, the S.D. of the residuals (Sy.x), the runs test, and
the square of residuals (R2) (see supplemental Tables S1
and S2 and Fig. S2) (29–34).
Tryptophan Fluorescence Measurements—For tryptophan
fluorescence emission scans, wild-type PAH, dimeric PAH
103–427, and variant PAHR68Swere diluted to 11!Msubunits
PAH (0.6 !g/!l) in 20 mM NaHepes and 200 mM NaCl, pH 7.0,
containing 10 !M ferrous ammonium sulfate and 2 mM DTT.
Fluorescence measurements were performed using a fluores-
cence spectrophotometer (Cary Eclipse, Varian) at an excita-
tionwavelength of 295 nmwith excitation and emission slits set
to 2.5 and 5 nm, respectively.
Differential Scanning Fluorimetry—Differential scanning
fluorimetry analyses were performed on a Cary Eclipse fluores-
cence spectrophotometer equipped with a temperature-con-
trolled Peltier multicell holder (Varian). Denaturation of 6 !M
MBP-PAH subunits diluted in 20 mM NaHepes and 200 mM
NaCl, pH 7.0, containing 2 mM DTT was performed by scan-
ning a temperature range of 25 to 70 °C at a rate of 1.2 °C/min.
In the cases indicated, L-Phe was added to a final concentration
of 1 mM. Changes in 8-anilino-1-naphtalenesulfonic acid fluo-
rescence emission (Sigma) were monitored at 500 nm (excita-
tion 395 nm, slit widths 5.0/10.0 nm). The phase transitions of
three to eight independent experiments were determined, and
the respective transition midpoints were calculated using the
Boltzmann sigmoidal equation. Transition midpoints for wild-
type and variant PAHwith and without L-Phe were plotted and
compared using a paired t test.
RESULTS
Direct Fluorescence Detection of Enzymatic L-Tyr Production—
To date measurement of PAH activity is routinely performed
using a standard reaction mixture containing the apoenzyme,
Fe2%, L-Phe, and BH4 followed by time-consuming chromato-
graphic separation of substrate and product. Yet differences in
the fluorescence properties of the aromatic amino acids L-Phe
and L-Tyr, such as emission and excitation wavelengths as well
as the quantum yield, would allow for spectral separation of
these substances even in a mixed solution.
To determine spectral separation of the two substances, we
assessed fluorescence signal intensities of varying L-Tyr con-
centrations at 304 nm (35), the L-Tyr emission wavelength, as a
function of increasing L-Phe concentrations. We showed that
direct in-well detection of L-Tyr was unaffected by the various
L-Phe concentrations used in our assay (Fig. 1A and sup-
plemental Fig. 1A). This was true for all L-Tyr concentrations
expected in the following enzyme kinetic measurements. How-
ever, L-Tyr fluorescence signal intensities decreased with
increasing BH4 concentrations (supplemental Fig. 1B), suggest-
ing an IFE of BH4 on L-Tyr excitation and emission. Therefore,
we determined specific correction factors on the basis of the
factorial decrease of signal intensity for every BH4 concentra-
tion added to account for the IFE (Fig. 1B) (27, 28). Evaluation of
the IFE of BH4 and calculation of the correction factor for each
BH4 concentration added to the reaction mixture was per-
formed before each enzyme kinetic measurement (Fig. 1B).
The analysis of steady state enzyme kinetics using direct in-
well detection of L-Tyr production revealed a time-dependent
change of enzyme activity upon the addition of BH4, with an
PAH Cooperativity for BH4
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initial high activity burst phase (Fig. 1C and Fig. 1D, top) fol-
lowed by a linear steady state rate of catalysis for the L-Phe
preincubated (activated) enzyme (Fig. 1C and Fig. 1E, top). In
contrast, the non-activated enzyme showed an initial lag-phase
(Fig. 1C and Fig. 1D, bottom) before a linear phase of L-Tyr
production (Fig. 1C and Fig. 1E, bottom).
In addition, time-dependent initial velocity measurements
require substrate turnover to remain less than 10% that of the
FIGURE 1. A novel continuous assay for the measurement of PAH activity. A, fluorescence intensity (I304) of L-Tyr concentrations (0 –150 !M) with increasing
L-Phe concentrations (0, 243, 490, and 958 !M) is shown. L-Tyr fluorescence intensity was not influenced by increasing L-Phe concentrations, confirming spectral
separation of the two substances in one mixed solution. Values are given as the mean ! S.E. of three independent measurements. B, quenching of L-Tyr
fluorescence intensity by BH4 is shown. Measurement of L-Tyr (0 –150 !M) subsequent to the addition of increasing BH4 concentrations (0, 25, 75, and 125 !M),
revealed an inner filter effect of BH4 on L-Tyr excitation and emission (left panel). For each BH4 concentration used in the assay, a correction factor was calculated
according to the factorial decrease in signal intensity to account for the inner filter effect (right panel). Values are given as the mean ! S.E. of three independent
measurements. C, continuous measurement of time-dependent wild-type PAH kinetics with and without preincubation of the enzyme with 1 mM L-Phe are
shown. D, L-Phe preincubation (activation) led to burst-phase kinetics within the first 30 s of the reaction (top) followed by a linear phase of L-Tyr production.
Without L-Phe preincubation, an initial lag-phase before steady state enzyme kinetics was found (bottom, a red line was used to guide the eye). E, the time frame
chosen for the measurement of steady state enzyme kinetics between 30 and 120 s showed a linear rate of reaction (top, with L-Phe preincubation; bottom,
without L-Phe preincubation). F, a 96-well plate for sequential measurement of PAH enzyme kinetics is shown. Direct in-well measurements of enzyme kinetics
of up to four different PAH enzymes (numbers 1– 4) were performed by the sequential analysis of 2 rows, consisting of 24 wells (red box). Each row contained the
PAH enzyme varying substrate concentrations (0 –1 mM) and one cofactor concentration (75 !M) or varying cofactor concentrations (0 –125 !M) and one
substrate concentration (1 mM). Repeated cycles allowed kinetic measurements of 24 wells over a time period of 60 s.
PAH Cooperativity for BH4
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substrate concentrations added to the reaction mixture (23). A
time frame of 60 s for measurement of steady state enzyme
kinetics starting 30 s after the addition of BH4 proved to best
fulfill the criteria of linearity and limited substrate turnover.
To allow for an accurate and efficient performance of the
enzyme kinetic assay, liquid handling and signal detection were
automated using a multi-well fluorescence detection device
with an integrated injection system. Various substrate or cofac-
tor concentrations were injected for L-Phe or BH4-dependent
kinetics, respectively, and process automation enabled sequen-
tial duplicate measurements of up to four different PAH
enzymes, resulting in reduced time for experimental prepara-
tion and procedure (Fig. 1F).
Thus, real-time measurement of PAH product formation
revealed that direct in-well detection of L-Tyr during the cata-
lytic reaction without prior separation of substrate and product
is feasible when BH4 quenching is taken into account. In addi-
tion, real-time kinetics give more insights into both pre-steady
state and steady state kinetics of phenylalanine hydroxylation,
allowing thorough analysis of PAH enzyme kinetics.
A Continuous PAH Activity Assay Reveals BH4-dependent
Cooperativity—The newly developed continuous assay was
used to determine enzyme kinetic parameters at varying sub-
strate concentrations (L-Phe, 1–1000 !M) and a constant
cofactor concentration (BH4, 75 !M) or at varying cofactor
concentrations (BH4, 0–125 !M) and a constant substrate
concentration (L-Phe, 1 mM).
Measurement of L-Phe-dependent PAH kinetics showed sig-
moidal behavior for the activated enzyme (Fig. 2A) as previ-
ously described (24, 36–38). Enzyme kinetic parameters were
calculated by nonlinear regression analysis using the Hill equa-
tion, accounting for substrate cooperativity and comparedwith
the results of a standard discontinuous PAH activity assay
(Table 1) (17). Values for Vmax were substantially higher when
determined by the continuous assay (6598 nmol Tyr/min!mg
protein) as compared with the discontinuous assay (3470 nmol
Tyr/min ! mg protein). However, apparent affinity to the sub-
strate (S0.5 156 !M), cooperativity (Hill coefficient, hPhe 3.0),
and substrate activation (activation-fold 2.8) showed virtually
identical results in both experiments (discontinuous assay; S0.5
155 !M, hPhe 3.0, activation-fold 3.0). As expected from previ-
ous studies using recombinant human PAH (26, 37) and the rat
enzyme (36), enzyme kinetic parameters obtained without
L-Phe preincubation gave different results (Table 1). Vmax was
markedly lower (2533 nmol Tyr/min ! mg protein), and the
apparent affinity of the enzyme to L-Phe (Km 318 !M) was
reduced. In addition, binding of L-Phe to the non-activated
enzyme was found to be non-cooperative (hPhe 1.0). This is in
concordance with studies using surface plasmon resonance
(25). The enzyme kinetic parameters determined for both acti-
FIGURE 2. Measurements of wild-type PAH kinetics. A, reaction rates at variable L-Phe concentrations (0 –1 mM) and one BH4 concentration (75 !M) are
shown. Before initiation of the reaction by BH4, the enzyme was preincubated for 5 min at 25 °C with L-Phe to activate the enzyme. Nonlinear regression analysis
was performed using the Hill equation. B and C, reaction rates at variable BH4 concentrations (0 –125 !M) and one L-Phe concentration (1 mM) are shown. B, data
obtained for the L-Phe preincubated (activated) enzyme were evaluated using the Michaelis-Menten equation (dashed line) and the Hill equation (solid line). C, a
comparison of enzyme kinetics measured using the non-activated (F) and the activated (E) wild-type PAH is shown. The non-activated enzyme showed
non-cooperative binding of BH4. The activated enzyme indicated positive cooperativity for the binding of BH4. D, enzyme kinetics of non-activated and
activated PAH at variable BH4 concentrations (0 –50 !M) and one L-Phe concentration (1 mM) are shown. Data obtained for the non-activated enzyme were fit
to the Michaelis-Menten equation (left panel). Data of the activated enzyme followed Hill kinetics (right panel). For all enzyme activity measurements, fluores-
cence intensity was recorded and after subtraction of the blank reaction converted to enzyme activity units (nmol L-Tyr/min ! mg protein) using the standard
curve obtained by L-Tyr concentration measurements. Values are given as the mean " S.E. of three independent experiments.
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vated and non-activated PAH were well comparable with the
data found in previous studies (Table 1) (17, 37).
Surprisingly, the data obtained for BH4-dependent PAH
kinetics did not fit to the well accepted Michaelis-Menten
kinetic model. Instead, the data showed a sigmoidal behavior,
indicating BH4-dependent cooperativity (Fig. 2B). Although
BH4-dependent kinetics was as yet mainly determined using
the non-activated enzyme (19, 26), we conducted the assay uti-
lizing the L-Phe-preincubated (activated) enzyme. To examine
whether the Hill kinetic model describing BH4-dependent
kinetic parameters depends on the activation state of the
enzyme, the assay was runwith andwithout prior incubation of
the enzyme by L-Phe, and the results were compared with data
from the literature (Table 2). Similar to L-Phe-dependent
enzyme kinetics, Vmax of the activated enzyme was markedly
lower in the discontinuous assay (3425 nmol Tyr/min ! mg
protein) when compared with the continuous assay (7288 nmol
Tyr/min ! mg protein), but the values for the apparent affinity
to the ligand were comparable for both methods used (Km 24
!M; C0.5 33 !M) (Table 2). Although the analysis of the non-
activated enzyme showed a reduction in Vmax (2277 nmol Tyr/
min!mg protein), an increased apparent affinity to BH4 (Km 8
!M) was observed. In addition, steady state kinetic analysis of
activated PAH indicated BH4-dependent-positive cooperativ-
ity (Hill coefficient, hBH4 2.2), whereas Michaelis-Menten
kinetics for the non-activated PAHwas confirmed (Fig. 2C). To
obtain a better resolution of the range that best discriminates
between both kinetic models, the assay was repeated in the
limits of 0–50 !M BH4 (Fig. 2D). The data obtained for the
activated enzyme clearly followed Hill kinetics (hBH4 2.0). This
was in contrast to the non-activated enzyme, where nonlinear
regression analysis showed hyperbolic kinetics following the
Michaelis-Menten kinetic model (hBH4 1.0).
The enzyme kinetic parameters determined for L-Phe- and
BH4-dependent enzyme kinetics were well comparable with
previous studies using the standard discontinuous assay (17,
19), confirming the accuracy of our newly developed continu-
ous assay. Furthermore, we aimed to determine the assay pre-
cision and calculated the coefficient of variation for all enzyme
kinetic parameters of the activated enzyme, comparing the
standard discontinuous with the continuous assay. The coeffi-
cients of variation for both L-Phe- and BH4-dependent kinetic
parameters were similar for the two assays, revealing equal pre-
cision in enzyme kinetic measurements (Tables 1 and 2).
In conclusion, allosteric parameters obtained using the
newly developed PAH activity assay were well comparable with
results from standard discontinuous assays. The assay accuracy
as well as precision confirmed the suitability of this method for
the evaluation of enzyme kinetic parameters of PAH. In addi-
tion, PAH kinetic analysis using the continuous assay gave evi-
dence for BH4-dependent cooperativity with PAH activation as
a prerequisite.
BH4-dependent Cooperativity Relies on an Activated Struc-
tural Conformation of PAH—Three variant PAH enzymes,
R68S, V106A, and the dimeric double-truncated form 103–427
(19, 37, 39, 40), were used to characterize the interrelation of
enzyme activation and BH4-dependent cooperativity in more
detail. In particular, we aimed to investigatewhether the shift in
enzyme kinetics from Michaelis-Menten to the Hill kinetic
model depends on the presence of the L-Phe substrate itself or
on structural attributes of the activated enzyme. It is known
that substrate activation induces conformational changes (16,
TABLE 1
Comparison of L-Phe-dependent enzyme kinetic parameters obtained by standard PAH activity assay and direct in-well detection of L-Tyr
production
Steady state kinetic parameters of WT MBP-PAH fusion protein are shown. Apparent affinities for L-Phe (S0.5, Km, and the Hill-coefficient (hPhe) as a measure of
cooperativity are shown. Measurements were performed with (") and without (#) L-Phe preincubation of the enzyme. Enzyme kinetic parameters were determined at
variable L-Phe concentrations (0–1000 !M) and standard BH4 concentrations (75 !M). CV, coefficient of variation, defined as the ratio of the S.D. to the mean value.
L-Phe preincubation Vmax CV S0.5 CV Km hPhe Activation folda
nmol L-Tyr/min ! mg protein % !M % !M
WTb # 495c 318c 1.5c —
" 1550c 154c 2.2c 3.1c
" 3470 $ 75d 2 155 $ 6d 4 3.0d 3.0d
WTe # 2533 $ 217 — 318 $ 68 1.0 —
" 6598 $ 190 3 156 $ 9 6 3.0 2.8
aFold increase in PAH activity by L-Phe preincubation calculated at the standard L-Phe (1 mM) and BH4 (75 !M) concentrations.
bMeasurement by standard discontinuous PAH activity assay (HPLC and fluorimetric detection). Values are given as the mean $ S.E. of three independent experiments.
cFrom Knappskog et al. (37); activation fold was calculated from Vmax.
dFrom Gersting et al. (17).
eMeasurement by continuous PAH activity assay (direct in-well fluorescence detection). Values are given as the mean $ S.E. of four independent experiments.
TABLE 2
Comparison of BH4-dependent enzyme kinetic parameters obtained by standard PAH activity assay and direct in-well detection of L-Tyr
production
Steady state kinetic parameters of WTMBP-PAH fusion protein are shown. Apparent affinities for BH4 (C0.5) and the Hill-coefficient (hBH4) as a measure of cooperativity
are shown. Measurements were performed with (") and without (#) L-Phe preincubation of the enzyme. Enzyme kinetic parameters were determined at variable BH4
concentrations (0–125 !M) and standard L-Phe concentrations (1 mM). CV, coefficient of variation, defined as the ratio of the S.D. to the mean value.
L-Phe preincubation Vmax CV Km CV C0.5 CV hBH4
nmol L-Tyr/min ! mg protein % !M % !M %
WTa " 3425 $ 139b 4 24 $ 3b 12.5 — 1.0
WTc # 2277 $ 84 8 $ 1 — 1.0
" 7288 $ 282 4 — 33 $ 2 6 2.2
aMeasurement by standard discontinuous PAH activity assay (HPLC and fluorimetric detection). Values are given as the mean $ S.E. of three independent experiments.
bFrom Gersting et al. (17).
cMeasurement by continuous PAH activity assay (direct in-well fluorescence detection). Values are given as mean $ S.E. of four independent experiments.
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37, 41–45) that convert the enzyme from a low activity T-state
to a high activity R-state (Monod Wyman Changeux model)
(46, 47). This is accompanied by an increase in quantum yield
and a red-shifted emission maximum of the Trp-120 residue
(48, 49). To determine the level of preactivation, structural
attributes of the variants were compared with wild-type PAH.
Spectral differenceswith andwithout preincubation by the sub-
strate were utilized to assess the activation state.
Tryptophan emission scans of wild-type PAH and the vari-
ants R68S and 103–427 were performed. As expected, wild-
type PAH revealed a red shift in the emissionmaximum (340 to
351 nm) and an increase in intrinsic tryptophan fluorescence
(247–296 arbitrary units) upon the addition of L-Phe (Fig. 3A)
(Table 3). Both variants showed a red-shifted emission maxi-
mum in the absence of L-Phe, which was more pronounced for
the dimeric variant.Upon L-Phe preincubation, R68S yielded an
emission maximum of the activated wild-type (351 nm),
whereas the emission maximum of the dimeric PAH remained
unchanged (350 nm). Both variants showed an increase in
quantumyield but to a lesser extent than observed forwild-type
PAH. Furthermore, we determined activation-induced struc-
tural rearrangements for all three variants by thermal unfolding
using temperature-dependent differential scanning fluorimetry
(Fig. 3B). Although the addition of L-Phe induced a highly sig-
nificant increase in the transition midpoint for wild-type PAH
(p ! 0.0006), no significant increase was found for the variants
R68S and V106A (Fig. 3B) (Table 4). These variants already
showed increased transition midpoints at the activated wild-
type level even without L-Phe preincubation. The dimeric PAH
103–427, although showing markedly decreased transition
midpoints in general, revealed a significant increase when
L-Phe was added (p ! 0.0345). Taken together, all variants dis-
played structural characteristics that are indicative of muta-
tion-induced conformational preactivation but to different
extents.
According to the results on structural preactivation, evalua-
tion of the activation-fold determined by the continuous assay
(Fig. 3C) (Table 5) confirmed functional preactivation of the
variants without L-Phe preincubation (R68S, 0.9; V106A, 1.0;
103–427, 1.3). Nonlinear regression analysis of BH4-dependent
kinetics of all three preactivated variants followed the Hill
model as shown for activated wild-type PAH. Although dis-
tinctly positive, the Hill-coefficients ranging from 1.6 to 2.1
were lower than that determined for activated wild-type PAH
(h, 2.2). The dimeric variant 103–427 showed a Vmax (1980
nmol Tyr/min " mg protein) comparable with that of the non-
activated wild-type PAH, which did not change markedly upon
L-Phe preincubation (2421 nmol Tyr/min " mg protein). This
is in contrast to an increase by 3.2-fold observed for wild-type
PAH preincubated with L-Phe. However, for the variants R68S
and V106A, a Vmax comparable with the activated wild-type
PAH was found without L-Phe preincubation, and no further
increase was measured when the substrate was present. R68S
and V106A without L-Phe preincubation showed lower cofac-
tor affinities than the non-activated wild-type PAH; however,
the values were at the same level as determined for the L-Phe
preincubatedwild-type PAH.C0.5 of the dimeric PAH103–427
was 2-fold higher as compared with the non-activated wild-
type PAH. Notably, no marked changes in sigmoidal behavior
and kinetic parameters were observed for all variants irrespec-
tive of whether they were preincubated by L-Phe (Fig. 3C)
(Table 5). In summary, analyses of structurally preactivated
variants substantiated BH4-dependent positive cooperativity of
FIGURE 3. Determining the activated structural and functional conformation. A, intrinsic tryptophan fluorescence emission spectra of the Factor Xa
cleaved wild-type PAH, variant PAH R68S, and 103– 427 are shown. Fluorescence emission spectra were acquired in the absence (dashed line) or presence (solid
line) of 1 mM L-Phe. The excitation wavelength for Trp fluorescence measurements was 295 nm, with an excitation and emission slit of 2.5 and 5 nm, respectively.
a.u., arbitrary units. B, differential scanning fluorimetry of the wild-type PAH and variant PAH R68S, V106A, and 103– 427 fusion protein are shown. Denaturation
of PAH was monitored by scanning a temperature range of 25 to 70 °C at a rate of 1.2 °C/min. Changes in 8-anilino-1-naphtalenesulfonic acid fluorescence
emission were monitored at 500 nm (excitation 395 nm, slit widths 5.0/10.0 nm). The fraction unfolded of three to four independent experiments for wild-type,
R68S, and 104 – 427 and seven to eight independent experiments for V106A without L-Phe (solid line) and with 1 mM L-Phe (dashed line) were determined (top
panel; wild-type (black), R68S (blue), V106A (green), and 103– 427 (red)), and the respective transition midpoints were calculated using the Boltzmann sigmoidal
equation. For comparison of the transition midpoints, a paired t test, two-tailed, was used. Transition midpoints for wild-type and variant PAH, with (E) and
without (F) L-Phe preincubation were plotted and compared (bottom panel) (ns, not significant; *, p # 0.05; **, p # 0.01; ***, p # 0.001). C, enzyme activity
measured for the wild-type PAH and the preactivated variants R68S, V106A, and 103– 427 without preincubation (F) and with preincubation of the enzyme (E)
with 1 mM L-Phe before initiation of the reaction by the addition of BH4. Data obtained for the non-preincubated and preincubated enzymes followed the Hill
kinetic model as shown for the activated wild-type PAH. For all enzyme activity measurements, fluorescence intensity was recorded and after subtraction of the
blank reaction converted to enzyme activity units (nmol of L-Tyr/min " mg protein) using the standard curve obtained by L-Tyr concentration measurements.
Values are given as the mean $ S.E. of three independent experiments.
TABLE 3
Trp emission scans of PAH cleaved by factor Xa
Tryptophan fluorescence emission spectra were obtainedwith andwithout L-Phe (1
mM) preincubation of the cleavedWTPAH and preactivated variants. Fluorescence
measurements were performed using a fluorescence spectrophotometer at an exci-
tation wavelength of 295 nm with excitation and emission slits set to 2.5 and 5 nm,
respectively. a.u., arbitrary units.
Without L-Phe
preincubation
With L-Phe
preincubation
Wavelength Fluorescenceintensity Wavelength
Fluorescence
intensity
nm a.u. nm a.u.
WT 340 247 351 296
R68S 345 266 351 304
103–427 350 288 350 310
TABLE 4
Mean transition midpoints of thermal denaturation assays
Calculation of transition midpoints from differential scanning fluorimetry of WT
PAH and preactivated variants with and without 1 mM L-Phe. Transition midpoints
were calculated using the Boltzmann sigmoidal equation. Transition midpoints are
given as themean$ S.E. of three to four for V106A eight independent experiments.
Mean transition midpoints with and without L-Phe were compared using a paired t
test, two-tailed. NS, not significant.
Tm
p valueWithout L-Phe
preincubation
With L-Phe
preincubation
°C
WT 47.49 $ 0.46 50.90 $ 0.38 p ! 0.0006
R68S 49.28 $ 0.78 50.15 $ 0.64 NS
V106A 49.63 $ 1.40 51.11 $ 0.21 NS
103–427 37.68 $ 0.32 40.99 $ 0.54 p ! 0.0345
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the activated enzyme, where the kinetic model does not rely on
the presence of L-Phe but is determined by activating confor-
mational rearrangements.
Evaluation of Model Fitting—To validate the experimental
data on conditions that determine PAH cooperativity, an
extended evaluation of model fitting by nonlinear regression
analysis of BH4-dependent kinetics was performed. The test
parameters goodness of fit (R2), root mean square (Sy.x), runs
test, and residuals of values were compared, and an F-test was
run to discriminate between the two nested kinetic models
Michaelis-Menten and Hill for activated and non-activated
PAH, respectively.
First we analyzed non-activated PAH.A simple calculation of
goodness of fit (R2) did not allow for distinction between the
two models used for data analyses (R2MM 0.97; R2H 0.97)
(supplemental Table 1). The residuals of values (supplemental
Fig. 2) and, thus, the S.D. of the residuals also showed no
marked improvement of data description by the more compli-
catedHill equation. Although the runs test showed amarginally
significant deviation of the data from the Michaelis-Menten
model (p ! 0.048), the F-test proved the simpler Michaelis-
Menten kinetics to be the correct model for data analysis of
BH4-dependent kinetics of non-activated PAH (F ratio 2.86;
p ! 0.125) (Table 6). This was confirmed by refined analysis of
BH4-dependent kinetics in the limits of 0–50!M. As before,R2,
Sy.x, and the residuals of values did not allow for a clear distinc-
tion between the twomodels (supplemental Table 1). However,
no significant deviation of the data from any of the two equa-
tions could be determined by the runs test. Yet again, the F-test
revealed that the data were best described by the simpler
Michaelis-Menten kinetic model (F ratio 0.58; p ! 0.463)
(Table 6).
In contrast to non-activated PAH, enzyme activation by
L-Phe now resulted in marked differences of the two models
even by goodness of fit (R2MM 0.96; R2H 0.99) (supplemental
Table 1) (Table 6). In addition, evaluation of the data by theHill
equation revealed a decrease of Sy.x by "2-fold, and the resid-
uals of values showed less fluctuation (supplemental Fig. 2). The
runs test showed no significant deviation from any of the two
models used, but comparison by the F-test resulted in a highly
significant p value (F ratio 274.28; p # 0.0001) (Table 6) favor-
ing Hill kinetics. Detailed analysis at low BH4 concentrations
(0–50 !M) additionally uncovered a significant deviation of the
data from Michaelis-Menten kinetics in the runs test (p !
0.024) (Table 6) (supplemental Table 1 and Fig. 2). Taken
together, the evaluation of model fitting provided clear evi-
dence for BH4-dependent positive cooperativity of activated
PAH,whereas the BH4-dependent kinetics of the non-activated
enzyme followed the non-cooperative Michaelis-Menten
model.
Next, we aimed to learn whether the presence of the L-Phe
substrate has an impact on the kinetic model beyond L-Phe
induced conformational changes upon PAH activation. To val-
idate structural preactivation of R68S, V106A, and of the
dimeric double-truncated 103–427 PAH, we first analyzed
whether BH4-dependent kinetic data would fit significantly
better to the more complex Hill equation even without L-Phe
preincubation. Indeed, we identified an increase in R2, a more
than 2-fold decrease in Sy.x, and a significant deviation of the
Michaelis-Menten model in the runs test for the variants R68S
and V106A (supplemental Table 2). Only the dimeric 103–427
showed a less pronounced reduction in Sy.x and no discrimina-
tion between the two models in the runs test. In all cases fluc-
tuation of the residuals of values was lower using the Hill equa-
tion (supplemental Fig. 2). This was in line with the results
obtained by the F-test (p # 0.01) (Table 7). Hence, the kinetic
data fit significantly better to the more complicated Hill equa-
tion, indicating substrate-independent structural preactiva-
tion. Second, model fitting of the structurally activated variants
was compared with and without prior incubation with L-Phe in
the next step. All in all, the presence of L-Phe only negligibly
changed the test results. Only for the dimeric 103–427, Sy.x
was markedly lower upon evaluation by sigmoidal kinetics,
and the runs test classifiedMichaelis-Menten as an incorrect
TABLE 6
Comparison of two nested non-linear regression models
F-test for two nested models after measurement of wild-type PAH kinetics without
and with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured
with L-Phe (1 mM) and BH4 (0–125 !M and 0–50 !M). The F-test assumes that the
Michaelis-Menten equation is a simpler case of the Hill equation. If the simpler
model is correct, the F ratio is near 1.0. To verify the correctness of the more
complicated model (if the F ratio is $1.0), the p value is calculated. If the p value is
less than the traditional significance level of 5%, it can be concluded that the data do
not randomly fit to the more complicated model but fit significantly better to Hill
than to Michaelis-Menten kinetics.
BH4
F-test
L-Phe preincubation F ratio p value
!M
0–125 % 2.86 0.125
0–125 & 274.28 #0.0001
0–50 % 0.58 0.463
0–50 & 62.79 #0.0001
TABLE 5
Comparison of BH4-dependent enzyme kinetic parameters of variant PAH proteins with and without L-Phe preincubation
Steady state kinetic parameters of variant MBP-PAH fusion proteins were determined by direct in-well activity measurements. Apparent affinities for BH4 (C0.5) and the
Hill-coefficient (h) as a measure of cooperativity are shown. Enzyme kinetic parameters determined at variable BH4 concentrations (0–125 !M) and standard L-Phe
concentrations (1 mM) with and without preincubation of the enzyme with L-Phe (1 mM).
Without L-Phe preincubation With L-Phe preincubation
Vmaxa Km C0.5a hBH4 Vmaxa C 0.5a hBH4 Activation foldb
nmol L-Tyr/min ' mg protein !M !M nmol L-Tyr/min ' mg protein !M
WT 2277 ( 84 8 ( 1 — 1.0 7288 ( 282 33 ( 2 2.2 2.8
R68S 7928 ( 232 — 29 ( 1 1.8 6940 ( 225 34 ( 2 1.8 0.9
V106A 9041 ( 489 — 40 ( 3 1.6 9773 ( 534 43 ( 4 1.8 1.0
103–427 1980 ( 100 — 16 ( 2 2.1 2421 ( 73 19 ( 1 2.6 1.3
aValues are given as the mean ( S.E. of three independent measurements.
bFold increase in PAH activity by L-Phe preincubation calculated at the standard L-Phe (1 mM) and BH4 (75 !M) concentrations.
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model (supplemental Table 2). Again, all data provided evi-
dence for a correct data description by the Hill kinetic model
(supplemental Table 2 and Fig. 2) (Table 7).
In summary, extended analysis and comparison of the two
non-linear regression models Michaelis-Menten and Hill
revealed non-cooperative kinetics of the non-activated enzyme,
whereas activation of the enzyme clearly induced cooperativity.
Moreover, L-Phe preincubation did not have a significant
impact on the kinetic model of structurally activated variant
PAH.
DISCUSSION
In this study we established a newmethod for the evaluation
of PAH kinetic parameters, allowing for real-time detection of
enzyme activity. Continuous assays are the safest means of
determining reaction velocity from the slope of a plot of signal
versus time (23). However, many assays used for the evaluation
of PAH enzyme kinetics are discontinuous due to chromato-
graphic separation of the substrate from the product before
product detection. We aimed to establish the measurement of
L-Tyr production without separation from the substrate L-Phe.
The spectral properties of the aromatic amino acids and differ-
ences in quantum yield allowed for direct detection of L-Tyr
uninfluenced by L-Phe concentrations. However, the IFE of
BH4 at the excitation and emission maxima of L-Tyr (274 and
304nm, respectively) had to be taken into account. By analyzing
the IFE of BH4 on L-Tyr fluorescence in the entire range of
concentrations used in the assay, a concentration-dependent
correction factor was defined (27, 28). This facilitated accurate
and precise quantification of L-Tyr product formation inside
the assay reaction mixture. In addition, all substances required
to perform the activity assay were applied by means of an inte-
grated injection system. Although equally precise, this led to
marked time reduction in sample preparation. Furthermore,
sequential duplicate measurements subsequent to sample
injections of up to four different PAH proteins in a 96-well
format substantially increased the throughput of enzyme kinet-
ics analyses. The addition of various substrate and cofactor con-
centrations as well as their injection at different time-points
proved this method to be very flexible, allowing for numerous
assay conditions in one single run.
By applying the new technique, we observed burst-phase
kinetics of preactivated and lag-phase kinetics of non-activated
PAH. The discontinuous assays used previously measured
product formation from the initiation of the reaction to a
defined end point, and burst- and lag-phase kinetics were not
taken into consideration. However, pre-steady state kinetics
should not be ignored as they may lead to erroneous interpre-
tations regarding the existence of cooperativity (50). A com-
pletemodel describing the enzyme reaction is a prerequisite for
comprehensive understanding of the mechanisms involved in
pre-steady state kinetics. Assumptions to approach such a
model have been made using a prokaryotic monomeric PAH
(51). Yet this enzyme lacks the regulatory properties of the
oligomeric multidomain human protein and is, therefore, not
applicable to human PAH. Therefore, we decided to assess
steady state kinetics at a 1-min time frame after the burst-phase
and provided a linear rate of reaction velocity for the non-acti-
vated and the activated enzyme while remaining within 10% of
substrate turnover.
The data of continuous measurements were compared with
our results obtained previously by the discontinuous assay as
well as to data described in the literature. Differences in Vmax
between the discontinuous and the continuous assay were
found. These variations may be due to the different methods
used, yet additional aspects such as different time frames for
measurement of steady state kinetics and the improvement of
protein purification methods in our laboratory within the last
years play an important role andmay further explain these find-
ings. Notably, large differences in enzyme activities, ranging up
to 7-fold, can also be found in the literature (16, 37, 52, 53).
However, kinetic parameters describing apparent affinity and
enzyme allostery (S0.5, Km/C0.5, Hill coefficient (h), and activa-
tion-fold) were similar to results obtained using discontinuous
assays and to results previously described (17, 37), confirming
the accuracy of our newly developed continuous assay. Further-
more, calculation of the coefficient of variation proved the new
assay to be as precise as the standard discontinuous assays
applied.
Interestingly, data points did not fit to theMichaelis-Menten
kinetic model when themethod was applied to determine BH4-
dependent enzyme kinetics. Instead, a good fit was found apply-
ing the Hill kinetic model. All previous studies using different
methods had shownhyperbolic non-cooperative binding kinet-
ics of the cofactor to PAH (17, 19, 25, 53). When applying the
continuous assay, BH4-dependent kinetics of wild-type PAH
revealed positive cooperativity. However, our experiments
were performed with an L-Phe-preincubated (activated) enzyme,
whereas inmost of the previous studies the non-activated enzyme
had been used. To elucidate whether PAH activation determines
cofactor dependent cooperativity, we compared enzyme kinetics
of non-activated and of activated PAH. In agreement with previ-
ous findings, the continuous assay without L-Phe preincubation
resulted in hyperbolic binding kinetics of BH4. Together with the
observed BH4-dependent cooperativity of activated PAH, these
results suggested that cooperativity of BH4 depends on an acti-
vated state of the enzyme.
Thus, we investigated whether the shift in enzyme kinetics
from Michaelis-Menten to the Hill kinetic model depends on
TABLE 7
Comparison of two nested non-linear regression models with and
without preincubation of preactivated variants
F-test for two nested models after measurement of enzyme kinetics without and
with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured with
L-Phe (1 mM) and BH4 (0–125 !M). The F-test assumes that the Michaelis-Menten
equation is a simpler case of the Hill equation. If the simpler model is correct, the F
ratio is near 1.0. To verify the correctness of the more complicated model (if the F
ratio is !1.0), the p value is calculated. If the p value is less than the traditional
significance level of 5%, it can be concluded that the data do not randomly fit to the
more complicated model but fit significantly better to Hill than to Michaelis-Men-
ten kinetics.
F-test
L-Phe preincubation F ratio p value
R68S " 58.02 #0.0001
R68S $ 69.63 #0.0001
V106A " 24.00 #0.001
V106A $ 35.44 #0.001
103–427 " 10.66 #0.01
103–427 $ 40.23 #0.001
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the presence of the L-Phe substrate itself or on structural
attributes of the activated enzyme. This was dissected bymeans
of conformationally preactivated genetic variants of PAH
(R68S, V106A, dimeric 103–427). Using two different spectro-
scopic techniques we analyzed local and global effects on pro-
tein structure bymutation/truncation or by L-Phe, respectively,
and correlated this with enzyme kinetic parameters. Preincu-
bation of wild-type PAH with L-Phe leads to a series of struc-
tural and functional changes resulting in enzyme activation (16,
37, 41–45). On the structural level these include a red-shifted
and enhanced tryptophan emission and a right-shifted thermal
denaturation profile. On the functional level an increase in
Vmax, a decreased apparent affinity, and a switch from non-
cooperative to positive cooperative kinetics accounted for acti-
vation. All three variants displayed characteristics of structural
and functional preactivation but to varying degrees. Preactiva-
tion of the variants was reflected by the activation-fold with
values ranging from 0.9 to 1.3. Furthermore, all variants dis-
played clear positive cooperativity without prior incubation
with the substrate. In the presence of L-Phe some selective
structural changes for single variants were observed, i.e. a
minor shift in tryptophan emission for R68S and a significantly
enhanced transition midpoint of the thermal denaturation for
103–427. However, no variant showed decisive changes in
enzyme kinetic parameters upon L-Phe preincubation. This
observation held true irrespective of whether the parameter
was at the same level as activated wild-type PAH. These data
provide evidence that the variants are activated at a struc-
tural level and that L-Phe does not have any additional effect
on their activity and cooperativity. We conclude that the
conformation associated with preactivation accounts for
positive cooperativity where L-Phe induces activating con-
formational changes that in turn lead to allostery. The addi-
tion of the substrate to the assay, however, does not induce
cooperativity by itself.
Mathematical analyses of the data obtained by enzyme
kinetic measurements were used to substantiate our findings
on the comparison of the kinetic models (29, 34, 54–58). A
simple calculation of best-fit parameters for enzyme kinetic
data (R2, root mean square, runs test) did not always allow for a
clear distinction between the Michaelis-Menten and the Hill
model. However, the application of an F-test made evident to
which biological mechanism the kinetic data are linked with
highest probability (29–32). Even though a more complex
model like the Hill equation would always fit the experimental
data better than a simpler model, the F-test revealed that kinet-
ics of non-preincubated wild-type PAHwere not described sig-
nificantly better by this model. However, analysis of the L-Phe-
activated enzyme gave a significant p value in the F-test for the
Hill equation and, thus, proved positive cooperativity. These
findings were corroborated when enzyme kinetic analyses were
focused on the area of distinct sigmoidality, i.e. on the range of
0 to 50 !M BH4. Statistical analyses of model fitting for preac-
tivated PAH variants verified BH4-dependent cooperativity
even without prior incubation with L-Phe. Taken together,
mathematical analyses of the cofactor-dependent enzyme
kinetic data confirmed that the non-activated enzyme follows
Michaelis-Menten kinetics, whereas the activated enzyme
shows cooperativity.
Cooperativity of PAH to the L-Phe substrate is reflected by a
Hill coefficient of !3.0 and has previously been described to be
propagated throughout the whole tetramer (59). Alterations in
the orientation of the oligomerization domain transfer cooper-
ative activating conformational changes from one to the other
dimer. This requires a switch between a low affinity “T-state”
conformation to a high affinity “R-state” conformation at ele-
vated L-Phe concentrations following the model proposed by
Monod, Wyman, and Changeux. The Hill coefficients of BH4-
dependent kinetics determined for the L-Phe preincubated
(activated) wild-type PAH and the preactivated variants in this
study were "2.0. The current study may, thus, allow speculat-
ing that enzyme activation leads to positive cooperativity in
BH4 binding. The dissimilar Hill coefficients for substrate and
cofactor binding may also show that cooperative binding of
BH4 follows different conformational alterations propagating
cooperativity than found for L-Phe binding. This may explain
that positive cooperativity was not only observed for the tet-
rameric enzyme but also for the truncated PAH 103–427 that
lacks the regulatory and the oligomerization domain and, thus,
only exists in dimeric form. However, whether there is cooper-
ative behavior of PAH upon BH4 binding in the strict mecha-
nistic sense or hysteresis leading to cooperative kinetics could
not be fully elucidated. Further crystallization andNMRstudies
are needed for a thorough understanding of the impact of L-Phe
and BH4 binding on cooperative allosteric changes in PAH
structure.
In conclusion, the development of a novel method for real-
time measurement of PAH activity provided accurate, fast,
and efficient PAH enzyme kinetic measurements in a 96-well
format. Application of this method for wild-type PAH
revealed BH4-dependent positive cooperativity previously
not described. Spectroscopic assessment of activating confor-
mational changes and statistical evaluation ofmodel-fitting dis-
closed PAH activation as a prerequisite for BH4-dependent
positive cooperativity. BH4 has recently been approved as a
pharmacological chaperone drug in the treatment of phenyl-
ketonuria. We showed that the presence of L-Phe affects the
BH4-dependent kinetic properties of PAH. These findingsmay,
thus, have implications for an individualized therapy, as they
support the hypothesis that patient metabolic state may have a
more significant effect on the interplay of the drug and the
conformation and function of the target protein than currently
appreciated.
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3. Muntau, A. C., Röschinger, W., Habich, M., Demmelmair, H., Hoffmann,
B., Sommerhoff, C. P., and Roscher, A. A. (2002) N. Engl. J. Med. 347,
2122–2132
4. Levy,H. L.,Milanowski, A., Chakrapani, A., Cleary,M., Lee, P., Trefz, F. K.,
Whitley, C. B., Feillet, F., Feigenbaum, A. S., Bebchuk, J. D., Christ-
PAH Cooperativity for BH4
30696 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 40 • OCTOBER 1, 2010
 at U
B
M
 B
ibliothek G
rosshadern on M
ay 7, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Schmidt, H., and Dorenbaum, A. (2007) Lancet 370, 504–510
5. Trefz, F. K., Burton, B. K., Longo, N., Casanova, M. M., Gruskin, D. J.,
Dorenbaum, A., Kakkis, E. D., Crombez, E. A., Grange, D. K., Harmatz, P.,
Lipson,M.H.,Milanowski, A., Randolph, L.M., Vockley, J.,Whitley, C. B.,
Wolff, J. A., Bebchuk, J., Christ-Schmidt, H., andHennermann, J. B. (2009)
J. Pediatr. 154, 700–707
6. Shiman, R., Gray, D. W., and Hill, M. A. (1994) J. Biol. Chem. 269,
24637–24646
7. Shiman, R., Xia, T., Hill, M. A., and Gray, D. W. (1994) J. Biol. Chem. 269,
24647–24656
8. Xia, T., Gray, D. W., and Shiman, R. (1994) J. Biol. Chem. 269,
24657–24665
9. Shiman, R., and Gray, D. W. (1980) J. Biol. Chem. 255, 4793–4800
10. Shiman, R., Jones, S. H., and Gray, D. W. (1990) J. Biol. Chem. 265,
11633–11642
11. Shiman, R., Mortimore, G. E., Schworer, C. M., and Gray, D. W. (1982)
J. Biol. Chem. 257, 11213–11216
12. Mitnaul, L. J., and Shiman, R. (1995) Proc. Natl. Acad. Sci. U.S.A. 92,
885–889
13. Andersen, O. A., Stokka, A. J., Flatmark, T., and Hough, E. (2003) J. Mol.
Biol. 333, 747–757
14. Solstad, T., Stokka, A. J., Andersen, O. A., and Flatmark, T. (2003) Eur.
J. Biochem. 270, 981–990
15. Andersen, O. A., Flatmark, T., and Hough, E. (2002) J. Mol. Biol. 320,
1095–1108
16. Stokka, A. J., Carvalho, R. N., Barroso, J. F., and Flatmark, T. (2004) J. Biol.
Chem. 279, 26571–26580
17. Gersting, S. W., Kemter, K. F., Staudigl, M., Messing, D. D., Danecka,
M. K., Lagler, F. B., Sommerhoff, C. P., Roscher, A. A., and Muntau, A. C.
(2008) Am. J. Hum. Genet. 83, 5–17
18. Waters, P. J., Parniak,M. A., Akerman, B. R., and Scriver, C. R. (2000)Mol.
Genet. Metab. 69, 101–110
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SUPPLEMENTAL MATERIALS AND METHODS 
 
Real-time multi-well kinetic analysis. The application of the enzyme reaction mixture to a 96-well plate 
with varying substrate concentrations was automated using a multi-well fluorescence detection device 
with integrated injection system (FLUOstar OPTIMA, BMG Labtech). The reaction was initiated by 
sequential injection of BH4 with and without simultaneous injection of L-Phe, allowing the determination 
of L-Tyr production in all wells after the following scheme. Following the injection of BH4, L-Phe and a 
final mixture of the samples, 2 rows consisting of 24 wells were measured in repeated cycles over a time 
period of 60 seconds (Fig. 1F), the time frame evaluated to be within the linear range of action for the 
enzyme concentration used (Fig. 1E).  
 
Defining the protein concentration. Enzyme activity was measured using the assay described under 
standard conditions with 1 mM L-Phe and 75 µM BH4, with varying protein concentrations (0.005-3 
mg/ml). Production of L-Tyr was measured directly over a time period of 10 minutes. Initial velocity was 
determined as the time period in which less than 10 % of the substrate is utilized. For all protein 
concentrations, steady state kinetics occurred 30 seconds after initiation of the reaction and burst-phase 
kinetics. With decreasing protein concentrations, steady state kinetics were linear over increasing periods 
of time, yet sensitivity for the measurement of L-Tyr production decreased. All measurements were 
assayed as triplicates and all concentrations refer to a final volume of 204 µl. 
A final protein concentration of 0.01 mg/ml with an optimal time range of 60 seconds for linear range of 
reaction was chosen for all activity assays (Fig. 1E). 
 
 
FIGURE LEGENDS 
 
SUPPLEMENTAL FIGURE 1. Verifying spectral separation and the inner filter effect of BH4. A, To 
verify spectral separation needed for the direct in-well fluorescence detection of enzymatic L-Tyr 
production, 190 µM L-Tyr were measured at the L-Tyr excitation wavelength 304 nm as a function of 
increasing L-Phe concentrations. L-Tyr fluorescence signal intensities uninfluenced by increasing L-Phe 
concentrations are shown. B, A decrease in L-Tyr fluorescence intensity with increasing BH4 
concentrations, as applied in the BH4-dependent enzyme activity assay, is shown. Specific correction 
factors were determined on the basis of the factorial decrease of signal intensity for every BH4 
concentration added to the reaction mixture to account for its inner filter effect. 
 
SUPPLEMENTAL FIGURE 2. Comparison of non-linear regression model fitting by the Michaelis-
Menten and the Hill kinetic model. Residuals of values calculated using the Michaelis-Menten and Hill-
equation for non-linear regression analysis of the enzyme kinetic data obtained for the wild-type PAH, 
R68S, V106A and the dimeric PAH 103-427, without (-) and with (+) preincubation of the enzyme with 1 
mM L-Phe, are shown. Enzyme kinetics were determined with varying BH4 concentrations (0-50 and 0-
125 µM) and one L-Phe concentration (1 mM). The residuals of values were used as the primary criteria 
for selecting one model over the other. In case of indifferent residuals of values, the simpler Michaelis-
Menten kinetic model was chosen for data-fitting because a more complex model like the Hill equation 
would always fit the experimental data better than a simpler model. A good model fitting reduces the 
residuals to zero. The model best describing the enzyme kinetic data obtained is shown in green. While 
BH4-dependent enzyme kinetics of the non-activated wild-type PAH were best described by the 
Michaelis-Menten equation, the activated wild-type PAH and the preactivated variants followed the Hill 
kinetic model.  
1
SUPPLEMENTAL TABLE 1. Comparison of two nested non-linear regression models 
  Henri-Michaelis-
Menten-Equation 
  Hill-Equation   
[BH4] µM 
L-Phe 
preincubation 
R2 Sy.x Runs R2 Sy.x Runs 
0-125  - 0.9660 127.5 3
§
 (P = 0.048) 0.9742 117.8 8 n.s. 
0-125 + 0.9609 559.2 5 n.s. 0.9943 225.6 7 n.s. 
0-50 - 0.9802 46.60 6 n.s. 0.9813 47.75 10 n.s. 
0-50 + 0.9806 287.0 3
§
 (P = 0.024) 0.9973 112.1 6 n.s. 
Analysis of goodness of fit, Sy.x and runs test for two nested models after measurement of wild-type PAH kinetics 
without and with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured with L-Phe (1 mM) 
and BH4 (0-125 µM and 0-50 µM). 
§
 If the data were randomly scattered above and below the curve, there is less than 5% chance of observing so few 
runs. The data systematically deviate from the curve. Most likely, the data were fit to the wrong equation. P < 0.05 
 
 
 
SUPPLEMENTAL TABLE 2. Comparison of two nested non-linear regression models with and without 
preincubation of preactivated variants  
  Henri-Michaelis-
Menten-Equation 
  
Hill-
Equation 
  
 L-Phe 
preincubation 
R2 Sy.x Runs R2 Sy.x Runs 
R68S  - 0.9788 412.4 3
§
 (P = 0.048) 0.9972 160.3 5 n.s. 
R68S  + 0.9762 385.1 3
§
 (P = 0.047) 0.9973 138.2 9 n.s. 
V106A  - 0.9850 341.4 3
§
 (P = 0.024) 0.9956 195.2 9 n.s. 
V106A  + 0.9790 454.7 3
§
 (P = 0.024) 0.9954 224.9 7 n.s. 
103-427  - 0.9231 197.4 5 n.s. 0.9628 144.8 7 n.s. 
103-427  + 0.9177 265.0 3
§
 (P = 0.033) 0.9836 124.6 7 n.s. 
Analysis of goodness of fit, Sy.x  and runs test for two nested models after measurement of enzyme kinetics 
without and with preincubation of the enzyme with L-Phe. Enzyme kinetics were measured with L-Phe (1 
mM) and BH4 (0-125 µM). 
§ If the data were randomly scattered above and below the curve, there is less than 5% chance of observing so 
few runs. The data systematically deviate from the curve. Most likely, the data were fit to the wrong 
equation. P < 0.05 
 
2
SUPPLEMENTAL FIGURE 1
A B
I 3
0
4
[BH4] µM
0 25 50 75 100 125 150
20000
30000
40000
50000
60000
I 3
0
4
  
  
 
[Phe] µM
0 250 500 750 1000
20000
30000
40000
50000
60000
3
     103 - 427
SUPPLEMENTAL FIGURE 2
WT
R68S
V106A
Michaelis-Menten Equation Hill Equation
+
+
+
-
+
-
-
-
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
25 50 75 100 125 150
-1000
-500
0
500
1000
[BH4] µM
10 20 30 40 50 60
-750
-500
-250
0
250
500
750
[BH4] µM
10 20 30 40 50 60
-750
-500
-250
0
250
500
750
[BH4] µM
10 20 30 40 50 60
-750
-500
-250
0
250
500
750
[BH4] µM
10 20 30 40 50 60
-750
-500
-250
0
250
500
750
[BH4] µM
Michaelis-Menten Equation Hill Equation
0 - 50 µM 0 - 50 µM
4
VO
LU
M
E 20  N
U
M
BER 13 
1
JU
LY
2011
PAG
ES 2495–2696        H
U
M
AN
 M
O
LECU
LAR GEN
ETICS
HUMAN
MOLECULAR
GENETICS
Volume 20 Number 13 1 July  2011
www.hmg.oxfordjournals.org
PRINT ISSN 0964-6906, ONLINE ISSN 1460-2083
Hmg..j_20_13_cover.qxd  6/4/11  2:25 PM  Page 1
The interplay between genotype, metabolic state
and cofactor treatment governs phenylalanine
hydroxylase function and drug response
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The discovery of a pharmacological treatment for phenylketonuria (PKU) raised new questions about func-
tion and dysfunction of phenylalanine hydroxylase (PAH), the enzyme deficient in this disease. To investigate
the interdependence of the genotype, the metabolic state (phenylalanine substrate) and treatment (BH4 cofac-
tor) in the context of enzyme function in vitro and in vivo, we (i) used a fluorescence-based method for fast
enzyme kinetic analyses at an expanded range of phenylalanine and BH4 concentrations, (ii) depicted PAH
function as activity landscapes, (iii) retraced the analyses in eukaryotic cells, and (iv) translated this into
the human system by analyzing the outcome of oral BH4 loading tests. PAH activity landscapes uncovered
the optimal working range of recombinant wild-type PAH and provided new insights into PAH kinetics.
They demonstrated how mutations might alter enzyme function in the space of varying substrate and cofac-
tor concentrations. Experiments in eukaryotic cells revealed that the availability of the active PAH enzyme
depends on the phenylalanine-to-BH4 ratio. Finally, evaluation of data from BH4 loading tests indicated
that the patient’s genotype influences the impact of the metabolic state on drug response. The results
allowed for visualization and a better understanding of PAH function in the physiological and pathological
state as well as in the therapeutic context of cofactor treatment. Moreover, our data underscore the need
for more personalized procedures to safely identify and treat patients with BH4-responsive PAH deficiency.
INTRODUCTION
Phenylketonuria (PKU; OMIM #261600), the most common
inborn error of amino acid metabolism, is an autosomal recessive
disorder caused by phenylalanine hydroxylase (PAH) deficiency
(PAH; EC 1.14.16.1) (1). Currently, 627 different disease-
causing mutations in the PAH gene are known (www.pahdb.m
cgill.ca; www.hgmd.org) and some of these were shown to
lead to protein misfolding with loss of function (2–4).
Pharmacological doses of 6R-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4), the enzyme’s natural cofactor, can reduce
blood phenylalanine concentrations (5–10) and increase
phenylalanine oxidation rates in vivo (11) in patients with
PAH deficiency without any evidence of cofactor deficiency.
The compound was shown to rescue the biochemical pheno-
type by correcting PAH misfolding and was thus classified
as a pharmacological chaperone (4,12). Following these
studies, sapropterin dihydrochloride, the synthetic form of
the natural PAH cofactor, was approved as an orphan drug
to alleviate or even replace burdensome dietary treatment in
a significant share of patients with PKU due to PAH deficiency
(13–16).
However, not all patients show BH4 responsiveness. Since
the introduction of sapropterin dihydrochloride as a pharmaco-
logical treatment, many attempts to predict BH4 responsive-
ness from a patient’s genotype were made (17–19).
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Combined evidence seems to support the view that residual
enzyme activity of individual mutations may be a parameter
that—to some extent—allows for discrimination of responders
and non-responders (19–22). In two studies performed on
Croatian and Turkish populations, calculation of mean in
vitro residual enzyme activity of the two PAH variants
arising from both alleles led to the identification of some
responders with high accuracy, whereas patients with two
fully inactive alleles were found to be always non-responders
(19,22). Yet, in many instances, no clear genotype–phenotype
correlation is found pointing to contributing factors such as the
patient’s age or initial blood phenylalanine concentrations
(17,19). Marked inconsistencies as to BH4 responsiveness
were observed for two of the most common PKU mutations
associated with this particular phenotype, R261Q and
Y414C (17) and for R252W, L48S and R241C homozygous
genotypes (22). In addition, interpretation of genotype
effects is hampered by the fact that .80% of BH4 responders
are compound heterozygous (17).
Hydroxylation of the substrate L-phenylalanine to the
product L-tyrosine with the use of the natural cofactor BH4
and molecular oxygen is a complexly regulated catalytic
mechanism. While L-phenylalanine induces activating confor-
mational rearrangements, BH4 leads to the formation of an
inactive dead-end PAH–BH4 complex (23–26). Recent
studies unraveled new aspects concerning the interplay of
phenylalanine and BH4 having an impact on enzyme kinetics
as well as on drug response. Adoption of an enzyme activity
assay using a newly developed fluorescence-based real-time
PAH activity assay revealed cooperativity of recombinant
PAH towards the BH4 cofactor. This was restricted to the
phenylalanine substrate-activated state of the enzyme indicat-
ing that conformational rearrangements of the PAH protein
induce cooperative binding (27). Moreover, investigations of
the BH4 effect in two different mouse models for BH4-
responsive PAH deficiency provided evidence that the
response to BH4 in terms of rescue of enzyme function by
increasing the effective intracellular PAH amount also
depends on phenylalanine concentrations and on the under-
lying genotype (12). These results suggested that the influence
of substrate and cofactor concentrations in the presence of a
certain genotype on enzyme function and on the response to
the pharmacological chaperone BH4 might be of even more
functional and therapeutic relevance than previously esti-
mated. In addition, the BH4 loading test routinely used world-
wide to assess BH4 responsiveness in PAH deficiency (28,29)
was shown to result in a number of inconsistencies that are
still not well understood. In some but not all cases, this may
be due to inadequate BH4 dosage or to initial blood phenyl-
alanine concentrations near to the physiological state. Unfortu-
nately, this may lead to false negative results precluding
cofactor treatment and thus increasing burden of treatment
in some BH4-responsive patients.
To address these issues, (i) we adapted our new
fluorescence-based method for fast enzyme kinetic analyses
to cover an expanded range of phenylalanine and BH4 concen-
trations when compared with previous analytical setups
enabling the investigation of the mutual impact of substrate
and cofactor on PAH enzyme kinetics, (ii) we depicted these
data as activity landscapes uncovering the optimal working
range of recombinant wild-type and mutated PAH, (iii) we
retraced these analyses in a eukaryotic cell culture system,
revealing that the availability of the active PAH enzyme
depends on both the metabolic state and drug dosage, and
(iv) we translated this into the human system by analyzing
the effect of the genotype, phenylalanine concentrations and
the BH4 dosage applied on the results of oral BH4 loading
tests from PAH-deficient patients.
RESULTS
Expanded insights into wild-type PAH kinetics unraveling
the mutual impact of substrate and cofactor concentrations
In order to investigate the interdependence of L-phenylalanine
and BH4 in PAH enzyme kinetics, we adapted a newly devel-
oped fluorescence-based real-time activity assay (27) to simul-
taneously analyze the effect of a wide range of substrate and
cofactor concentrations on PAH activity. Process automation
now allowed for continuous measurement of tyrosine
product formation over time in one single operation consisting
of six sequential runs for all 96 wells (Fig. 1A). The assay was
expanded to cover the space of 0 to 4000 mM L-phenylalanine
and 0–500 mM BH4 (Fig. 1B). First, we validated the data
obtained with the new method by comparison with previous
findings using a standard high-performance liquid chromato-
graphy (HPLC) based discontinuous assay (2). Data points
determined at either varying L-phenylalanine concentrations
(0–1000 mM) and one BH4 concentration (75 mM) or at one
L-phenylalanine concentration (1000 mM) and varying BH4
concentrations (0–125 mM), respectively, were used to calcu-
late enzyme kinetic parameters. Prior to calculation, an F-test
was used to decide whether the Michaelis–Menten or the Hill
kinetic model was more appropriate (27). Both L-phenylalanine
and BH4-dependent PAH enzyme kinetics showed clear data-
fitting to the Hill equation (Fig. 1C), as previously described
for the L-phenylalanine-activated enzyme (27). Although
Vmax values for L-phenylalanine and BH4-dependent kinetics
were higher in the new assay, allosteric parameters, i.e. appar-
ent substrate affinity, the Hill coefficient and apparent cofactor
affinity, were similar in both assays (Table 1).
We depicted the data analyzed by non-linear and poly-
nomial regression fitting as three-dimensional landscapes of
enzyme activity (30). This enabled a visual representation of
the mutual impact of substrate (x-axis) and cofactor concen-
trations (y-axis) on PAH kinetics (color code) representing
functional conditions of the PAH enzyme. Wild-type PAH
showed a peak maximum enzyme activity at 575 mM
L-phenylalanine and 125 mM BH4, respectively (Fig. 1D).
The analysis of PAH enzyme kinetics at BH4 and
L-phenylalanine concentrations extended to supraphysiological
levels led to a number of interesting observations. High PAH
enzyme activity was determined at a surprisingly wide range
of substrate and cofactor concentrations. The optimal
working range reflected by PAH enzyme activity in the bound-
aries of [S]0.5 to Ki for the substrate and [C]0.5 to Ki for the
cofactor spanned from 252 to 2026 mM L-phenylalanine and
from 44 to 306 mM BH4 (Table 2). At L-phenylalanine concen-
trations above 561 mM, we observed the well-known substrate
inhibition of enzyme activity (30,31). Notably, at cofactor
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concentrations above 108 mM cofactor inhibition occurred. In
addition, a mutual interdependence of both inhibitory events
was found. These observations represent previously
unknown findings. Over and above that, at L-phenylalanine
concentrations within the range naturally occurring in the
pathological state (500–1500 mM), the enzyme requires more
BH4 with increasing L-phenylalanine concentrations to main-
tain the same level of enzyme activity.
Taken together, the considerable extension of analysis con-
ditions and the evaluation of data by compiling activity land-
scapes provided new insights into PAH kinetics. It allowed for
a precise evaluation of peak PAH enzyme activity and the
Figure 1. Optimal working range of wild-type PAH activity. (A) Scheme of sequential measurements of PAH enzyme kinetics in a 96-well plate. One sequence
consists of two columns (red box). In each column, cofactor concentrations (0–500 mM) were varied at a fixed substrate concentration (0–4000 mM), respectively.
Repeated cycles allowed for kinetic measurements of 16 wells over a time period of 90 s. (B) Extension of substrate and cofactor concentrations. The range of
L-phenylalanine and BH4 concentrations was expanded from standard conditions (BH4, 75 mM; L-phenylalanine 1000 mM, red box) to 500 mM BH4 and 4000 mM
L-phenylalanine (arrows), respectively. (C) Cooperativity of PAH towards substrate and cofactor. Pre-activated PAH showed sigmoidal behavior for
L-phenylalanine- (upper panel) and BH4-dependent (lower panel) PAH enzyme kinetics. (D) Activity landscape of human wild-type PAH. Data for PAH
enzyme activity assayed at varying L-phenylalanine and BH4 concentrations were interpolated and depicted by a color code. The dot-and-dash line represents
Ki for substrate inhibition at varying cofactor concentrations, the dotted line represents Ki for cofactor inhibition at varying substrate concentrations. With
increasing substrate concentrations, more BH4 is needed to maintain the same level of enzyme activity (solid line).
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optimal working range spanning a wide area of substrate and
cofactor concentrations. Moreover, cofactor inhibition as
well as a mutual impact of substrate and cofactor concen-
trations on PAH activity have been identified.
Activity landscapes: the effect of PAH mutations on PAH
enzyme kinetics
Variant PAH proteins harboring mutations mapping to the
regulatory (F39L, I65T), the catalytic (R216Q, P275L,
P314S, V388M) and the dimerization motif of the oligomeri-
zation domain (Y414C, Y417H) of the enzyme were analyzed.
The results from kinetic measurements were depicted as
activity landscapes and compared with those from wild-type
PAH (Fig. 2). For each variant analyzed, enzyme kinetic par-
ameters and peak enzyme activities with their corresponding
L-phenylalanine or BH4 concentrations were determined
(Tables 2 and 3). The area of optimal enzyme activity
defined as the range [S]0.5 to Ki for the substrate and [C]0.5
to Ki for the cofactor, respectively, was calculated (Table 2).
The variant proteins bearing the mutation F39L or I65T,
both located in the regulatory domain, showed at first glance
a landscape pattern comparable with that of the wild-type.
Besides enzyme activity (F39L, 92%; I65T, 55%), the variants
displayed unaffected enzyme kinetic parameters as well as
similar effects of substrate and cofactor inhibition as found
for the wild-type enzyme. However, a more detailed analysis
revealed that peak PAH activities were found at similar sub-
strate concentrations, but at !1.3-fold higher cofactor concen-
trations when compared with the wild-type. This indicates that
in the presence of these mutations, more cofactor is needed to
achieve optimal PAH function.
All mutations mapping to the catalytic domain induced
marked alterations of activity landscapes. For the variant
R261Q, the area of substantial PAH activity was much
larger than for the wild-type, but residual enzyme activity
was reduced to 42%. The concentrations of substrate and
cofactor needed to achieve peak PAH activity were shifted
to higher values (L-phenylalanine, 1.5-fold; BH4, 1.4-fold).
We observed reduced affinity to the substrate by a factor of
0.5 ([S]0.5 282 mM). Binding of BH4 followed Michaelis–
Menten kinetics representing a loss of cooperativity that
occurred with reduced affinity (Km 66 mM). Broadening of
the landscape resulted from a significant shift of enzyme inhi-
bition. Notably, the variant did not display cooperative binding
of BH4 when activated. Taken together, the unique feature of
Table 2. Peak enzyme activity and range of substrate and cofactor concentrations of wild-type and variant PAH
Peak activity L-phenylalanine BH4
(nmol L-tyrosine/min
" mg protein)
Residual
activity (%)
concentration at
peak activity (mM)
[S]0.5–Ki
§ concentration at
peak activity (mM)
[C]0.5–Ki or Km–Ki
§
WT 6370 100 561 252–2026 108 44–306
F39L 5865 92 622 187–2275 143 35–331
I65T 3533 55 612 254–2075 135 29–322
R261Q 2654 42 842 344–2825 149 41–321
P275L 5215 82 1293 238–1980 334 71–435
P314S 1956 31 612 76–1043 80 42–218
V388M 6355 100 591 201–1933 105 47–296
Y414Ca 3106 49 591 124–1048a 105 43–274
Y417H 5206 82 471 147–1501 92 63–262
Peak enzyme activity of variant tetrameric MBP–PAH fusion proteins measured by direct in-well activity measurements. The apparent affinities for L-phenylalanine (S0.5)
and BH4 (C0.5/Km) as well as Ki for substrate and cofactor inhibition were calculated based on non-linear regression analysis at L-phenylalanine and BH4 concentrations
of peak enzyme activity.
§Ki calculated at peak L-phenylalanine and BH4 concentrations using the Boltzman-sigmoidal equation.
aCalculation of Ki at a range of L-phenylalanine 0–1624 mM.
Table 1. Comparison of enzyme kinetic parameters of human wild-type MBP–PAH at standard L-phenylalanine (1000 mM) and BH4 (75 mM) concentrations
L-phenylalaninea BH4
b
Vmax (nmol L-tyrosine/min " mg protein) [S]0.5 (mM) hPhe Vmax (nmol L-tyrosine/min " mg protein) [C]0.5 (mM) Km (mM) hBH4
Continuous assay 5407+210 145+11 3.3 5222+286 23+2 2.0
Discontinuous assay 3470+75 155+6 3.0 3425+139 24+3
Steady-state kinetic parameters of wild-type MBP–PAH fusion proteins. Vmax and the apparent affinities for L-phenylalanine (S0.5) and BH4 (C0.5, Km) as well as
the Hill coefficient (h) as a measure of cooperativity are shown. Enzyme kinetic parameters were determined from enzyme activities measured using the newly
developed fluorescence-based continuous assay and compared with enzyme activities measured by the standard HPLC-based discontinuous assay (2). Data were
analyzed using the F-test for model comparison and the kinetic parameters of the best-fitting model (cooperative versus non-cooperative) were calculated. Values
are given as mean+SEM of three independent measurements.
aEnzyme kinetic parameters determined at variable L-phenylalanine concentrations (0–1000 mM) and standard BH4 concentration (75 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
bEnzyme kinetic parameters determined at variable BH4 concentrations (0–125 mM) and standard L-phenylalanine concentration (1000 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
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the R261Q variant was the right shift of PAH enzyme activity
towards higher L-phenylalanine concentrations indicating a
reduced affinity of this variant to its substrate and that the
enzyme displays low activity at L-phenylalanine concen-
trations below 600 mmol/l. At these substrate concentrations,
even very high BH4 doses would not produce any response
in PAH activity. The presence of the mutation P275L resulted
in an enzyme with overall high residual enzyme activity
(82%), yet with a shift of peak enzyme activity to 2.3-fold
higher L-phenylalanine and 3-fold higher BH4 concentrations
(L-phenylalanine 1293 mM, BH4 334 mM) than the wild-type.
In comparison to the wild-type, the enzyme had a substantially
higher need for BH4 to achieve the optimal working range. As
a consequence, substrate and cofactor inhibition was almost
abolished. The variant protein bearing the mutation P314S
showed a severe loss in residual enzyme activity (31%) with
Figure 2. Activity landscapes of recombinant wild-type and variant PAH. The interpolated specific enzyme activities are color-coded and given as a function of
different L-phenylalanine and BH4 concentrations. Substrate and cofactor inhibition are depicted as a summation line (black dotted line). Positions of S0.5 and Ki
for L-phenylalanine and C0.5 and Ki for BH4, respectively, are indicated at peak enzyme activities (open circles). Marked changes in the activity landscape of
variant PAH when compared with the wild-type (WT) are highlighted (open triangles) and BH4 concentrations needed to maintain the same enzyme activity with
increasing L-phenylalanine concentrations are shown (red dotted line).
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a narrow optimal working range that was shifted towards
lower L-phenylalanine as well as BH4 concentrations. In
addition, enzyme kinetics revealed a significantly increased
apparent affinity to the substrate with marked reduction in
cooperativity. In contrast to previous findings (3,32), where
the variant protein V388M was described as a Km variant
with reduced affinity to the cofactor, we detected high residual
enzyme activity over an expanded range of substrate and
cofactor concentrations. Residual PAH activity was 100%
and peak catalysis (L-phenylalanine 591 mM, BH4 105 mM) as
well as effects of substrate and cofactor inhibition were
similar to that of the wild-type enzyme.
Mutations mapping to the oligomerization domain, Y414C
and Y417H, showed a narrowed optimal working range that
was shifted to lower substrate concentrations. However, this
was less pronounced for the milder mutation Y417H (82%
residual enzyme activity) when compared with Y414C
(49%). On the other hand, Y417H needed less BH4 to
achieve the area of optimal function. Interestingly, different
to all variants analyzed, Y414C showed two peaks of high
enzyme activity.
Taken together, we identified many similarities between the
activity landscapes of the wild-type and variant PAH proteins,
showing generally high residual enzyme activity as well as
substrate and cofactor inhibition. However, these activity land-
scapes also revealed important differences in the regulation of
PAH activity by BH4 and L-phenylalanine and helped to visu-
alize the interdependence of substrate and cofactor concen-
trations on variant PAH enzyme activity.
Cofactor action on PAH function in respect of kinetic
behavior and the chaperone effect
We used two different approaches to analyze different aspects
of cofactor action on the wild-type, R261Q and Y414C PAH
enzyme in HEK293 cells. First, we in part retraced the activity
landscapes analyzing the kinetic behavior by assaying enzyme
activity of cell lysates at different L-phenylalanine
concentrations (0–1000 mM) while keeping the BH4 concen-
tration constant (75 mM) (Fig. 3A). Secondly, we analyzed
the chaperone effect of the BH4 cofactor at different phenyl-
alanine and BH4 concentrations after a 72 h incubation.
As expected, the wild-type protein showed the highest
enzyme activity of all three proteins analyzed with a peak
activity at about 250 mM L-phenylalanine. The latter finding
differed from the peak activity observed for recombinant
PAH at !500 mM. As seen for prokaryotic PAH, a further
increase in L-phenylalanine concentrations resulted in sub-
strate inhibition. The variant R261Q displayed !50% residual
enzyme activity and a lower slope of the curve that leveled off
at a plateau. Reduced enzyme function, which was shifted
toward higher substrate concentrations with a broadened
working range, substantiated results from activity landscapes.
Residual enzyme activity of eukaryotic Y414C was substan-
tially lower than the specific activity of the corresponding
recombinant variant. In addition to peak activity at 180 mM
L-phenylalanine, a second slight incline of activity was
observed at high L-phenylalanine concentrations (1000 mM).
Although generally shifted toward lower substrate concen-
trations, this is in line with the two peaks observed in the
activity landscape.
Next, we aimed to elucidate the long-term chaperone effect
of varying intracellular phenylalanine and BH4 concentrations
on PAH function. The determination of enzyme activity at stan-
dard conditions after previous incubation of cells with different
substrate and cofactor concentrations assays the availability of
functionally active PAH. For this purpose, stably transfected
cells were cultivated with L-phenylalanine concentrations of
91, 500 or 1200 mM and BH4 concentrations of 0, 40 or
75 mM for 72 h. First, cells were cultivated at L-phenylalanine
levels representing the physiological state (91 mM), mild PKU
(500 mM) or classical PKU (1200 mM) without the addition of
BH4 to the medium (Fig. 3B). Wild-type PAH activity
showed a trend towards an increase only at clearly pathological
L-phenylalanine concentrations. For R261Q, a steady but stat-
istically not significant increase in enzyme activity was seen
Table 3. Enzyme kinetic parameters at standard L-phenylalanine (1000 mM) and BH4 (75 mM) concentrations calculated from activity landscapes
L-phenylalaninea BH4
b
Vmax (nmol L-tyrosine/min " mg protein) [S]0.5 (mM) hPhe Vmax (nmol L-tyrosine/min " mg protein) [C]0.5 (mM) Km (mM) hBH4
WT 5407+210 145+11 3.3 5222+286 23+2 2.0
F39L 4961+342 115+15 2.7 5669+311 36+3 1.7
I65T 3166+96 161+10 2.7 3277+196 27+3 1.7
R261Q 3041+128 282+18 3.4 4693+598 66+17
P275L 3204+126 112+8 2.6 3022+179 36+3 2.8
P314S 1650+91 76+9 1.8 991+25 24+1 5.2
V388M 5639+112 140+6 2.7 5895+236 26+2 1.8
Y414C 2895+206 120+17 2.4 2148+203 28+4 2.6
Y417H 4434+247 111+10 3.6 3011+93 23+1 2.5
Steady-state kinetic parameters of variant tetrameric MBP–PAH fusion proteins determined by direct in-well activity measurements. Data were analyzed using the
F-test for model comparison and the kinetic parameters of the best-fitting model (cooperative versus non-cooperative) were calculated. Vmax and the apparent
affinities for L-phenylalanine (S0.5) and BH4 (C0.5, Km) as well as the Hill coefficient (h) as a measure of cooperativity are shown. Values are given as mean+SEM
of three independent measurements.
aEnzyme kinetic parameters determined at variable L-phenylalanine concentrations (0–1000 mM) and standard BH4 concentration (75 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
bEnzyme kinetic parameters determined at variable BH4 concentrations (0–125 mM) and standard L-phenylalanine concentration (1000 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
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upon increasing substrate concentrations in the medium (35+5
to 52+9 pmol L-tyrosine/min ! mg total protein). For Y414C,
residual activity was very low without any effect of increasing
L-phenylalanine concentrations.
To further evaluate the mutual impact of the substrate and
the cofactor on enzyme activity in the eukaryotic system, 40
or 75 mM BH4 were added to the medium at L-phenylalanine
concentrations of 91 or 1200 mM, respectively (Fig. 3C).
Figure 3. Cofactor action on PAH function in respect of kinetic behavior and the chaperone effect. (A) Enzyme activity of eukaryotic expressed PAH assayed at
varying substrate concentrations. Enzyme activities in cell lysates of HEK293 cells stably transfected with wild-type PAH, R261Q or Y414C were determined at
varying L-phenylalanine concentrations (0–1000 mM) and a fixed BH4 concentration (75 mM). (B) Effect of varying intracellular phenylalanine concentrations on
functionally active PAH. PAH enzyme activity in HEK293 cell lysates expressing wild-type PAH, R261Q or Y414C was determined at standard assay concen-
trations (1000 mM L-phenylalanine and 75 mM BH4) after prior incubation with different L-phenylalanine concentrations (black, 91 mM; dark gray, 500 mM; white,
1200 mM) for 72 h. (C) Mutual impact of varying substrate and cofactor concentrations on functionally active PAH. Cells stably expressing wild-type PAH,
R261Q or Y414C were cultivated at different phenylalanine (left column, 91 mM; right column, 1200 mM) and BH4 concentrations (white, 0; dark gray,
40 mM; and black, 75 mM). PAH enzyme activities were analyzed at standard assay conditions. PAH activities are given as mean+SEM of three independent
experiments. Significant differences in enzyme activities were calculated using one-way ANOVA and Dunnett’s multiple comparison test (ns, not significant;
"P , 0.05; ""P , 0.01).
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Interestingly, at physiological L-phenylalanine concentrations
(91 mM), the addition of 40 and 75 mM BH4 induced a trend
towards increased enzyme activity of wild-type PAH (57+
9 to 98+ 22 and 105+ 18 pmol L-tyrosine/min ! mg total
protein), whereas the opposite effect was observed at elevated
L-phenylalanine concentrations (1200 mM L-phenylalanine,
108+ 37 to 40+ 7 and 35+ 5 pmol L-tyrosine/min ! mg
total protein). For the variant R261Q, the addition of 40 mM
BH4 at physiological L-phenylalanine concentrations resulted
in a significant increase in enzyme activity (35+ 5 to 86+
17 pmol L-tyrosine/min ! mg total protein), but the inhibitory
effect at elevated L-phenylalanine concentrations as seen for
the wild-type was not observed. At physiological
L-phenylalanine concentrations, the variant Y414C showed
low residual enzyme activity with only a minor increase
upon the addition of 40 mM BH4. Interestingly, at high
L-phenylalanine concentrations (1200 mM), the addition of 40
but not 75 mM BH4 led to a significant increase in residual
enzyme activity (23+ 4 pmol L-tyrosine/min ! mg total
protein) achieving as much as 40% of the wild-type level.
Taken together, findings from the prokaryotic system
depicted by activity landscapes were substantiated in the
eukaryotic environment. Also in this system probing lysates
of cultured cells, the mutual impact of different
L-phenylalanine and BH4 concentrations on enzyme activity
varied among different PAH variants with substrate inhibition
for the wild-type as well as constant activity levels for R261Q
also at very high L-phenylalanine concentrations. Residual
enzyme activity of Y414C was substantially lower in cell
culture when compared with the specific activity of the recom-
binant protein, but enzyme function was rescued by the
addition of BH4. This may point to impaired protein stability
in the eukaryotic environment and a stabilizing pharmacologi-
cal chaperone effect by BH4.
The mutual impact of substrate and cofactor
concentrations on results from BH4 loading tests
performed in PAH deficient patients
So far, data pointed to a simultaneous dependency of PAH func-
tion from available substrate and cofactor concentrations. After
having confirmed results from the prokaryotic system in the
eukaryotic system, we aimed to investigate whether our obser-
vations may be transferred to the human situation by analyzing
data from BH4-loading tests performed in patients with PAH
deficiency. To address this issue, we collected data of patients
homozygous or functionally hemizygous for the mutations
F39L, I65T, R261Q or Y414C, that underwent a BH4-loading
test with a dose of 20 mg/kg body weight and a duration of at
least 24 h from the literature (19,33–37) and from the
BIOPKU database (www.biopku.org). First, we compiled the
course of blood phenylalanine values within 24 h after a single
dose of BH4 as a function of initial blood phenylalanine concen-
trations. For all mutations analyzed, different blood phenyl-
alanine concentrations at the beginning of the test led to
differences in the extent of BH4 responsiveness, i.e. the
percent decrease in blood phenylalanine after drug adminis-
tration. Patients carrying the mutations F39L, I65T and
Y414C showed a peak level of BH4 responsiveness below an
initial blood phenylalanine concentration of 500 mM (Fig. 4A).
In the presence of F39L and I65T increasing initial blood
phenylalanine concentrations were associated with a decrease
in BH4 responsiveness. While patients with F39L still displayed
positive response at 1000 mM phenylalanine (.30% decrease in
blood phenylalanine), those carrying I65T did not show a drug
response when initial blood phenylalanine concentrations
were .800 mM. The mutation Y414C led to inconsistent
response to BH4 with maximum responsiveness at initial
blood phenylalanine concentrations up to 750 mM phenylalanine
and at 1000 mM phenylalanine. In general, patients bearing the
mutation Y414C showed a high degree in BH4 responsiveness
with the lowest response remaining within the range of 30%
decrease in blood phenylalanine.
Patients bearing the mutation R261Q showed strong incon-
sistencies in BH4 responsiveness with some patients display-
ing high levels of responsiveness (.60% decrease of blood
phenylalanine) and others no response at all (Fig. 4B). To
investigate the basis of these inconsistencies, we analyzed
the impact of both the genotype on BH4 response and of
phenylalanine concentrations on different genotypes compris-
ing the R261Q mutation. The decrease in blood phenylalanine
concentrations was significantly stronger in individuals carry-
ing the R261Q mutation in the homozygous state (median,
37.5%) than those carrying it in the functional hemizygous
state (median, 6.5%). However, among homozygous patients,
some were responders and some were not, whereas all func-
tionally hemizygous patients had to be classified as non-
responders. Interestingly, the level of initial blood phenyl-
alanine did not allow differentiating either homozygous
responders from homozygous non-responders or homozygotes
from functional hemizygotes.
In addition to the influence of initial blood phenylalanine
concentrations on BH4 response, we analyzed the impact of
the genotype on BH4 dose response to investigate the
optimal PAH working range in vivo. Literature data providing
information on BH4 dosage revealed clear differences for
patients homozygous for R261Q, patients homozygous for
Y414C and those compound heterozygous for these two
mutations (Fig. 4C). In the presence of the mutation R261Q,
the percent decrease in blood phenylalanine levels remained
nearly unchanged for the range of BH4 dosages between 10
and 30 mg/kg body weight. In contrast, patients bearing the
mutation Y414C showed a gain in BH4 response with increas-
ing BH4 doses (5–20 mg/kg body weight). Interestingly,
patients compound heterozygous for R261Q and Y414C
showed an intermediate response with respect to the BH4
dosage administered (10–20 mg/kg body weight) when com-
pared with patients homozygous for these mutations.
As a conclusion, in vivo PAH activity is a function of the
phenylalanine substrate and the BH4 cofactor as well as the
patient’s genotype. Hence, enzyme function in the individual
patient at a given time point is the resultant of the metabolic
state and the dosage of cofactor treatment both in turn deter-
mined by the underlying mutations.
DISCUSSION
Regulation of PAH activity is essentially governed by the
abundance of the phenylalanine substrate and the BH4
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cofactor. The supply of substrate, e.g. upon food intake,
induces enzyme activation and subsequently full catalytic
activity. In contrast, at low blood phenylalanine levels, e.g.
under fasting conditions, BH4-induced PAH inhibition pre-
vents from undue elimination of the essential amino acid
phenylalanine. Thus, it is the ratio of phenylalanine to BH4
that determines activation and inhibition of the enzyme.
However, the concentration of BH4 in the liver cell is held
rather constant, whereas phenylalanine levels undergo
substantial fluctuations in function of the metabolic state
and—in the presence of PAH deficiency—of the underlying
genotype. While treating patients with BH4 we intervene in
this system without disposing of profound knowledge concern-
ing the effect of shifts of the substrate-to-cofactor ratio. In the
work presented here, we first wanted to apply the newly devel-
oped real-time fluorescence-based PAH enzyme activity assay
to identify the optimal working range of the enzyme with
respect to these substances. Secondly, we aimed to analyze
Figure 4. Evaluation of BH4 responsiveness in PAH-deficient patients. (A) The impact of the genotype and of initial blood phenylalanine concentrations on BH4
response. The graphs show the percent decrease in blood phenylalanine levels 24 h after a single dose of BH4 (20 mg/kg bw) in patients homozygous or func-
tional hemizygous for the mutations F39L (n ! 3), I65T (n ! 5) or Y414C (n ! 10) as a function of different blood phenylalanine values at the beginning of the
test. The horizontal dashed line indicates 30% decrease in blood phenylalanine concentrations, the arbitrary criterion of BH4 responsiveness. The vertical dashed
line shows the initial blood phenylalanine concentration, above which BH4 leads to a blood phenylalanine decrease of ,30%. (B) BH4 responsiveness in patients
carrying the mutation R261Q (n ! 28). (Left) Percent decrease in blood phenylalanine 24 h after a single dose of BH4 (20 mg/kg bw) as a function of initial
blood phenylalanine values in patients homozygous or functional hemizygous for the R261Q mutation. (Middle) Percent decrease in blood phenylalanine
24 h after a single dose of BH4 (20 mg/kg bw) in patients carrying the R261Q mutation in the homozygous state (n ! 22) in comparison to functional hemi-
zygotes (n ! 6). The boxes show the interquartile ranges (25th to 75th percentiles), the horizontal black bars represent the median, the bars indicate the
range. Significance is indicated (!!P , 0.01, unpaired Student’s t-test). (Right) Percent decrease in blood phenylalanine concentrations in function of initial
blood phenylalanine values in homozygous responders (n ! 13) and non-responders (n ! 9) as well as functional hemizygous patients (n ! 6) displaying the
mutation R261Q. (C) The impact of the genotype on BH4 dose response. Percent decrease in blood phenylalanine 24 h after a single application of BH4 in
different dosages in patients homozygous for R261Q (n ! 24) (left), homozygous for Y414C (n ! 10) (middle) or compound heterozygous for R261Q/
Y414C (n ! 3) (right).
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the influence of changes in the phenylalanine-to-BH4 ratio on
PAH function of the wild-type and variant enzymes.
Analyses of wild-type PAH revealed two interesting new
findings. In addition to the well-known enzyme inhibition by
the substrate, cofactor inhibition was identified by the exten-
sion of the enzyme activity assay to much higher cofactor con-
centrations. Moreover, we learned that with increasing
phenylalanine concentrations, more BH4 is needed to maintain
the same level of PAH activity. Still, it has to be considered
that the full range of substrate and cofactor concentrations
applied in our novel assay provided new insights into theoreti-
cal aspects of PAH enzymology, but it is well beyond physio-
logical levels. However, our approach allowed for detailed
visualization and better understanding of conditions corre-
sponding to those occurring at the edges of classical pathologi-
cal situations in PKU patients and in the therapeutic context
upon cofactor treatment.
The optimal working range of the wild-type enzyme
occurred at phenylalanine concentrations of 250–500 mM.
From a physiological point of view, this appears reasonable,
since upon food intake liver phenylalanine concentrations
are expected to reach levels up to 500 mM rather than around
1000 mM, the phenylalanine concentration at which standard
PAH enzyme activity assays are performed (2,38). Our
results showed that the optimal BH4 concentration for PAH
enzyme activity is !100 mM, while standard PAH activity
assays are run at 75 mM BH4 (2,38). In any case, the physio-
logical cellular BH4 concentration in the liver is by far
lower (!8.5 mM) (26), implying that the cell has always to
be considered BH4 deficient in view of the enzymatic task.
Yet, in light of the inhibitory potential of BH4 on the
enzyme, a cellular cofactor concentration significantly below
the Km value of 23 mM reduces inhibition when activity is
needed, i.e. at phenylalanine concentrations above the physio-
logical range. The trade-off between these two tasks is
balanced by a 6-fold higher affinity of the enzyme toward
the cofactor (Km, 23 mM) than toward the substrate (S0.5,
145 mM). As a consequence, PAH binds BH4 and phenyl-
alanine at a ratio of 0.5 at 100 mM blood phenylalanine (inhi-
bition) when compared with 0.09 at 561 mM blood
phenylalanine (no inhibition). These theoretical assumptions
are corroborated by previous in vivo 13C-phenylalanine oxi-
dation tests performed in a PKU mouse model (39). In the
euphenylalaninemic state, a hypothetical BH4 deficiency is
overruled by an inhibitory effect following the application of
BH4 in wild-type animals. However, in hyperphenylalanine-
mia phenotypes, the administration of BH4 leads to an
immediate increase in 13C-phenylalanine oxidation. In view
of a time to effect of ,5 min, this has to be considered inde-
pendent of a pharmacological chaperone effect and rather
points to compensation of BH4 deficiency in this metabolic
state. Comparable studies in humans addressing phenylalanine
concentrations, BH4 concentrations, the effect of BH4 in
healthy individuals, time to onset of action and effect duration
would be of interest, but have not yet been performed.
Next, we investigated the effect of selected missense
mutations in the PAH gene on the optimal working range of
the enzyme. In general, activity landscapes of the wild-type
and variant PAH proteins displayed comparable patterns
with rather high residual enzyme activity and a limited area
of maximum activity. More detailed analyses, however,
revealed various alterations with respect to the extension and
position of the optimal working range in the coordinates of
substrate and cofactor concentrations. Most variant proteins
were in need of more BH4 to achieve peak activity (F39L,
I65T, R261Q, P275L, Y417H, Y414C). For two variants
(R261Q and P275L), maximum activity was determined at
markedly higher phenylalanine concentrations (842 and
1293 mM). In contrast, three variants (P314S, Y414C and
Y417H) presented a narrowed optimal working range that
was shifted to lower phenylalanine concentrations when com-
pared with the wild-type.
Two of these mutations, R261Q and Y414C, are frequent,
but inconsistently associated with BH4 responsiveness
(17,34–37). The analysis of activity landscapes provided
first evidence for an impact of the metabolic state on variant
PAH function. R261Q displayed marked reduction in
enzyme activity at phenylalanine concentrations in the thera-
peutic range below 240 mM giving rise to the hypothesis that
patients bearing this mutation in the homozygous or functional
hemizygous state would not benefit from a restrictive dietary
regime. On the other hand, the mutation Y414C that induces
a shift of activity to lower phenylalanine concentrations
would require a rather strict metabolic adjustment with low
blood phenylalanine values to achieve optimized PAH
activity. Thus, observations from the analysis of activity land-
scapes could be of importance for a deeper understanding of
inconsistent results from BH4 loading tests or some disap-
pointing experiences upon BH4 treatment of our patients. To
perform a further step in this direction, we carried out cell
culture experiments and analyzed data from BH4 loading
tests performed in PKU patients.
Data extracted from activity landscapes were reproduced in
the setting of stably transfected cells. Having gained insights
into the mutual impact of varying substrate and cofactor con-
centrations on PAH activity, we were then interested in
answering the question of how changes in the metabolic
state would affect the effective PAH concentration, that is,
the intracellular amount of functional PAH enzyme available
for phenylalanine conversion. Since BH4 has been classified
as a pharmacological chaperone, i.e. a stabilizing compound
that helps to overcome PAH degradation in the cell, it is
expected to raise the amount of PAH in cell culture. In
addition, we had previously shown that the effective PAH con-
centration is influenced by changes in the
phenylalanine-to-BH4 ratio in the mouse (12). To address
these issues in cell culture, we mimicked physiological
(euphenylalaninemic) and pathologic (hyperphenylalanine-
mic) conditions representing classical PKU. The supplemen-
tation of BH4 induced diverse results in the presence of
R261Q and Y414C, respectively. BH4 was beneficial for cat-
alytic PAH function of the R261Q variant particularly at low
phenylalanine levels, whereas a significant increase in PAH
enzyme activity reflecting an increase in the effective PAH
amount was observed for Y414C under PKU conditions. Inter-
estingly, the therapeutic range for BH4 was narrow for Y414C,
a finding confirming the observations from the activity land-
scapes.
As a next step, we aimed to verify the clinical relevance
of our findings and analyzed the effect of different substrate
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and cofactor concentrations on the outcome of single dose
BH4-loading tests in individuals carrying different PAH gen-
otypes. In clinical routine, the initial phenylalanine concen-
tration at the beginning of the BH4-loading test is not
expected to significantly affect the outcome of the test. In
general, only a minimum phenylalanine concentration of
400 mM is considered to be required for reliable test
results. Surprisingly, data from BH4 loading tests available
in the BIOPKU database and in the literature (19,33–
37,40) does not confirm this view. We learned that patients
carrying one of the mutations F39L, I65T or Y414C in
either a homozygous or a functional hemizygous state
show substantially different responses to the BH4-loading
test in function of the phenylalanine concentration at the
beginning of the test. For example, in presence of the
mutation I65T, the response may vary from 60% at
500 mM phenylalanine to 0% at 1500 mM blood phenyl-
alanine. This is a new finding that may undermine our
trust in current BH4-loading test protocols. Our results
may, for instance, allow for the hypothesis that patients car-
rying the I65T mutation are at risk to show false negative
test results at phenylalanine concentrations .750 mM. In
the case of the R261Q mutation, phenylalanine concen-
trations did not significantly influence test results
(Fig. 4B). However, the kind of genotype significantly
affected BH4 responsiveness with carriers of the R261Q
mutation in the homozygous state showing a higher
response (37.5% decrease in phenylalanine after BH4
loading) than individuals with the mutation in the functional
hemizygous state (6.5% decrease). Further analysis revealed
that none of the patients carrying the R261Q mutation in
combination with a null mutation met the criterion of BH4
responsiveness of 30% decrease of phenylalanine concen-
trations, whereas 12 out of 21 patients with a homozygous
genotype did and 9 out of 21 patients did not. Similar
observations were recently reported in 27 Turkish PKU
patients with a homozygous R261Q genotype and variable
clinical phenotypes (11% mild hyperphenylalaninemia,
67% mild PKU, 22% classic PKU), from which only
39.1% were BH4 responsive (22). Taken together, our
results show that the outcome of a BH4-loading test may
much more vary in function of individual test circumstances
than previously assumed. Unfortunately, it has to be
expected that this is true for a number of mutations and
in view of the lifelong consequences for our patients
arising from the initial classification of being a responder
or not it has to be emphasized that with the knowledge
available today results from single-loading tests are not suf-
ficient to determine BH4 responsiveness in patients with
PAH deficiency.
Last, we analyzed the effect of BH4 dosage on the results of
single BH4-loading tests. Since !10 years, a dosage of 20 mg/
kg body weight is internationally recommended (11,28,29,41).
However, in some centers and countries, this recommendation
may not be followed. In homozygous R261Q patients, the
dosage of BH4 (10, 20 and 30 mg/kg body weight) did not
seem to influence test results (26, 27 and 25% decrease,
respectively). In presence of the Y414C mutation, increasing
BH4 dosages increased BH4 responsiveness in terms of
percent decrease of blood phenylalanine after BH4 application.
Interestingly, compound heterozygous patients carrying both
the R261Q and the Y414C mutation also showed a dose
dependency of response, but to a lower extent than homozy-
gous Y414C patients.
In summary, we developed a rapid PAH enzyme activity
assay allowing for a much higher throughput than previous
assays and for detailed analysis of a broad range of substrate
and cofactor concentrations on PAH enzyme kinetics. This
enabled new insights into optimal PAH working range at phys-
iological, pathological and therapeutic conditions. As to
enzyme kinetics, two main conclusions can be drawn from
our experimental work: phenylalanine concentrations for
optimal working range of PAH are lower, whereas BH4 con-
centrations for optimal PAH activity are higher than pre-
viously assumed. The validity of our observations was
substantiated and expanded by the fact that we were able to
translate data from the prokaryotic system into the eukaryotic
cell culture system and into patient data. Of relevance for the
clinical context, we revealed a significant impact of the geno-
type, substrate concentrations and BH4 dosage on the assess-
ment of BH4 responsiveness.
Since the discovery of the pharmacological effect of BH4 in
patients with PAH deficiency (5), the scientific community
discusses possible mechanisms of BH4 responsiveness in
PKU. The initial concept was kinetic action, in particular the
hypothesis that PAH gene mutations lead to decreased affinity
of the variant protein to the cofactor, that is overcome by the
administration of pharmacological doses of BH4. Kinetic
studies using the recombinant PAH protein revealed that this
is true only in rare instances (2,32,42). Subsequent work
moved the concept away from kinetic effects toward the
view of BH4 acting as a molecular chaperone by increasing
the stability of partially misfolded PAH proteins and by this
the effective intracellular concentration of functional PAH
enzyme (3,4,12). A deeper view into PAH enzyme kinetics
using a technology that allows for the analysis of a broad
range of substrate and cofactor concentrations on PAH activity
now showed that besides the indubitable chaperone effect,
kinetic aspects also have to be taken into account. Thus, we
may now put forward the view of both concepts being of rel-
evance for the diagnosis and the treatment of patients with
PAH deficiency. The diagnostic loading test with BH4 or long-
term BH4 treatment has to be seen in the light of the fact that
short-term supply of BH4 can compensate for latent BH4
deficiency as to optimal catalytic function (kinetic effect),
whereas long-term treatment with pharmacological doses of
BH4 increases the stability of PAH and by this the amount
of metabolically active enzyme (chaperone effect). In
addition, individual mutations may shift the impact of one or
the other therapeutic effect.
For daily clinical routine, this underscores the need for even
more standardized and at the same time individualized test
procedures including detailed documentation of phenylalanine
concentrations before the BH4 load and the awareness that the
metabolic status of the patient will influence the outcome of
the test. In non-responders with suggestive genotypes, re-
petition of the loading test at different initial phenylalanine
concentrations may help rule out false negative results. More-
over, we suggest to combine short-term BH4 loading tests
(assessment of kinetic effects) and long-term BH4 treatment
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tests (assessment of chaperone effects) with in vivo 13C-
phenylalanine oxidation tests (assessment of the effect of
BH4 on in vivo PAH enzyme activity) (11,43). The test is non-
invasive, innocuous, easy to perform and may add important
information about an individual’s response to the drug at a
functional level.
In conclusion, our work pinpoints the importance of geno-
typing PKU patients even in clinical routine and underscores
the need for more personalized testing procedures addressing
individual patient characteristics, the metabolic state and the
dosage of the test compound to safely identify BH4 respon-
siveness in PAH-deficient patients.
MATERIALS AND METHODS
Patients and mutations
Mutations previously identified in BH4 responsive patients
(4,11) were analyzed in terms of the effect of various substrate
(L-phenylalanine) and cofactor (BH4) concentrations on PAH
enzyme activity. The mutations mapped to the regulatory
domain (F39L, I65T), the catalytic domain (R261Q, P275L,
P314S, V388M) or to the dimerization motif of the oligomer-
ization domain (Y414C, Y417H). Forty-six patients homozy-
gous and functional hemizygous for the mutations F39L
(n ! 3), I65T (n ! 5), R261Q (n ! 28) and Y414C (n ! 10)
were identified performing a comprehensive literature survey
and by extracting data from the BIOPKU database (www.
biopku.org). Patients were included in the analysis, when
data on a BH4-loading test using 20 mg/kg body weight and
blood phenylalanine concentrations over a period of at least
24 h were available. In addition, the effect of different BH4
dosages, ranging from 5 to 30 mg/kg body weight, on the
course of blood phenylalanine concentrations was analyzed
(16,19,34,35,37).
Expression and purification of recombinant PAH proteins
The cDNA of human PAH (EST clone obtained from ima-
Genes, formerly RZPD, Germany) was cloned into the prokar-
yotic expression vector pMAL-c2E (New England Biolabs)
encoding an N-terminal maltose-binding protein (MBP) tag.
PAH mutants were constructed by site-directed mutagenesis
as previously described (2). Expression plasmids containing
the wild-type PAH and variants were transformed to Escheri-
chia coli DH5a. Expressed proteins were purified by affinity
chromatography (MBPTrap, GE Healthcare) followed by
size-exclusion chromatography using a HiLoad 26/60 Super-
dex 200 column (GE Healthcare) on an ÄKTAxpress system
(2). Obtained tetramers of the fusion proteins were collected
and protein concentrations were determined spectrophotome-
trically using 1280 (1mg/ml) ! 1.63.
PAH activity assay
Enzyme activity of the recombinantly expressed PAH. The
multi-well PAH activity assay and data evaluation were per-
formed as previously described (27) with modifications.
L-phenylalanine and 22.35 mM Na HEPES, pH 7.3, were
added to all wells of a 96-well plate with different volumes.
This resulted in 12 columns of varying L-phenylalanine con-
centrations (0–4000 mM). A reaction buffer containing 1 mg/
ml catalase (Sigma-Aldrich), 10 mM ferrous ammonium
sulfate (Sigma-Aldrich) and the tetrameric MBP–PAH
fusion protein (0.01 mg/ml) was prepared and injected in all
96 wells. After pre-incubation with L-phenylalanine for 5–
20 min, the reaction was initiated by the addition of variable
concentrations of BH4 (6R-L-erythro-5,6,7,8-tetrahydrobiop-
terin, Cayman Chemical) (0–500 mM) stabilized in 100 mM
dithiothreitol (DTT; Fluka Chemie). PAH activity was deter-
mined at 258C and 90 s measurement time per well. Using
sets of 16 wells and 10 measurement cycles per set, total
measurement time for all 96 wells was 22 min. Substrate pro-
duction was measured by the detection of the increase in
L-tyrosine fluorescence intensity, at an excitation wavelength
of 274 nm and an emission wavelength of 304 nm, using a flu-
orescence photometer (FLUOstar OPTIMA, BMG Labtech)
and assayed as triplicates. Measured fluorescence intensity
signals were corrected by the inner filter effect of BH4 for
every BH4 concentration added. Enzyme activity measure-
ments were quantified by the measurement of L-tyrosine stan-
dards (0–200 mM) before each experiment, and fluorescence
intensity was converted to enzyme activity units (nmol
L-tyrosine/min ! mg protein). Data were analyzed by non-
linear regression analysis using the Michaelis–Menten or the
Hill kinetic model after comparison of model-fitting using
the F-test (GraphPad Prism 4.0c) (27). All concentrations
mentioned refer to the final concentration in a 202 ml reaction
mixture.
Standard PAH activity assay of eukaryotic expressed PAH.
PAH enzyme activity was determined as previously described
(2,39) with modifications. Twenty microliters of total lysates
obtained from cell culture were pre-incubated with 1000 mM
L-phenylalanine and 1 mg/ml catalase (Sigma-Aldrich) for
5 min (258C) in 15 mM Na HEPES pH 7.3, followed by
1 min incubation with 10 mM ferrous ammonium sulfate
(Sigma-Aldrich). The reaction was initiated by the addition
of 75 mM BH4 stabilized in 2 mM DTT, carried out for
60 min at 258C and stopped by acetic acid followed by
10 min incubation at 958C. All concentrations mentioned
refer to the final concentration in a 100 ml reaction mixture.
The amount of L-tyrosine production was measured and quan-
tified by HPLC, assayed as duplicates. Three independent
experiments were performed.
PAH activity landscapes
The data set of multi-well enzyme activity assayed in a 12 ! 8
matrix corresponding to 12 different L-phenylalanine concen-
trations ranging from 0 to 4000 mM (columns) at 8 BH4 con-
centrations ranging from 0 to 500 mM (rows) was loaded into
non-linear regression analysis software (GraphPad Prism
4.0c). A non-linear regression analysis was performed for
each column of the data matrix in order to extend the sparse
data set for BH4 concentrations from 8 measured to 400
newly calculated values following a substrate inhibition
curve. This resulted in a 12 ! 400 matrix of activity values.
For further calculation of the data and for the creation of land-
scapes, this data matrix was exported to the free software
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package R (www.r-project.org). In order to draw a smooth
surface of the landscape, we used the function interp.loess
from additional R package tgp (http://cran.r-project.org/
web/packages/tgp/index.html), which interpolates between
two data points by using local polynomial regression fitting
to find a function between them. This resulted in an increase
in data from an originally measured 12 ! 8 (96-well format)
over a 12 ! 400 to a 400 ! 400 data set. This grid was
then depicted as a smooth landscape plot using the function
image.plot from package fields (http://cran.r-project.org/
web/packages/fields/index.html). To facilitate calculation of
landscapes, a script was written accepting comma-separated
files and automatically coloring landscapes depending on the
measured and interpolated fluorescence intensities.
Stable expression of PAH in HEK293
Stably transfected cells were generated using the Flp-In
system (Invitrogen) according to the manufacturer’s protocol.
The Flp-In-293 cell line was maintained in basic DMEM
(PAA Laboratories) supplemented with L-glutamine, high
glucose (4.5 g/l), 10% fetal bovine serum (GIBCO), 1% anti-
biotics (Antibiotic-Antimycotic; PAA) and 100 mg/ml Zeocin
(Invitrogen). Cells were stably transfected with pEF5/FRT/
V5-DEST cDNA constructs coding for the wild-type, R261Q
or Y414C PAH, respectively. Positive clones were selected
and maintained in medium containing 150 mg/ml hygromycin
B (Invitrogen).
For all further experiments, cells were cultured for 72 h
under three different conditions: (i) basic RPMI 1640
medium (91 mM phenylalanine, PAA Laboratories) sup-
plemented with stable glutamine, 10% fetal bovine serum
(GIBCO), 1% antibiotics (Antibiotic-Antimycotic; PAA) and
150 mg/ml of hygromycin B, (ii) basic medium (as described
above) with 500 mM phenylalanine, and (iii) basic medium
with 1200 mM phenylalanine. Additionally, culture conditions
were modified by adding 40 or 75 mM BH4, respectively.
Culture medium was changed every 24 h. Cells were harvested
and lysed by three freeze-thaw cycles in a Tris–KCl lysis
buffer (0.03 M Tris, 0.2 M KCl, pH 7.2) containing protease
inhibitors (Roche), followed by 20 min centrifugation at
3000 rcf, 48C. Recovered supernatants were subsequently
used for activity assays.
Statistics
Group mean values were compared by Student’s unpaired
two-tailed t-test. Eukaryotic PAH activities following BH4
treatment were analyzed by one-way ANOVA and Dunnett’s
post-test. Statistical analyses were performed using GraphPad
Prism 4.0c (GraphPad Software).
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ABSTRACT
Background In phenylketonuria, genetic heterogeneity,
frequent compound heterozygosity, and the lack of
functional data for phenylalanine hydroxylase genotypes
hamper reliable phenotype prediction and individualised
treatment.
Methods A literature search revealed 690 different
phenylalanine hydroxylase genotypes in 3066
phenylketonuria patients from Europe and the Middle
East. We determined phenylalanine hydroxylase function
of 30 frequent homozygous and compound heterozygous
genotypes covering 55% of the study population,
generated activity landscapes, and assessed the
phenylalanine hydroxylase working range in the
metabolic (phenylalanine) and therapeutic
(tetrahydrobiopterin) space.
Results Shared patterns in genotype-specific functional
landscapes were linked to biochemical and
pharmacological phenotypes, where (1) residual activity
below 3.5% was associated with classical
phenylketonuria unresponsive to pharmacological
treatment; (2) lack of defined peak activity induced loss
of response to tetrahydrobiopterin; (3) a higher cofactor
need was linked to inconsistent clinical phenotypes and
low rates of tetrahydrobiopterin response; and (4)
residual activity above 5%, a defined peak of activity,
and a normal cofactor need were associated with
pharmacologically treatable mild phenotypes. In addition,
we provide a web application for retrieving country-
specific information on genotypes and genotype-specific
phenylalanine hydroxylase function that warrants
continuous extension, updates, and research on demand.
Conclusions The combination of genotype-specific
functional analyses with biochemical, clinical, and
therapeutic data of individual patients may serve as a
powerful tool to enable phenotype prediction and to
establish personalised medicine strategies for dietary
regimens and pharmacological treatment in
phenylketonuria.
INTRODUCTION
The large number of phenylalanine hydroxylase
(PAH) mutations (625 entries (public total), http://
www.hgmd.org), the high incidence of compound
heterozygosity, and the variability in distribution of
common mutations between ethnic groups and
geographical areas makes phenylketonuria (PKU,
OMIM #261600) a genetic disease with pronounced
allelic heterogeneity. PKU caused by deficiency of the
PAH enzyme1 2 has an overall incidence of 1:10 000
in European descendants, which varies considerably
among different populations.3 4
The clinical phenotype of PKU is driven by
mutation-induced loss of PAH function. A con-
tinuum of residual in vivo PAH enzyme activity
determines the clinical picture, ranging from severe
classical PKU via mild PKU to mild hyperphenylala-
ninaemia (MHP) with increasing activity and
decreasing blood phenylalanine concentrations
from severe to mild.5 6 In addition to standard
treatment using a phenylalanine-restricted diet, a
significant proportion of patients is amenable to
pharmacological treatment with the PAH cofactor
tetrahydrobiopterin (BH4).7 8 This constitutes a
superordinate phenotype that requires residual
PAH activity9 10 and further adds to the phenotypic
variability of PAH deficiency.11
Mutations in the PAH gene can induce PAH
loss-of-function by different molecular mechanisms.
Splicing mutations, nonsense mutations, and
out-of-frame indels lead to a complete loss of the
PAH protein, whereas missense mutations as well as
some in-frame indels still lead to the production of
variant PAH proteins. Loss of function of variant
PAH is a consequence of loss of specific enzymatic
activity and/or loss of effective intracellular PAH
protein amount caused by protein misfolding.12–16
Databases such as PAHdb (http://www.pahdb.
mcgill.ca) and BIOPKU (http://www.biopku.org)
provide general information on PAH mutations and
associated phenotypes; however, there is no data-
base access on occurrence and frequency of geno-
types in individual countries. A significant gap of
knowledge concerns the enzymatic function asso-
ciated with PAH genotypes. Available data on
residual PAH enzyme activity is limited to single
mutations expressed in different cellular systems
using diverse enzyme assay protocols.5 13 16–19
Non-invasive functional assays, for example, in
blood cells, are not feasible because metabolic PAH
function is restricted to the liver. Therefore, PAH
activity is commonly determined by means of
experimental in vitro systems. Since calculated
enzyme activities based on heterogeneous data on
single mutations do not reliably reflect residual
activity in the patient, a consistent model system to
assess PAH enzyme function arising from two dif-
ferent alleles reflecting the most common geno-
types is needed. In addition, previous work has
revealed that PAH function depends on the meta-
bolic phenotype and a potential pharmacologic
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administration of BH4.20 Genotype-specific data on PAH func-
tion assessed at different substrate and cofactor concentrations
may thus assist physicians in managing the dietary treatment
and in predicting the probability of pharmacological response in
clinical practice. In order to provide this information, we (1)
mapped the most common reported PAH genotypes in Europe
and Middle East; (2) determined PAH residual function of fre-
quent homozygous and compound heterozygous genotypes in a
cell based model; (3) generated activity landscapes; and (4)
assessed the PAH working range.
This study provides the first comprehensive dataset on PAH
function arising from the most common genotypes carried by
PKU patients in Europe and the Middle East. PAH enzyme
activity assessed at a wide range of phenylalanine and BH4 con-
centrations mirrors metabolic and therapeutic conditions and
thus provides information on the optimal range of substantial
PAH enzyme function in PKU patients. This may allow for
genotype-specific optimisation of phenylalanine restricted
dietary regimens and treatment with BH4.
METHODS
Data sources for PAH genotypes and phenotypes
Data from 24 publications reporting PAH genotypes in 19 coun-
tries in Europe and the Middle East and unpublished data from
German and French medical centres were analysed (see online
supplementary table S1). Types and frequencies of mutations
were obtained from the Human Gene Mutation Database
(http://www.hgmd.org), the PAHdb (http://www.pahdb.mcgill.ca)
and the BIOPKU database (http://www.biopku.org). Data on
PKU clinical phenotypes and BH4 responsiveness were obtained
from BIOPKU.
Assay of PAH activity
In this study, we analysed 30 PAH genotypes consisting of 18 PAH
missense mutations and one intronic mutation c.1066-11G>A
(previously known as IVS10-11G>A),16 which results in the inser-
tion of three amino acids (p.Gln355_Tyr356insGlyLeuGln) (see
online supplementary table S2). Constructs carrying PAH muta-
tions were co-expressed in COS-7 cells reflecting PAH genotypes.
The multi-well PAH activity assay for determination of activity
landscapes from eukaryotically expressed PAH was performed as
previously described for recombinantly expressed and purified
PAH20 with modifications. Varying volumes of a 5 mM
L-phenylalanine (Sigma-Aldrich) solution and 22.35 mM
NaHEPES, pH 7.3, were injected (FLUOstar OPTIMA, BMG
Labtech) into all wells of a 96-well plate. This resulted in 12
columns of varying L-phenylalanine concentrations (0–4000 mM).
A reaction buffer containing 1 mg/mL catalase (Sigma-Aldrich),
10 mM ferrous ammonium sulfate (Sigma-Aldrich), and 20 mL
protein lysate per well was subsequently injected in all 96 wells.
After pre-incubation for 5 min, the reaction was triggered by the
addition of variable concentrations of BH4 (6R-L-erythro-5,6,7,8-
tetrahydrobiopterin, Schircks Laboratories) (0–500 mM, rows of
the 96-well plate) stabilised in 100 mM dithiothreitol (DTT,
Sigma-Aldrich). The PAH activity assay was incubated at 25°C for
15 min and stopped by acetic acid. All concentrations mentioned
refer to the final concentration in a 200 mL reaction mixture. The
formation of the L-Tyr product was quantified by high perform-
ance liquid chromatography (HPLC) using a Hypersil ODS-2
column (ThermoScientific). All PAH activity landscapes were
assayed in three independent experiments and the data were com-
bined. Genotypes were divided into three groups based on PAH
activity determined at the area of peak activity (group 1, PAH
residual activity <3.5%; group 2, !3.5% and <5%; group 3
!5%). If no area of peak activity was delimitable, activity at stand-
ard conditions (L-phenylalanine, 1 mM; BH4, 75 mM) was used
for classification.
PAH activity landscapes
PAH activity landscapes were generated as previously described20
with modifications. The dataset obtained from the multi-well PAH
activity assayed in a 12!8 matrix corresponding to 12 different
L-phenylalanine concentrations (0–4000 mM; columns) at eight
BH4 concentrations (0–500 mM; rows) was loaded into an analysis
software (GraphPad Prism 5.0a). Non-linear regression analysis
allowed for expanding the dataset for BH4 concentrations from
eight measured to 200 interpolated values following a substrate
inhibition curve. This resulted in a 12!200 matrix of activity
values. For the generation of landscapes, the data matrix was
exported to the free software package R (http://www.r-project.
org). In order to draw a smooth surface of the landscape, the func-
tion interp.loess from an additional R package tgp (http://cran.
r-project.org/web/packages/tgp/index.html) was applied, which
interpolates between two data points by using local polynomial
regression fitting to find a function between them. This resulted in
a matrix of 400!400 data points, which was then depicted as a
smooth landscape plot using the function image.plot from package
fields (http://cran.r-project.org/web/packages/fields/index.html). To
facilitate calculation of landscapes, a web application (http://
pah-activitylandscapes.org/calcLandscapes.php) was set up accept-
ing comma-separated files and automatically colouring landscapes
depending on the measured and interpolated enzyme activity
values.
Web application
An interactive website provides country- and region-specific infor-
mation on PAH genotypes and links genotypes to graphical repre-
sentation of activity landscapes (http://pah-activitylandscapes.org).
The site will be updated and users can request the generation of
landscapes of additional genotypes.
More detailed information on material and methods is avail-
able in the online supplementary data.
RESULTS
PAH genotypes in Europe and the Middle East
We performed a comprehensive PubMed literature search to
determine the frequency and region-specific distribution of PAH
genotypes. The study focused on Europe and the Middle East
owing to the shared ethnic background in this region and data
from 20 countries spanning from Portugal to Iran were selected
for evaluation (figure 1 and see online supplementary table S1).
The 3066 PKU patients of this study population displayed 690
different genotypes based on 264 mutations (http://
pah-activitylandscapes.org).
The type and frequency of single PAH mutations constituting
the genotypes in our study cohort matched well with the fre-
quency documented in gene databases (table 1), and mutations
considered as prevalent in the European population4 covered
80.3% of alleles in our cohort (see online supplementary table
S2). The predominant variant p.Arg408Trp (37%) occurred in
all countries except Lebanon and Cyprus, while the second
most common variant, p.Gln355_Tyr356insGlyLeuGln (10.2%),
did not appear in Croatian, Slovenian, and Swedish populations.
A region-specific distribution was also observed for other muta-
tions (see online supplementary figure S1).
The most common full PAH genotypes for eight countries are
shown in figure 1. Of all genotypes analysed, 9% were homozy-
gous, 91% compound heterozygous, and 49% of PKU patients
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carried missense mutations on both alleles. The 30 most fre-
quent genotypes encoding expressible PAH proteins from both
alleles (table 1) covered 55% of patients in our study population
(BIOPKU, 33%; PAHdb, 18%). The frequency of these geno-
types was high in Croatia (88%), Turkey (87%), and France
(61%) and lower in Slovenia (11%) and Spain (10%). The geno-
type p.[Arg408Trp];[Arg408Trp] occurred in 21% of patients
and was predominant in Northern and Eastern Europe
(Lithuania, Norway, Poland, Slovakia), followed by homozygous
p.Gln355_Tyr356insGlyLeuGln (5.2%), which was frequent in
the Middle East (Iran, Turkey, Israel, Lebanon, Armenia).
Genotype frequencies in five geographical regions (Northern
Europe, Southern Europe, Western Europe, Eastern Europe, and
Middle East) and country-specific frequencies are summarised in
online supplementary figure S2 and are available at http://
pah-activitylandscapes.org.
Residual PAH function of wild-type PAH and
frequent PAH genotypes
Ex vivo assessment of PAH enzyme activity in liver tissue
requires unjustifiable invasive procedures. Thus, we aimed to
provide a cellular model that quantifies genotype-specific
residual PAH function and takes into account PAH protein
homeostasis and the metabolic environment. PAH activity of
Figure 1 Phenylalanine hydroxylase (PAH) genotypes in Europe and Middle East. Countries included in the study are marked in blue. The graphs
below show the frequencies of the most common PAH genotypes in individual countries for which data from more than 100 patients were available.
In case the effect of intronic mutation on protein level is not known, the substitution at DNA level was used. The map was created using http://
www.stepmap.de.
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cells expressing variant PAH encoded by both alleles of individ-
ual PAH genotypes was determined at the physiological to
pathological range of phenylalanine concentrations (25–4000
mM) as well as a physiological to supratherapeutic range of BH4
cofactor concentrations (9–500 mM).
The activity landscape of the wild-type enzyme showed a peak
maximum enzyme activity of 72 658 pmol L-Tyr/min x mg
protein at 431 mM L-phenylalanine and 130 mM BH4 (figure 2,
see online supplementary figure S3 and table 2). This was in line
with previous results for purified wild-type PAH protein
expressed in Escherichia coli.20 The optimal working range for
L-phenylalanine spanned from 135 mM ([S]0.5) to 747 mM (Ki).
Thus, the PAH enzyme displayed very low activity at
L-phenylalanine concentrations <120 mM and a broader range
of considerable activity at higher L-phenylalanine concentrations,
even >600 mM. In addition, the wild-type enzyme showed high
activity at cofactor concentrations between 30 mM ([C]0.5) and
294 mM (Ki). At L-phenylalanine concentrations above the thera-
peutic threshold of 360 mM21 the enzyme showed a need for
increased BH4 concentrations to maintain the same level of
activity.
Residual PAH activity of eukaryotically expressed genotypes
(table 2, see online supplementary tables S3 and S4) ranged
from 1.7% (p.[Arg408Trp];[Arg408Trp]) to 11% (p.
[Arg261Gln];[Arg261Gln]) of wild-type PAH, which fits well
with the threshold of 15% PAH activity related to metabolic
decompensation.2 Genotypes were divided into three groups:
those with PAH residual activity <3.5% (group 1, n=9); those
Table 1 PAH genotypes in PKU patients from Europe and the Middle East and associated frequencies
Frequency [%]
Allele 1 Allele 2 Our study* BIOPKU† PAHdb†
1‡ p.Arg408Trp p.Arg408Trp 21.0 10.7 5.0
2‡ p.Gln355_Tyr356insGlyLeuGln p.Gln355_Tyr356insGlyLeuGln 5.2 2.3 1.5
3‡ p.Arg408Trp p.Arg158Gln 2.9 1.7 0.8
4‡ p.Arg408Trp p.Gln355_Tyr356insGlyLeuGln 2.8 1.5 0.2
5‡ p.Arg261Gln p.Arg261Gln 2.1 1.7 1.7
6‡ p.Arg408Trp p.Ala403Val 2.0 1.2 –
7 p.Arg408Trp c.1315+1G>A 2.0 1.5 1.7
8‡ p.Arg408Trp p.Pro281Leu 1.7 1.0 0.5
9‡ p.Arg408Trp p.Arg261Gln 1.6 1.4 1.8
10‡ p.Pro281Leu p.Pro281Leu 1.6 0.9 1.2
11‡ p.Arg408Trp p.Tyr414Cys 1.4 1.1 1.2
12‡ p.Arg408Trp p.Ala300Ser 1.3 0.8 0.2
13‡ p.Leu48Ser p.Leu48Ser 1.1 0.8 –
14‡ p.Arg408Trp p.Ile306Val 1.0 0.5 –
15‡ p.Arg261Gln p.Gln355_Tyr356insGlyLeuGln 0.9 0.7 0.5
16‡ p.Arg408Trp p.Glu390Gly 0.8 0.6 0.2
17‡ p.Arg408Trp p.Arg252Trp 0.7 0.6 0.5
18‡ p.Arg408Trp p.Leu48Ser 0.7 1.0 0.3
19‡ p.Arg252Trp p.Arg252Trp 0.6 0.4 0.2
20‡ p.Arg408Trp p.Arg297His 0.6 0.2 –
21‡ p.Pro281Leu p.Gln355_Tyr356insGlyLeuGln 0.6 0.3 0.3
22‡ p.Ala300Ser p.Gln355_Tyr356insGlyLeuGln 0.6 0.4 0.2
23 p.Tyr414Cys c.1315+1G>A 0.6 0.6 1.7
24‡ c.441+5G>T c.441+5G>T 0.5 0.2 0.2
25‡ p.Leu48Ser p.Gln355_Tyr356insGlyLeuGln 0.5 0.4 0.3
26‡ p.Leu48Ser p.Arg261Gln 0.5 0.5 0.2
27‡ p.Arg408Trp p.Val245Ala 0.5 0.3 0.3
28‡ p.Leu48Ser p.Arg158Gln 0.4 0.3 0.2
29‡ p.Ile65Thr p.Gln355_Tyr356insGlyLeuGln 0.4 0.4 0.6
30 p.Arg408Trp g.47563_51794del4232 g.56161_56430ins268 0.4 – –
31‡ p.Arg408Trp p.Ile283Phe 0.4 0.2 0.3
32‡ p.Arg408Trp p.Val388Met 0.4 0.2 –
33‡ p.Arg408Trp p.Arg241His 0.4 0.3 –
34 p.Arg261Gln c.1315+1G>A 0.4 0.4 0.8
35 p.Arg408Trp p.Phe55fs 0.4 0.4 0.2
36‡ p.Arg408Trp p.Leu348Val 0.4 0.4 0.2
Total number of patients (n) 3066 7453 658
Population of patients covered by 30 genotypes (%) 55.0 32.8 18.4
Population of patients covered by 36 genotypes (%) 59.4 35.9 22.9
The table shows the 36 most frequent genotypes in Europe and the Middle East and their relative frequencies.
*Frequencies of genotypes retrieved from the literature (PubMed search) and obtained via personal communications.
†Frequencies of genotypes retrieved from public databases: BIOPKU (query 23 April 2014) and PAHdb (query 19 April 2014).
‡30 PAH genotypes encoding expressible PAH proteins from both alleles selected for experimental studies.
PAH, phenylalanine hydroxylase; PKU, phenylketonuria.
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with activities !3.5% and <5% (group 2, n=3); and those
!5% (group 3, n=18) (table 2, figures 3–5). Group 3 contained
all genotypes with mutations known to be associated with mild
clinical phenotypes (p.Val245Ala, p.Ala300Ser, p.Glu390Gly, p.
Ala403Val). Although p.Gln355_Tyr356insGlyLeuGln is com-
monly considered a null mutation,16 it reached up to 5% of
activity in the homozygous state, suggesting preservation of
some residual function in patients. Taking into consideration the
30 most frequent genotypes, 37% of PKU patients in this
cohort carried a genotype associated with low residual PAH
function <5%, and 19% of patients can be expected to have a
considerable residual enzyme function with activities >5%.
Armenia, Croatia, Iran, Lithuania, Poland, Slovakia and Turkey
showed a predominance of severe genotypes, whereas France,
Italy, and the Czech Republic are countries where milder bio-
chemical phenotypes are more frequent than severe ones (see
online supplementary table S5).
Peak enzyme activity and optimal working
range of PAH genotypes
We aimed to identify the metabolic context for best PAH function.
Peak PAH enzyme activity— that is, the relation of optimal
enzyme activity to substrate and cofactor concentrations—consti-
tutes an important functional feature in phenylalanine metabolism
and is of clinical relevance. We defined the working optimum for
the PAH enzyme as the range of activity between [S]0.5 and (Ki) for
the substrate and between [C]0.5 and (Ki) for the cofactor— that is,
the ranges of all activities above 50% (table 2 and see online sup-
plementary figure S4). Functional activity landscapes from group 1
displayed very low activity with no defined peak (figure 3). In
group 2, enzyme activities were still low but an area of peak activ-
ity mapping to the area of wild-type PAH was delimitable
(figure 4). Group 3 genotypes showed considerable residual activ-
ities and delimitable peak areas with the exceptions of p.
[Pro281Leu];[Gln355_Tyr356insGlyLeuGln] and homozygous p.
[Gln355_Tyr356insGlyLeuGln ];[Gln355_Tyr356insGlyLeuGln]
(figure 5). However, the position and shape of areas of peak
enzyme activity showed large variation within this group. The sub-
strate concentration at peak activity ranged from 251–882 mM for
genotypes that displayed a defined peak area. For p.[Ile306Val];
[Arg408Trp], p.[Ala403Val];[Arg408Trp], and p.[Tyr414Cys];
[Arg408Trp] peak activity mapped to significantly lower phenyl-
alanine concentrations than observed for the wild-type. These left-
shifts were associated with higher apparent affinity of the enzymes
towards the substrate, as reflected by lower values for [S]0.5.
On the other hand, p.[Arg261Gln];[Arg261Gln], p.[Arg261Gln];
[Arg408Trp], p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln], and
p.[Arg297His];[Arg408Trp] led to peak activities at higher phenyl-
alanine concentrations associated with lower apparent affinity of
the enzyme towards the substrate, as reflected by higher values for
[S]0.5. All but one of these genotypes contained p.Arg261Gln. All
other genotypes displayed peak activities at L-phenylalanine con-
centrations in the wild-type range.
The working range of wild-type PAH with respect to the
substrate covered an interval of >600 mM. Broadening of
the working range of the PAH enzyme (interval >900 mM),
denoting high residual enzyme activity over a wide range of
phenylalanine concentrations, was observed for p.[Leu48Ser];
[Arg261Gln], p.[Arg261Gln];[Arg261Gln], p.[Arg261Gln];
[Gln355_Tyr356insGlyLeuGln], and p.[Arg297His];[Arg408Trp].
Three of these genotypes contained the allele p.Arg261Gln
and 4.1% of the patients in our study population carried a geno-
type associated with this activity landscape feature. On the other
hand, a narrow working range leading to considerable PAH
activity only in a tight window of substrate concentrations
(interval <460 mM) was observed for p.[Leu48Ser];[Leu48Ser],
p.[Leu48Ser];[Arg158Gln], p.[Leu48Ser];[Arg408Trp], p.
[Leu48Ser];[Gln355_Tyr356insGlyLeuGln], p.[Ala300Ser];
[Gln355_Tyr356insGlyLeuGln], p.[Ile306Val];[Arg408Trp], p.
[Ala403Val];[Arg408Trp], and p.[Tyr414Cys];[Arg408Trp], with
p.Leu48Ser and p.Arg408Trp being the leading mutations in this
group. These occurred in 7.7% of the patients. Genotypes
showing a left-shift always showed a smaller area of enzyme activ-
ity, but not all genotypes with narrow working ranges were left-
shifted. Thus, high affinity towards the substrate and a smaller area
of phenylalanine-dependent activity range may be due to inde-
pendent mechanisms.
The cofactor concentration at peak activity ranged from
94–409 mM. All genotypes with a residual activity
!3.5% and peak enzyme activities at lower cofactor concentra-
tions than the wild-type (p.[Leu48Ser];[Arg261Gln], p.
[Arg261Gln];[Arg261Gln], p.[Arg261Gln];[Arg408Trp], p.
[Arg297His];[Arg408Trp], p.[Glu390Gly];[Arg408Trp], p.
[Ala403Val];[Arg408Trp]) included the alleles p.Arg261Gln or
p.Arg408Trp. Interestingly, a shift towards lower cofactor con-
centrations was not associated with an increase in the apparent
affinity of the enzymes towards the cofactor as reflected by
comparable values for [C]0.5. Genotypes p.[Leu48Ser];
[Arg408Trp], p.[Leu48Ser];[Gln355_Tyr356insGlyLeuGln], p.
[Ile65Thr];[Gln355_Tyr356insGlyLeuGln], p.[Ala300Ser];
[Gln355_Tyr356insGlyLeuGln], p.[Leu48Ser];[Arg158Gln],
and p.[Leu348Val];[Arg408Trp] led to peak activities at higher
BH4 concentrations. It is of note that the presence of the allele
p.Gln355_Tyr356insGlyLeuGln correlated with a shift of peak
activity towards higher BH4 concentrations when residual
activity is !5%. Most of these genotypes contained a mutation
previously classified as being inconsistently linked to clinical
phenotypes (p.Leu48Ser, p.Ile65Thr, p.Ala300Ser) (see online
supplementary figure S5). Patients carrying these genotypes
may need higher cofactor concentrations for optimal enzyme
activity. All other genotypes induced peak activities at similar
BH4 concentrations than the wild-type.
Impact of PAH function on clinical phenotypes
Next, we linked functional data to clinical phenotypes retrieved
from BIOPKU (see online supplementary figure S5). Group 1 geno-
types with very low PAH activities lacking a well-defined peak of
activity were consistently associated with BH4 non-responsive clas-
sical PKU. One exception, p.[Arg241His];[Arg408Trp], showed a
Figure 2 Phenylalanine hydroxylase (PAH) activity landscape of
human wild-type (WT) PAH expressed in cell culture. Data for PAH
enzyme activity assayed at varying L-phenylalanine and BH4
concentrations were interpolated and depicted by a colour code. With
increasing substrate concentrations, more BH4 is needed to maintain
the same level of enzyme activity (solid line).
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leading phenotype of mild PKU (70% of patients), yet responsive-
ness to BH4 was only assessed for two cases. Group 2 genotypes,
all displaying intermediate residual activity and a defined area of
peak activity, showed phenotypic heterogeneity with both mild and
classical PKU phenotypes and a significant share of patients
responding to BH4. Among group 3, two subgroups were analysed.
Group 3 genotypes without area of peak activity (p.[Pro281Leu];
[Gln355_Tyr356insGlyLeuGln], p.[Gln355_Tyr356insGlyLeu
Gln];[Gln355_Tyr356insGlyLeuGln]), leading to a total loss of
landscape architecture, were mainly associated with classical PKU
and a low response rate to BH4 (10–25%). These also displayed
rather low residual activities within this group (5.1%, 5.7%). Yet
other genotypes with residual activities in the same range, but
showing a defined area of peak activity, displayed higher response
rates suggesting that a loss of landscape architecture is linked to a
loss of BH4 responsiveness.
Group 3 genotypes with peak activity were predominantly asso-
ciated with MHP or mild PKU and high response rates to cofactor
treatment. This was not the case for p.[Leu48Ser];
[Gln355_Tyr356insGlyLeuGln], p.[Ile65Thr];[Gln355_Tyr356ins
GlyLeuGln], p.[Arg261Gln];[Arg408Trp], p.[Arg261Gln];
[Gln355_Tyr356insGlyLeuGln], and p.[Leu348Val];[Arg408Trp],
with the predominance of classical PKU and unresponsiveness to
pharmacological treatment. Interestingly, three of these genotypes
contained p.Gln355_Tyr356insGlyLeuGln and three of these geno-
types were associated with peak activities at increased cofactor con-
centrations. Therefore, dosages used in standard response tests may
not be sufficient to meet the high need for BH4 of patients carrying
one of these genotypes.
Taken together, the results from this study indicate that
residual PAH activity alone is not a reliable predictor of the clin-
ical phenotype but other factors may be taken into account.
Table 2 Residual PAH activity and optimal enzymatic working range of PAH proteins
Genotype Group
*Peak PAH
activity
Residual
activity at
peak
(% of WT)
†L-Phenylalanine
concentration
at peak activity ‡[S]0.5—Ki
§BH4
concentration
at peak activity ¶[C]0.5—Ki
WT 72 658±13 134 100 431±23 135–747 130±11 30–294
p.[Leu48Ser];[Leu48Ser] 3 4769±411 6.6 351±3 92–533 146±11 37–463
p.[Leu48Ser];[Arg158Gln]** 2 3041±134 4.2 330±7 78–542 200±15 89–458
p.[Leu48Ser];[Arg261Gln] 3 6229±61 8.6 501±17 146–1164 100±1 31–302
p.[Leu48Ser];[Arg408Trp] 2 2534±118 3.5 351±0 90–543 268±13 33–432
p.[Leu48Ser];[Gln355_Tyr356insGlyLeuGln] 3 5468±337 7.5 391±9 103–556 235±73 32–432
p.[Ile65Thr];[Gln355_Tyr356insGlyLeuGln] 3 4978±185 6.8 441±30 119–605 409±76 43–424
p.[Arg158Gln];[Arg408Trp]†† 1 2470±708 n. a. n. a. n. a. n. a. n. a.
p.[Arg241His];[Arg408Trp]†† 1 2071±156 n. a. n. a. n. a. n. a. n. a.
p.[Val245Ala];[Arg408Trp] 3 7486±360 10 391±9 120–643 157±12 34–468
p.[Arg252Trp];[Arg252Trp]†† 1 2699±74 n. a. n. a. n. a. n. a. n. a.
p.[Arg252Trp];[Arg408Trp]†† 1 2267±202 n. a. n. a. n. a. n. a. n. a.
p.[Arg261Gln];[Arg261Gln] 3 8031±861 11 762±10 283–1314 94±2 28–249
p.[Arg261Gln];[Arg408Trp] 3 4598±351 6.3 752±6 252–1023 99±14 35–258
p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln] 3 6013±903 8.3 802±119 197–1118 149±39 32–247
p.[Pro281Leu];[Pro281Leu]†† 1 2265±252 n. a. n. a. n. a. n. a. n. a.
p.[Pro281Leu];[Arg408Trp]†† 1 2297±117 n. a. n. a. n. a. n. a. n. a.
p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln]†† 3 4163±663 5.7 n. a. n. a. n. a. n. a.
p.[Ile283Phe];[Arg408Trp]†† 1 2534±307 n. a. n. a. n. a. n. a. n. a.
p.[Arg297His];[Arg408Trp] 3 7162±123 9.8 882±141 319–1938 99±11 29–219
p.[Ala300Ser];[Arg408Trp] 3 3819±375 5.2 391±4 120–615 135±11 30–461
p.[Ala300Ser];[Gln355_Tyr356insGlyLeuGln] 3 5011±439 6.9 431±11 131–576 219±70 34–429
p.[Ile306Val];[Arg408Trp] 3 4494±453 6.2 271±6 64–513 105±6 52–298
p.[Leu348Val];[Arg408Trp] 3 5700±395 7.8 511±31 156–1046 215±29 31–331
p.[Val388Met];[Arg408Trp] 3 5365±110 7.4 361±4 112–730 159±8 32–371
p.[Glu390Gly];[Arg408Trp] 3 6005±314 8.3 501±7 150–770 100±15 30–288
p.[Ala403Val];[Arg408Trp] 3 6444±1054 8.8 251±14 52–510 100±0 44–226
p.[Arg408Trp];[Arg408Trp]†† 1 1273±157 n. a. n. a. n. a. n. a. n. a.
p.[Arg408Trp];[Gln355_Tyr356insGlyLeuGln]†† 1 2919±453 n. a. n. a. n. a. n. a. n. a.
p.[Tyr414Cys];[Arg408Trp] 2 3560±271 4.9 301±3 87–528 139±9 33–404
p.[Gln355_Tyr356insGlyLeuGln]; [Gln355_Tyr356insGlyLeuGln]†† 3 3710±369 n. a. n. a. n. a. n. a. n. a.
The table summarises height and position of peak PAH enzyme activities and the optimal working ranges arising from group 1, 2 and group 3 PAH genotypes. Residual PAH activity at
standard conditions is summarised in table S3.
*Peak PAH enzyme activity is given as [pmol L-tyrosine/min x mg protein]±SEM.
†L-Phenylalanine concentration at peak activity is given as [mM]±SEM.
‡[S]0.5—Ki indicates the optimal PAH working range (>50% of the respective residual activity) as to substrate concentrations.
§BH4 concentration at peak activity is given as [mM]±SEM.
¶[C]0.5—Ki indicates the optimal PAH working range (>50% of the respective residual activity) as to cofactor concentrations.
**Calculated parameters refer to a peak mapping to the area of WT peak PAH activity; a second area of high activity was observed for L-phenylalanine > 2500 mM.
††Calculated parameters refer to the area of highest PAH activity; a defined peak area was not delimitable.
n. a., not applicable, no peak area was delimitable.
PAH, phenylalanine hydroxylase; WT, wild-type.
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Our analyses led to the recognition of the following orienteer-
ing rules for the implementation of personalised medicine strat-
egies. (1) Low residual activity is associated with mostly BH4
unresponsive classical PKU. (2) Lack of a defined area of peak
activity leads to a loss of response to BH4. (3) The occurrence
of inconsistent clinical phenotypes with low rates of BH4
response is linked to a higher need for BH4. (4) Residual activity
>5%, a defined peak of activity, and normal need for BH4 are
associated with mostly BH4 responsive mild PKU or MHP.
Moreover, the occurrence of the allele p.Arg261Gln is
often associated with inconsistent phenotypes, whereas the
allele p.Gln355_Tyr356insGlyLeuGln is linked to a higher
cofactor need.
DISCUSSION
The healthcare practitioner’s view on genetic disease underwent
change during the last decade. Genotyping has become easier
and databases provide access to a wealth of data related to
genetic variation. In addition, an increasing number of therapies
evolved from an improved understanding of the molecular basis
of maladies. After diagnosis of an inherited disease, families
request reliable prediction of the clinical phenotype and the long
Figure 3 Group 1 phenylalanine hydroxylase (PAH) activity landscapes. The interpolated residual enzyme activities after expression of homozygous
and compound heterozygous PAH genotypes were colour-coded and given as a function of different L-phenylalanine and BH4 concentrations. Group
1 refers to genotypes associated with a PAH residual activity of <3.5% of the wild-type.
Figure 4 Group 2 phenylalanine hydroxylase (PAH) activity landscapes. The interpolated residual enzyme activities after expression of homozygous
and compound heterozygous PAH genotypes were colour-coded and given as a function of different L-phenylalanine and BH4 concentrations. Group
2 refers to genotypes associated with a PAH residual activity of !3.5% and <5% of the wild-type.
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Figure 5 Group 3 phenylalanine hydroxylase (PAH) activity landscapes. The interpolated residual enzyme activities after expression of homozygous
and compound heterozygous PAH genotypes were colour-coded and given as a function of different L-phenylalanine and BH4 concentrations. Group
3 refers to genotypes associated with a PAH residual activity !5% of the wild-type.
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term outcome. In the specific case of PKU, the approval of a drug
providing the first pharmacological therapy for the disorder7 22 23
added a new dimension to diagnosis and treatment. Clinical gen-
etics at the service of patients faces the challenge of combining
empirical evidence buried in databases with functional evidence
from basic research. To this end, an experimental basis to assess
molecular consequences of genetic alteration and to generate
solid functional data considering full genotypes is required.
In this study, we aimed to provide a tool for the thorough
analysis of genotype-related PAH function for PKU patients in
Europe and the Middle East. A comprehensive literature search
revealed that the 30 most frequent genotypes represent 55% of
patients. Thus, the experimental investigation of a convenient
number of genotypes can cover significant shares of a given
population and thus provide meaningful information to physi-
cians in clinical practice.
Residual enzyme activities reported for a number of single
PAH mutations16 24 25 do not reflect the patient’s situation since
values well above 50% are not expected to produce a biochem-
ical and clinical phenotype. A study investigating in vivo PAH
function provided evidence for a threshold, where enzyme activ-
ities >15% were linked to normal biochemical parameters and
thus normal function.2 Moreover, it is well known that conse-
quences arising from full genotypes consisting of both alleles
differ from the average induced by the two mutations involved
and that proteins arising from different alleles influence
each other—a phenomenon termed interallelic complementa-
tion.26–28 Furthermore, although residual PAH enzyme activity
assessed at fixed substrate and cofactor conditions for single
mutations shows a general correlation with clinical severity and
BH4 responsiveness,29 30 there is still significant inconsistency
that hampers solid phenotype prediction in clinical care. This
prompted us to develop a model system that mimics the cellular
situation in carriers of both homozygous and compound hetero-
zygous genotypes. Our system was calibrated at the equilibrium
of PAH synthesis and degradation and takes into account the
contributions of protein misfolding and accelerated degrad-
ation.12 13 31 In the liver, the PAH enzyme is subjected to fluctu-
ation of phenylalanine and, under treatment, of BH4. In order
to reflect the situation in vivo, we analysed PAH activity land-
scapes for full genotypes at a wide range of substrate and
cofactor concentrations. These conditions assessed PAH func-
tion in the context of metabolic and therapeutic states and mir-
rored major molecular mechanisms underlying missense
mutation-induced PKU; however, data obtained in vitro may
still differ from residual activity in patients.
We observed several patterns of changes in the architecture
of PAH activity landscapes and the combined evidence from
functional analyses with biochemical, clinical, and therapeutic
data delivered means to generate hypotheses about the
mechanisms behind individual genotypes. Changes in PAH
activity landscapes as regards to substrate concentrations may
impact dietary management. Some genotypes (p.[Arg261Gln];
[Arg261Gln], p.[Arg261Gln];[Arg408Trp], p.[Arg261Gln];
[Gln355_Tyr356insGlyLeuGln], p.[Arg297His];[Arg408Trp])
induced a right-shift of the activity landscape. As a conse-
quence, these genotypes are associated with very low enzyme
activity at low phenylalanine concentrations. On the one
hand, the enzyme is inactive at phenylalanine concentrations
<200 mM. On the other hand, the right-shift results in good
metabolic PAH function at higher phenylalanine concentra-
tions (peak activity, !800 mM phenylalanine). Therefore,
internationally accepted target phenylalanine concentrations
<360 mM in the patient may in these cases be difficult to
achieve. In turn, phenylalanine tolerance may be dispropor-
tionately higher at phenylalanine concentrations slightly above
the target, lowering the burden of diet. This has to be con-
firmed by clinical studies with appropriate analysis of dietary
phenylalanine intake and blood phenylalanine concentrations.
Notably, different dietary regimens leading to different meta-
bolic states may at least in part explain the significant pheno-
typic variability of homozygous p.Arg261Gln and p.
[Arg261Gln];[Arg408Trp] with respect to disease severity and
BH4 responsiveness (http://www.biopku.org) (see online sup-
plementary figure S5).20 32 In the experimental dataset pre-
sented here, the presence of the mutation p.Arg261Gln in the
genotype often induced broadening of the PAH working
range, with rather high enzyme activities at a wide range of
phenylalanine concentrations. This may be associated with
fewer phenylalanine fluctuations, known to be a major factor
of brain damage.33 Eight genotypes showed a narrow range of
L-phenylalanine concentrations associated with considerable
PAH activity. In three cases this was accompanied by a shift of
the area of peak PAH activity below 300 mM L-phenylalanine.
The carrier of such a genotype may need to keep blood
phenylalanine concentrations in a tight range to optimise
phenylalanine flux and could thus benefit from avoidance
of phenylalanine fluctuations.
Another group of genotypes induced changes in PAH activity
landscapes as regards to cofactor concentrations that may have
implications not only for pharmacological treatment with BH4.
Some genotypes showed PAH activity peaks at lower BH4 concen-
trations. Among these, the presence of the p.Arg261Gln mutation
was associated with inconsistent BH4 response, whereas the
mutation p.Arg408Trp led to consistent BH4 response. An activity
peak at increased BH4 concentrations was associated with the
occurrence of p.Gln355_Tyr356insGlyLeuGln. Moreover, geno-
types in this group also harboured mutations typically associated
with inconsistent clinical phenotypes (p.Leu48Ser, p.Ile65Thr, p.
Ala300Ser). Patients carrying these genotypes may need more
BH4 to achieve their optimal enzyme function. As a consequence
BH4 dosages used in standard BH4 response tests may be insuffi-
cient to achieve an increase of enzyme activity and decrease of
phenylalanine concentrations, the endpoint in response tests.
Interestingly, genotypes with loss of landscape architecture p.
[Gln355_Tyr356insGlyLeuGln];[Gln355_Tyr356insGlyLeuGln],
p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln] also contained p.
Gln355_Tyr356insGlyLeuGln and are associated with severe
BH4 non-responsive phenotypes. The apparent affinity of PAH
to BH4 in eukaryotic cells is !30 mM and peak PAH activity
was reached at 130 mM in our setting, which is in line with
values obtained from recombinant PAH.20 In addition, liver
cells keep BH4 at a concentration of about 9 mM.34 Therefore,
the PAH system suffers from a constant shortage of BH4.
Oxidative stress35 or other environmental factors with negative
impact on BH4 availability may trigger PAH deficiency and thus
may further aggravate clinical phenotypes. Taken together,
alterations in BH4 demand may add to the molecular mechan-
isms underlying phenotypic variability related to both disease
severity and BH4 responsiveness.
Our results confirm the frequent observation that residual
PAH enzyme activity is not only the determinant as to the sever-
ity of the biochemical phenotype but also a prerequisite for BH4
response and thus correlates with it.9 However, this correlation
is not absolute. For instance, in group 3 genotypes with residual
enzyme activity >5%, we observed a significant proportion of
genotypes associated with little or no BH4 response. On the one
hand, they were associated with relatively low residual activity
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within this group; on the other hand, lack of response to cofac-
tor treatment was linked to a higher cofactor need. The defin-
ition of three groups provides a classification of genotypes with
different overall PAH enzyme activity that allows for a global
estimation of the severity of the disease. Beyond that, our study
revealed that PAH activity landscapes not only provide informa-
tion on the quantitative value of residual activity but also on the
position of enzyme activity in the metabolic and therapeutic
space, and that this is another important determinant of the
phenotype.
Inconsistent phenotypes in individuals carrying identical geno-
types are well known in clinical practice. In Leuders et al,36 five
patients carrying the genotype p.[Leu48Ser];[Leu48Ser] all
showed responsiveness at a low BH4 dosage. In databases, four
cases with non-responsive PAH deficiency (9%) and four cases
with slow response to BH4 (9%) are reported for individuals car-
rying this genotype (see online supplementary figure S5). These
observations, however, are not necessarily in contradiction to
each other. We observed a higher need for BH4 to achieve peak
activity for three genotypes containing the mutation p.Leu48Ser.
Notably, Leuders et al36 tested BH4 response after 7 days of treat-
ment. Repeated administration of BH4 may lead to constantly
elevated concentrations of cellular BH4 and thus provide the
variant PAH protein with a sufficient amount of cofactor, which
may explain the consistent positive response. On the other hand,
inconsistent BH4 responsiveness has previously been reported for
genotypes containing the p.Arg261Gln mutation.37 38 Following
our observation of a right-shifted area of peak activity with
respect to phenylalanine values for p.[Arg261Gln];[Arg408Trp],
the variability in the phenotype of patients carrying this genotype
may, at least in part, be due to fluctuations in substrate concentra-
tions, particularly with regard to blood phenylalanine concentra-
tions at the time of the BH4 loading test. As a conclusion for
these observations, the assessment of PAH activity landscapes
testing PAH function revealed how varying metabolic and thera-
peutic conditions may contribute to variability in the clinical
phenotype. Nevertheless, other genetic and non-genetic factors39
may also influence phenylalanine clearance and thus the clinical
phenotype in PKU patients. Among these, differences in the dis-
posal of excess phenylalanine by transamination when the
hydroxylation reaction is blocked, variation in the carrier-
mediated uptake of phenylalanine by the brain and the liver, and
environmental factors such as oxidative stress are the best recog-
nised modifiers to date.25 33 35 40–42
In conclusion, this work may exemplify how application of
molecular genetics translates into medical practice. It gives new
significance to gene analysis of the PAH locus in clinical routine
and shows the importance of considering full genotypes. The
analysis of activity landscapes in the metabolic and therapeutic
space provided clinically relevant new insights into
genotype-related impaired PAH function beyond the known link
between residual activity and clinical phenotype. In the presence
of specific genotypes we observed different patterns of activity
landscape architecture and established orienteering rules for
their interpretation. In addition, the work provides a web-based
tool to assist clinicians in clinical care of PKU patients (http://
pah-activitylandscapes.org). The web application allows for
retrieving country- and region-specific information on geno-
types and their related PAH function. Its sustainability and
increasing representativeness will be ensured by continuous
extension and updates as well as research on demand delivering
new PAH activity landscapes upon request.
The analysis of individual genotype-related PAH activity land-
scapes together with the information provided on genotype-
related clinical phenotypes may permit improved long term
phenotype prediction and the implementation of personalised
medicine strategies for dietary regimens and pharmacological
treatment.
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Figure'S1'CountryNwise*distribuRon*of*30*most*common*PAH*mutaRons*idenRfied*in*European*and*
Middle* East* cohort* of* PKU* paRents.* A* comprehensive* literature* research* and* personal*
communicaRons*were* the*data*sources* for* informaRon*on*PAH$genotypes.*The* frequency*and* the*
countryNwise* distribuRon* of* the* underlying* mutaRons* is* shown.* Each* mutaRon* showed* a* unique*
distribuRon*paYern.**
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Figure S2 
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Poland((1,286(pa8ents)(
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Southern(Europe((Spain,(Portugal,(Italy,(Croa8a,(Serbia,(
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Figure S2 
Figure' S2'RegionT( and( countryTwise( distribu8on( of( 30(most( frequent(PAH( genotypes.( 20' countries(were(
classified( into(five(geographical(groups:(Northern(Europe((Lithuania,(Sweden),(Western(Europe((Germany,(
France),(Eastern(Europe((Poland,(Czech(Republic,(Slovakia),(Southern(Europe((Spain,(Portugal,(Italy,(Croa8a,(
Serbia,(Slovenia)(and(Middle(East((Armenia,(Cyprus,(Iran,(Israel,(Lebanon,(Syria,(Turkey).(In(each(region,(the(
overall(frequency(of(individual(genotype(was(calculated.(Addi8onally,(the(frequency(of(each(genotype(was(
evaluated( separately( for( each( country( belonging( to( the( respec8ve( group.( In( case( of( muta8on(
p.Gln355_Tyr356insGlyLeuGln,(the(trivial(name((IVS10T11G>A)(was(used.(
14 
Turkey((252(pa8ents)(
80000 
60000 
40000 
20000 
0
[L-Tyr] pm
ol/m
in*m
g protein 
Figure S3!
NT 
0 1000 2000 3000 4000 
[L-Phe] µM!
10
0 
20
0 
30
0 
40
0 
50
0 
[B
H
4]  
µM
 
Figure S3 PAH activity landscape of not transfected (NT) COS-7 cells, used as a negative control. 
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Figure'S4'Determina,on"of"op,mal"working"ranges"of"PAH"ac,vity"with"respect"to"substrate"and"cofactor."
The"op,mal"working" range"of"PAH"ac,vity"assessed" for"p.[Arg261Gln];[Arg261Gln]" is"given"as"an"example"
(peak"ac,vity:"762"µM"LNPhe"and"94"µM"BH4)."A)"Op,mal"working"range"for"BH4"is"depicted"as"boundaries"set"
by"[C]0.5,"which"reflects"the"concentra,on"of"the"cofactor"at"half"maximal"enzyme"ac,vity"and"Ki,"which"is"the"
concentra,on"of"the"cofactor"needed"to"inhibit"the"enzyme"by"50"%."Similarily,"B)"the"op,mal"working"range"
for" LNphenylalanine" is" described" by" [S]0.5" and" Ki" values" where" [S]0.5" is" the" concentra,on" of" the" substrate"
needed"for"the"enzyme"to"achieve"50"%"of"enzyme’s"maximal"ac,vity"and"Ki"is"the"substrate"concentra,on"at"
which"the"ac,vity"of"the"enzyme"is"decreased"by"50"%.""
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p.#[Arg158Gln];[Arg408Trp]##
(117$incidents$with$known$phenotype)]$
p.#[Arg158Gln];[Arg408Trp]##
(68$incidents$with$known$type$of$BH4:responsiveness)]$
p.[Arg241His];[Arg408Trp]#
(18$incidents$with$known$phenotype)]$
#
p.[Arg241His];[Arg408Trp]#
(2$incidents$with$known$type$of$BH4:respo siveness)]$
#
p.[Arg252Trp];[Arg252Trp]#
(26$incidents$with$known$phenotype)]$
#
p.[Arg252Trp];[Arg252Trp]#
(4$incidents$with$known$type$of$BH4:responsiveness)]$
#
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(40$incidents$with$known$phenotype)]$
#
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p.[Pro281Leu];[Pro281Leu]#
(53$incidents$with$known$phenotype)]$
#
p.[Pro281Leu];[Pro281Leu]#
(38$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Pro281Leu];[Arg408Trp]#
(68$incidents$with$known$phenotype)]$
#
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p.#[Gln355_Tyr356insGlyLeuGln];[Arg408Trp]#
(102$incidents$with$known$phenotype)]$
#
p.#[Gln355_Tyr356insGlyLeuGln];[Arg408Trp]##
(21$incidents$with$known$type$of$BH4:responsiveness)]$
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p.[Leu48Ser];[Arg158Gln]#
(22$incidents$with$known$phenotype)]$
#
p.[Leu48Ser];[Arg158Gln]#
(14$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Leu48Ser];[Arg408Trp]#
(70$incidents$with$known$phenotype)]$
#
p.[Leu48Ser];[Arg408Trp]#
(28$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Tyr414Cys];[Arg408Trp]#
(81$incidents$with$known$phenotype)]$
#
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(4 $incidents$with$know $type$of$BH4:responsiveness)]$
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p.[Leu48Ser];[Leu48Ser]#
(60$incidents$with$known$phenotype)]$
#
p.[Leu48Ser];[Leu48Ser]#
(44$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Leu48Ser];[Arg261Gln]#
(35$incidents$with$known$phenotype)]$
#
p.[Leu48Ser];[Arg261Gln]#
(28$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Leu48Ser];[Gln355_Tyr356insGlyLeuGln]##
(24$incidents$with$known$phenotype)]$
#
p.[Leu48Ser];[Gln355_Tyr356insGlyLeuGln]###
(20$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Ile65Thr];[Gln355_Tyr356insGlyLeuGln]##
(26$incidents$with$known$phenotype)]$
#
p.[Ile65Thr];[Gln355_Tyr356insGlyLeuGln]###
(17$incidents$with$known$type$of$BH4:responsiveness)]$
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p.[Val245Ala];[Arg408Trp]#
(25$incidents$with$known$phenotype)]$
#
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(5$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Arg261Gln];[Arg261Gln]#
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#
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(78$incidents$w th$known$type$of$BH4:responsiveness)]$
#
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(96$incidents$with$known$phenotype)]$
#
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#
p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln]##
(43$incidents$with$known$phenotype)]$
#
p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln]###
(31$incidents$with$known$type$of$BH4:responsiveness)]$
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p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln]##
(17$incidents$with$know $phenotype)]$
#
p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln]###
(7$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Arg297His];[Arg408Trp]#
(18$incidents$with$known$phenotype)]$
#
p.[Arg297His];[Arg408Trp]#
(0$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Ala300Ser];[Arg408Trp]#
(48$incidents$with$known$phenotype)]$
#
p.[Ala300Ser];[Arg408Trp]#
(7$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Ala300Ser];[Gln355_Tyr356insGlyLeuGln]##
(26$incidents$with$known$phenotype)]$
#
p.[Ala300Ser];[Gln355_Tyr356insGlyLeuGln]###
(17$incidents$with$known$ty $ $BH4:respon iveness)]$
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p.[Ile306Val];[Arg408Trp]#
(36$incidents$with$known$phenotype)]$
#
p.[Ile306Val];[Arg408Trp]#
(2$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Leu348Val];[Arg408Trp]#
(29$incidents$with$known$phenotype)]$
#
p.[Leu348Val];[Arg408Trp]#
(17$incidents$with$known$type$of$BH4:responsiveness)]$
#
p.[Val388Met];[Arg408Trp]#
(15$incidents$with$known$phenotype)]$
#
p.[Val388Met];[Arg408Trp]#
(2$incide ts$with$known$type$of$BH4:re po siveness)]$
#
p.[Ala403Val];[Arg408Trp]#
(88$incidents$with$known$phenotype)]$
#
p.[Ala403Val];[Arg408Trp]#
(8$incidents$wi h$known$type$of$BH4:responsiveness)]$
#
24 
E390G/R408W (19 incidents with known type of responsiveness)
Yes No Slow
0
20
40
60
80
100
%
 o
f c
as
es
 w
ith
  k
no
w
n 
ty
pe
 
of
 re
sp
on
si
ve
ne
ss
E390G/R408W (39 incidents with known phenotype)
MHPA mPKU cPKU
0
20
40
60
80
100
%
 o
f c
as
es
 w
ith
 k
no
w
n 
ph
en
ot
yp
e
Group 3 
IVS10/IVS10  (123 incidents with known phenotype)
MHPA mPKU cPKU
0
20
40
60
80
100
%
 o
f c
as
es
 w
ith
 k
no
w
n 
ph
en
ot
yp
e IVS10/IVS10 (85 incidents with known type of responsiveness)
Yes No Slow
0
20
40
60
80
100
%
 o
f c
as
es
 w
ith
  k
no
w
n 
ty
pe
 
of
 re
sp
on
si
ve
ne
ss
Figure S5 
p.[Glu390Gly];[Arg408Trp]#
(39$incidents$with$known$phenotype)]$
#
p.[Glu390Gly];[Arg408Trp]#
(19$incidents$with$known$type$of$BH4: nsiveness)]$
#
p.[Gln355_Tyr356insGlyLeuGln];
[Gln355_Tyr356insGlyLeuGln]##
#(123$incidents$with$known$phenotype)]$
#
p.[Gln355_Tyr356insGlyLeuGln];
[Gln355_Tyr356insGlyLeuGln]##
(85$incidents$with$known$type$of$BH4:responsiveness)]$
#
Figure#S5#Clinical$phenotypes$associated$with$analyzed$PAH$genotypes.$The$data$on$clinical$phenotypes$
and$BH4:responsiveness$were$obtained$from$BIOPKU$(www.biopku.org).$$
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Figure S6 
A B 
Figure'S6'Assessment'of'the'PAH'protein'produc3on'over'3me.'COS97'cells'were'transiently'transfected'with'
PAH'plasmids'harboring' the'WT,'p.Glu390Gly,' p.Tyr414Cys' and'p.Arg158Gln' genes' respec3vely.'Next,' the'
cells'were'harvested'at'different'3me'points'(12'–'60'h'aSer'transfec3on).'The'produc3on'of'PAH'protein'
was'analyzed'by'the'dot'blot'accompanied'by'the'PAH'ac3vity'assay.'This'allowed'for'the'determina3on'of'
an'op3mal'3me'point'(∼'40'h)'where'the'protein'produc3on'is'in'balance'with'the'protein'degrada3on.'A)'
The' PAH' protein' produc3on' analyzed' by' dot' blots' and' evaluated' with' the' Dot' Blot' Analyzer' for' ImageJ'
toolset' (image.bio.methods.free.fr/dotblot.html).' B)' Analysis' of' the' PAH' ac3vity' in' transfected' cells'
harvested'at'different'3me'points'post9transfec3on.'
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A B 
Figure'S7'Assessment'of'transfec-on'efficiency'in'co1transfec-on'experiments.'The'posi-ve'control'plasmid'
pEF/GW151/lacZ,'coding'for'β1galactosidase,'was'co1transfected'together'with'plasmids'coding'for'wild1type'
PAH'(WT),'p.Arg261Gln'or'p.Arg408Trp.'The'molar'ra-o'of'control'plasmid'to'plasmids'coding'for'PAH'was'
1:5.' On' the' protein' level,' the' produc-on' of' the' control' protein' β1galactosidase' did' not' change' in' the'
presence' of' wild1type' or' variant' PAH' proteins.' A)' Western' blot' analysis' of' transient' expression' of' β1
galactosidase' protein' in' the' presence' of' WT' PAH,' p.Arg261Gln' or' p.Arg408Trp' of' three' independent'
transfec-ons' (I1III).' β1galactosidase' was' detected' using' primary' an-1V5' an-body' (life' technologies)' and'
secondary'an-1mouse'HRP1conjugated'an-body'(Santa'Cruz'Biotechnology).'For'the'detec-on'of'β1ac-n,'the'
an-1β1ac-n'(C4)'HRP1conjugated'an-body'was'used'(Santa'Cruz'Biotechnology).'The'resul-ng'protein'bands'
were' visualized' with' Pierce' ECL' Western' Blo\ng' Substrate' (ThermoScien-fic).' B)' ImageJ' analysis' of' β1
galactosidase'protein'produc-on'(h_p://imagej.nih.gov/ij/download.html).'
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Figure S8 
Figure'S8'Western'blot'analysis'verifying'a'1:1'molar'ra4o'of'wild7type'PAH'derived'from'co7transfec4on'of'
two'different'wild7type'PAH'expression'plasmids'(pEF7DEST517V5'and'pEF7DEST7STOP)'in'three'independent'
experiments' (I7III).'PAH'protein'was'detected'using'mouse'monoclonal'an47PAH'an4body' (PH8;'Millipore)'
and'an47mouse'HRP7conjugated'secondary'an4body'(Santa'Cruz'Biotechnology)'wherease'for'the'detec4on'
of'β7ac4n'the'an47β7ac4n'(C4)'HRP7conjugated'an4body'was'used'(Santa'Cruz'Biotechnology).'The'resul4ng'
protein'bands'were'visualized'with'Pierce'ECL'Western'BloXng'Substrate'(ThermoScien4fic).'
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Table&S1.&Sources!for!PAH!genotypes!from!different!countries!included!in!the!study.!
&
Country& References& No.&of&patients&&
Armenia! Konstandyan!et!al.!2011[1]! 34!
Croatia! Karačić!et!al.!2009[2]! 58!
Cyprus! Georgiou!et!al.!2012[3]! 12!
Czech!Republic! Réblová!et!al.!2013[4]! 46!
France! own!data! 97!
Germany! own!data!
Gramer!et!al.!2009[5]!
217!
Iran! ZareRKarizi!et!al.!2011[6]& 122!
Israel! Bercovich!et!al.!2008[7]! 171!
Italy! Fiori!et!al.!2005[8]!
Daniele!et!al.!2009[9]!
Guzetta!et!al.!1997[10]!
154!
Lebanon! Karam!et!al.!2013[11]! 23!
Lithuania! Kasnauskiene!et!al.!2003[12]! 92!
Poland! BikRMultanowski!et!al.!2013[13]! 1286!
Portugal! Rivera!et!al.!2011[14]! 67!
Serbia! Stojiljkovic!et!al.!2006[15]!
Djordjevic!et!al.!2012[16]!
92!
Slovakia! Polak!et!al.!2013[17]! 207!
Slovenia! Tansek!et!al.!2012[18]! 36!
Spain! Couce!et!al.!2013[19]!
Desviat!et!al.!2004[20]!
Bueno!et!al.!2013[21]!
175!
Sweden! Svensson!et!al.!1993[22]! 50!!
Syria! Murad!et!al.!2013[23]! 39!
Turkey! Dobrowolski!et!al.!2011[24]! 252!
! Total&number&of&patients& 3230&
! Number&of&patients&with&full&genotypes& 3066&
!
Resources!for!PAH!genotypes.!On!the!basis!of!a!PubMed!literature!search,!24!publications!were!selected.!In!addition,!data!
from!Medical!Centers!in!Munich!and!Nancy!were!included.!
!
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Table&S2.&Frequent!PAH!mutations!in!the!study!population.!!
&
& Mutation& & %&of&mutant&alleles&
! Protein! Nucleotide! !
1& #&p.Arg408Trp! c.1222C>T& 36.3&
2! #!p.Gln355_Tyr356insGlyLeuGln$ c.1066B11G>A!(IVS10B11G>A)! 10.2!
3& #&p.Arg261Gln! c.782G>A& 5.4&
4& #&p.Pro281Leu! c.842C>T& 3.8&
5& #&p.Arg158Gln! c.473G>A& 3.4&
6& #&p.Leu48Ser! c.143T>C& 3.1&
7! #!p.?$ c.1315+1G>A!(IVS12+1G>A)! 2.9!
8& #&p.Ala403Val! c.1208C>T& 2.8&
9& #&p.Ala300Ser! c.898G>T& 2.2&
10& #&p.Tyr414Cys! c.1241A>G& 2.2&
11& #&p.Arg252Trp! c.754C>T& 1.4&
12& #&p.Glu390Gly! c.1169A>G& 1.2&
13& p.Ile306Val& c.916A>G& 1.1&
14! p.?! c.441+5G>T!(IVS4+5G>T)! 1.1!
15& #&p.Ile65Thr! c.194T>C& 1.0&
16! #!p.Arg243*$ c.727C>T! 0.9!
17& #&p.Val388Met! c.1162G>A& 0.9&
18! p.Phe55Leufs*6! c.165delT! 0.9!
19& p.Val245Ala& c.734T>C& 0.7&
20! #!p.Arg261*$ c.781C>T! 0.7!
21! #!p.Ser349Pro$ c.1045T>C! 0.6!
22! p.?! c.168+5G>C!(IVS2+5G>C)! 0.6!
23! p.Arg243Gln! c.728G>A! 0.5!
24& #&p.Leu348Val! c.1042C>G& 0.5&
25& p.Arg297His& c.890G>A& 0.4&
26& p.Arg241His& c.722G>A& 0.4&
27! #!p.Gly272*$ c.814G>T! 0.4!
28! #!p.Glu280Lys$ c.838G>A! 0.4!
29! p.Asp415Asn! c.1243G>A! 0.4!
30! p.Arg270Lys! c.809G>A! 0.4!
&&
The!30!most!frequent!mutations!in!the!PAH!gene!based!on!the!analysis!of!6273!mutant!alleles!identified!in!3230!PKU!
patients!from!Europe!and!the!Middle!East.!!
#!PAH!mutations!previously!identified!as!frequent!in!the!European!population!(Zschocke!2003).!Mutations!contributing!
to!genotypes!analyzed! in! this!study!are!given! in!bold.!The!mutation!c.847A>T!(p.Ile283Phe),!additionally!analyzed! in!
this!study,!contributes!to!the!30!most!frequent!genotypes!but!was!not!among!the!30!most!frequent!mutations.!
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Table&S3.!PAH!enzyme!activity!determined!at!standard!conditions!
!
Genotype&
PAH&enzyme&activity&&
[pmol&L:tyrosine/min&x&mg&
protein]&± &SEM&
Residual&activity&&
(%&of&WT)&
WT! 52!981!±!10!769! 100!
NT! 664!±!142! 1.2!
p.[Leu48Ser];[Leu48Ser]! 3501!±!258! 6.6!
p.[Leu48Ser];[Arg158Gln]! 1818!±!354! 3.4!
p.[Leu48Ser];[Arg261Gln]! 5948!±!67! 11!
p.[Leu48Ser];[Arg408Trp]! 1981!±!99! 3.7!
p.[Leu48Ser];[Gln355_Tyr356insGlyLeuGln]! 4882!±!418! 9.2!
p.[Ile65Thr];[Gln355_Tyr356insGlyLeuGln]! 4808!±!195! 9!
p.[Arg158Gln];[Arg408Trp]! 815!±!212! 1.5!
p.[Arg241His];[Arg408Trp]! 1246!±!67! 2.3!
p.[Val245Ala];[Arg408Trp]! 5632!±!238! 10.6!
p.[Arg252Trp];[Arg252Trp]! 953!±!14! 1.8!
p.[Arg252Trp];[Arg408Trp]! 937!±!44! 1.8!
p.[Arg261Gln];[Arg261Gln]! 7678!±!775! 14.5!
p.[Arg261Gln];[Arg408Trp]! 4445!±!329! 8.4!
p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln]! 5690!±!919! 10.7!
p.[Pro281Leu];[Pro281Leu]! 1081!±!106! 2!
p.[Pro281Leu];[Arg408Trp]! 1307!±!134! 2.5!
p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln]! 2877!±!324! 5.4!
p.[Ile283Phe];[Arg408Trp]! 1288!±!121! 2.4!
p.[Arg297His];[Arg408Trp]! 7655!±!135! 14.4!
p.[Ala300Ser];[Arg408Trp]! 2909!±!245! 5.5!
p.[Ala300Ser];[Gln355_Tyr356insGlyLeuGln]! 4654!±!480! 8.8!
p.[Ile306Val];[Arg408Trp]! 2143!±!228! 4!
p.[Leu348Val];[Arg408Trp]! 4682!±!697! 8.8!
p.[Val388Met];[Arg408Trp]! 3842!±!120! 7.2!
p.[Glu390Gly];[Arg408Trp]! 5616!±!345! 10.6!
p.[Ala403Val];[Arg408Trp]! 3210!±!245! 6!
p.[Arg408Trp];[Arg408Trp]! 609!±!66! 1.1!
p.[Arg408Trp];[Gln355_Tyr356insGlyLeuGln]! 1736!±!116! 3.3!
p.[Tyr414Cys];[Arg408Trp]! 2120!±!88! 4!
p.[Gln355_Tyr356insGlyLeuGln];[Gln355_Tyr356insGlyLeuGln]! 3192!±!473! 6!
!
PAH!enzyme!activities!associated!with!frequent!PAH!genotypes!as!determined!at!standard!conditions!(1!mM!LU
phenylalanine!and!75!µM!BH4).!Data!were!extracted!from!the!96!well!PAH!activity!matrix.!!
WT!refers!to!wildUtype!PAH,!NT!refers!to!the!negative!control!of!not!transfected!COSU7!cells.!
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Table&S4.!PAH!enzyme!activity!of!PAH!homozygotes!determined!at!standard!conditions!!
!
Genotype&
PAH&enzyme&activity&&
[pmol&L:tyrosine/min&x&mg&
protein]&± &SEM&
Residual&
activity&&
(%&of&WT)&
NT! 907!±!139! 1.5!
pEF/GWE51/lacZ!control!vector! 636!±!18! 1.1!
WT! 60!853!±!4!505! 100!
p.[Leu48Ser];[Leu48Ser]! 4!395!±!561! 7.2!
p.[Ile65Thr];[Ile65Thr]! 6!474!±!610! 10.6!
p.[Arg158Trp];[Arg158Trp]! 1!101!±!163! 1.8!
p.[Arg241His];[Arg241His]! 3!639!±!416! 6!
p.[Val245Ala];[Val245Ala]! 37!713!±!2!845! 62!
p.[Arg252Trp];[Arg252Trp]! 543!±!22! 0.9!
p.[Arg261Gln];[Arg261Gln]! 9!443!±!336! 15.5!
p.[Pro281Leu];[Pro281Leu]! 569!±!25! 0.9!
p.[Ile283Phe];[Ile283Phe]! 1!762!±!70! 2.9!
p.[Arg297His];[Arg297His]! 58!412!±!1!777! 96!
p.[Ala300Ser];[Ala300Ser]! 10!615!±!1!864! 17.4!
p.[Ile306Val];[Ile306Val]! 4!266!±!65! 7!
p.[Leu348Val];[Leu348Val]! 14!497!±!852! 24!
p.[Val388Met];[Val388Met]! 7!173!±!1!203! 12!
p.[Glu390Gly];[Glu390Gly]! 33!504!±!2!177! 55!
p.[Ala403Val];[Ala403Val]! 7!498!±!1!264! 12!
p.[Arg408Trp];[Arg408Trp]! 772!±!48! 1.3!
p.[Tyr414Cys];[Tyr414Cys]!! 5!865!±!839! 10!
p.[Gln355_Tyr356insGlyLeuGln];[Gln355_Tyr356insGlyLeuGln]! 3!863!±!135! 6.3!
PAH!enzyme!activities!associated!with!homozygous!PAH! genotypes!as!determined!at! standard!conditions! (1!mM!LE
phenylalanine!and!75!µM!BH4).!
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Table&S5.!Frequency!of!null!genotypes!and!active!genotypes!in!different!countries!
!
&
Country&
&
Null&genotypes&[%]&
&
Active&genotypes&[%]&
&
Lithuania! 89! 11!
Iran! 75! 25!
Poland! 76! 24!
Slovakia! 76! 24!
Armenia! 75! 25!
Turkey! 71! 29!
Croatia! 71! 29!
Lebanon! 67! 33!
Syria! 62! 38!
Spain! 61! 39!
Portugal! 54! 46!
Israel! 52! 48!
Germany! 54! 46!
Sweden! 54! 46!
Slovenia!! 50! 50!
Serbia! 50! 50!
Czech!Republic! 45! 55!
Italy! 41! 59!
France! 29! 71!
!
Percentages! of! patients! carrying! genotypes! with! residual! activity! below! 5! %! (null! genotypes)! or! above! 5! %! (active!
genotypes)!in!different!countries.!Data!are!sorted!by!decreasing!percentages!for!null!genotypes.!
The!calculation!only!applies!to!the!30!most!frequent!PAH!genotypes!selected!for!experimental!work!in!this!study!(Table!1).!
Null! genotypes:! p.[Arg408Trp];[Arg408Trp],! p.[Gln355_Tyr356insGlyLeuGln];[Gln355_Tyr356insGlyLeuGln],!
p.[Arg408Trp];[Arg158Gln],! p.[Arg408Trp];[Gln355_Tyr356insGlyLeuGln],! p.[Pro281Leu];[Pro281Leu],!
p.[Arg408Trp];[Pro281Leu],! p.[Arg408Trp];[Arg252Trp],! p.[Leu48Ser];[Arg408Trp],! p.[Arg252Trp];[Arg252Trp],!
p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln],! p.[Leu48Ser];[Arg158Gln],! p.[Arg408Trp];[Ile283Phe],!
p.[Arg241His];[Arg408Trp].!
Active! genotypes:! p.[Arg261Gln];[Arg261Gln],! p.[Leu48Ser];[Leu48Ser],! p.[Ala403Val];[Arg408Trp],!
p.[Arg261Gln];[Arg408Trp],! p.[Tyr414Cys];[Arg408Trp],! p.[Ala300Ser];[Arg408Trp],! p.[Ile306Val];[Arg408Trp],!
p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln],! p.[Glu390Gln];[Arg408Trp],! p.[Arg297His];[Arg408Trp],!
p.[Ala300Ser];[Gln355_Tyr356insGlyLeuGln],! ! p.[Leu48Ser];[Gln355_Tyr356insGlyLeuGln],! p.[Leu48Ser];[Arg261Gln],!
p.[Val245Ala];[Arg408Trp],! p.[Val388Met];[Arg408Trp],! p.[Ile65Thr];[Gln355_Tyr356insGlyLeuGln],!!
p.[Leu348Val];[Arg408Trp].!
!
!
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Table&S6.!PAH!enzyme!activity!determined!at!standard!conditions!without!and!with!co8transfection!of!
control!plasmid!
!
Genotype&
PAH&enzyme&activity&&
[pmol&L:tyrosine/min&x&mg&protein]&± &
SEM&
Residual&activity&&
(%&of&WT)&
WT! 60!853!±!4!505! 100!
WT!+!pEF/GW851/lacZ! 62!340!±!2!691! 100!
p.[Arg261Gln];[Arg261Gln]! 9!443!±!336! 15.5!
p.[Arg261Gln];[Arg261Gln]!+!pEF/GW851/lacZ! 11!546!±!435! 18.5!
p.[Arg408Trp];[Arg408Trp]! 772!±!48! 1.3!
p.[Arg408Trp];[Arg408Trp]!+!pEF/GW851/lacZ! 624!±!121! 1.0!
!
PAH!enzyme!activities!determined!at!standard!conditions!(1!mM!L8phenylalanine!and!75!µM!BH4)!with!and!without!
co8transfection!of!the!positive!control!plasmid!pEF/GW851/lacZ.!Residual!activities!of!p.[Arg261Gln];[Arg261Gln]!and!
p.[Arg408Trp];[Arg408Trp]! refer! to! WT,! residual! activities! of! p.[Arg261Gln];[Arg261Gln]! +! pEF/GW851/lacZ! and!
p.[Arg408Trp];[Arg408Trp]!+!pEF/GW851/lacZ!refer!to!WT!+!pEF/GW851/lacZ.!
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SUPPLEMENTARY MATERIALS AND METHODS 1!
 2!
Data sources for PAH genotypes and phenotypes 3!
A PubMed literature search using the terms <phenylketonuria> and <genotypes> resulted in 4!
687 hits covering publications from 1967 to present (access date 17 March 2014). Only 5!
papers describing full genotypes of PKU patients due to PAH deficiency were selected. 6!
Studies with pre-selection constraints that focus on specific subgroups such as mild 7!
phenotypes or the phenotype of BH4-responsiveness were excluded. Twenty-four 8!
publications reporting PAH genotypes from 19 countries in Europe and Middle East 9!
published between 1993 and 2013 were selected. Additional unpublished data on PAH 10!
genotypes was included from German and French medical centers. For comparison of types 11!
and frequency of mutations, data were accessed from the Human Gene Mutation Database 12!
(www.hgmd.org; access date 17 March 2014), the PAH locus knowledgebase PAHdb 13!
(www.pahdb.mcgill.ca; access date 19 April 2014) and the BIOPKU database 14!
(www.biopku.org; access date 23 April 2014). Data on PKU clinical phenotypes and BH4-15!
responsiveness associated with PAH genotypes were obtained from BIOPKU. 16!
 17!
Mutations 18!
For functional analyses, 18 PAH missense mutations, c.143T>C (p.Leu48Ser), c.194T>C 19!
(p.Ile65Thr), c.473G>A (p.Arg158Gln), c.722G>A (p.Arg241His), c.734T>C (p.Val245Ala), 20!
c.754C>T (p.Arg252Trp), c.782G>A (p.Arg261Gln), c.842C>T (p.Pro281Leu), c.847A>T 21!
(p.Ile283Phe), c.890G>A (p.Arg297His), c.898G>T (p.Ala300Ser), c.916A>G (p.Ile306Val), 22!
c.1042C>G (p.Leu348Val), c.1162G>A (p.Val388Met), c.1169A>G (p.Glu390Gly), 23!
c.1208C>T (Ala403Val), c.1222C>T (p.Arg408Trp), and c.1241A>G (p.Tyr414Cys), were 24!
generated by site-directed mutagenesis (KAPAHiFi Hot Start PCR Kit; peqlab). In addition, a 25!
construct based on the intronic mutation c.1066-11G>A (IVS10-11G>A), which results in the 26!
insertion of three amino acids (p.Gln355_Tyr356insGlyLeuGln)[1] was generated. All mutant 27!
PAH constructs were cloned into the eukaryotic expression vector pEF-DEST51 (life 28!
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technologies). Authenticity of constructs was verified by DNA sequencing. Other PAH 1!
mutations appearing in tables and figures were not expressed in cells; c.1315+1G>A 2!
(IVS12+1G>A), c.441+5G>T (IVS4+5G>T), c.165delT (p.Phe55fs), c.727C>T (p.Arg243*), 3!
c.781C>T (p.Arg261*), c.168+5G>C (IVS2+5G>C), c.728G>A (p.Arg243Gln), c.809G>A 4!
(p.Arg270Lys), c.814G>T (p.Gln272*), c.838G>A (p.Glu280Lys), and c.1243G>A 5!
(p.Asp415Asn). See online supplementary table S2. 6!
 7!
Transient expression of PAH in COS-7 8!
COS-7 cells were maintained in basic RPMI 1640 medium with stable glutamine 9!
supplemented with 10!% fetal bovine serum and 1!% antibiotic-antimycotic (gibco by life 10!
technologies). In order to assess the time point of PAH expression at the equilibrium of 11!
synthesis and degradation, cells transfected with plasmids coding for wild-type PAH or the 12!
variants p.Arg158Gln, p.Glu390Gly, and p.Tyr414Cys were harvested at different time points 13!
(12 to 60 h) followed by quantitative dot blot analysis (ImageJ, 14!
http://image.bio.methods.free.fr/dotblot.html) and analysis of PAH enzyme activity (figure 15!
S6). Based on these data, landscape experiments were performed 36 h to 40 h post-16!
transfection. In order to rule out potential variation in transfection efficiency in co-expression 17!
experiments, the positive control plasmid pEF/GW-51/lacZ (life technologies) was co-18!
transfected with wild-type PAH, p.Arg261Gln or p.Arg408Trp in a 1:5 ratio (control:PAH). On 19!
the protein level, the production of the control protein β-galactosidase did not change in the 20!
presence of wild-type or variant PAH proteins (figure S7). Accordingly, wild-type or variant 21!
PAH enzyme activity did not vary in the presence or absence of the control vector (table S6). 22!
A total of 6 µg DNA per 6 million cells was used in single transfections (homozygotes) or in 23!
co-transfections (1:1 molar ratio of two different PAH expression plasmids) accounting for 24!
compound heterozygosity. Western blot analysis verified a 1:1 molar ratio of wild-type PAH 25!
derived from transfection of two different wild-type PAH expression plasmids (figure S8). 26!
Cells were harvested and lysed by three freeze-thaw cycles in a lysis buffer containing 20 27!
mM HEPES (Sigma-Aldrich), 200 mM NaCl (Millipore), pH 7.0 and protease inhibitors 28!
! 38!
(cOmplete Protease Inhibitor Cocktail Tablets, Roche) followed by 20 min centrifugation at 1!
20 000 g, 4°C. Recovered supernatants were subsequently used for PAH activity landscapes 2!
and the total protein amount in the lysate was determined by Bradford assay (BioRad). All 3!
transfections were performed using single cuvette Amaxa electroporation system (Lonza). 4!
 5!
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